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ABSTRACT 
 
Human serum transferrin (hTF) is a bilobal glycoprotein that plays a central role 
in iron metabolism.  Each lobe of hTF (N- and C-lobe) can reversibly bind a single ferric 
iron.  Iron binds to hTF at neutral pH in the plasma; diferric hTF binds to specific hTF 
receptors (TFR) on the cell surface and the complex undergoes receptor mediated 
endocytosis.  The pH within the endosome is lowered to ~5.6 and iron is released from 
hTF.  Apo hTF remains bound to the TFR and recycles back to the cell surface.  Upon 
fusion with the plasma membrane, apo hTF dissociates from the TFR and is free to bind 
more iron and continue the cycle.  The iron release process is complicated by various 
factors which include pH, anions, a chelator, lobe-lobe cooperativity and interaction with 
the TFR.  All of these influence iron release in a complex manner.  Because they are 
intricately linked, it is difficult to determine the effect of any single parameter.   
We have utilized stopped-flow and steady-state fluorescence and urea gel 
electrophoresis to dissect the iron release process as a function of lobe-lobe interactions, 
the presence of the TFR, and changes in pH and salt concentration.  Application of 
recombinant protein production and site-directed mutagenesis has allowed us to generate 
a variety of hTF constructs in which the iron status of each lobe is completely controlled.  
Thus, we have created authentic monoferric hTFs unable to bind iron in one lobe, diferric 
hTFs with iron locked in one lobe and diferric hTF in which iron can be removed from 
both lobes.  Importantly, we have produced the soluble portion of the TFR (sTFR) to 
analyze interactions between hTF and the sTFR and to monitor iron release from 
hTF/sTFR complexes.  Together, we are able to provide a more precise picture of iron 
release from the two lobes of hTF in the presence and absence of the TFR. 
 Steady-state fluorescence emission scans and urea gel electrophoresis provide a 
qualitative evaluation of the iron status of each construct after a predetermined incubation 
in iron removal buffer (i.e. an endpoint).  However, these techniques do not provide 
information regarding the kinetic pathway to reach that endpoint.  Combined with 
stopped-flow fluorescence time-based kinetics, a more precise assessment of the iron 
release process has been obtained.  We have determined that changes in pH and salt 
affect endpoint iron release from the C-lobe, but not the N-lobe, however, the kinetics of 
iron release from both lobes are highly sensitive to pH and salt.  Kinetic analysis in the 
absence and presence of the sTFR reveals the complexity of the iron release process.  In 
the absence of the sTFR, the kinetics of iron release are insensitive to the iron status of 
the opposite lobe.  However, in the presence of the sTFR, the kinetics of iron release 
from both lobes are affected by the iron status of the opposite lobe.  Determination of 
conformational changes induced by anion binding, lobe-lobe communication and sTFR 
interactions have now been confidently assigned.  We have created kinetic models of iron 
release from diferric hTF ± the sTFR and incorporated specific events pertaining to anion 
binding, lobe-lobe communication and conformational changes associated with sTFR 
interactions.  We provide irrefutable evidence that a critical role of the sTFR is to 
accelerate the rate of iron release from the C-lobe, while decreasing the rate of iron 
release from the N-lobe such that the two lobes effectively release iron on a time scale 
relevant to one cycle of endocytosis. 
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COMPREHENSIVE LITERATURE REVIEW 
Iron and its Properties 
Iron, a major constituent of the Earth’s crust, is the most biologically relevant and 
abundant metal across all life forms from Archaea to man (1).  As a transition metal, iron 
can readily adopt two oxidation states, ferrous (Fe2+), and ferric (Fe3+).  Conversion 
between these states is accomplished through a one-electron oxidation-reduction reaction 
(2).  Ferrous iron reacts with molecular oxygen via Fenton chemistry and generates toxic 
hydroxide radicals; these hydroxide radicals cause extensive cell damage by attacking 
proteins, nucleic acids, lipids and carbohydrates (3).  On the other hand, ferric iron is 
virtually insoluble in aqueous solution (its concentration cannot exceed 10-17 M at neutral 
pH) and requires a complexing agent (4).  Despite its toxicity, iron is essential to several 
life processes including, but not limited to, the synthesis of DNA, the respiratory electron 
transport chain, as well as oxygen storage and transport (some examples of iron 
containing proteins are shown in Table 1).  Cellular iron deficiency arrests cell growth 
and leads to cell death (3).  Iron transport and storage proteins are essential to prevent 
ferrous iron from generating reactive oxygen species and to maintain solubility of ferric 
iron.  Iron homeostasis is maintained through the coordinated regulation of uptake, 
storage and secretion.  In vertebrates, iron is transported by the serum protein, transferrin 
(TF), which can bind two molecules of ferric iron in a reversible manner.  Iron is stored 
in the cytosolic storage protein, ferritin, which can accommodate up to 4500 iron atoms 







Table 1. Iron containing proteins and their biological function 
 
Protein Function 
Hemoglobin Oxygen transport 
Myoglobin Oxygen storage 
Cytochromes  Electron transport/ATP synthesis 
Ribonucleotide reductase Deoxyribonucleotide synthesis 
Aconitase Citric acid cycle 
Transferrin Iron transport 
Lactoferrin Iron binding, antimicrobial 
Ferritin Iron storage 
Dehydrogenases Electron transfer 
Hydroxylases Detoxification 
Hemopexin Heme delivery 









Most bacteria also require iron for survival.  In order to attain iron, they produce 
small molecule chelators, siderophores, which bind ferric iron and transport it to cells 
through specific membrane receptors (6).  Siderophores are typically produced in iron 
replete conditions and have been grouped into three classes: hydroxamates, catecholates 
and hydroxycarboxylates (7).  Interestingly, to date only two organisms have been 
identified that do not require iron to survive:  Borrelia burgdorferi, the pathogenic 
bacterium that causes Lyme disease and lactobacillus plantarum, a free living soil 
bacterium commonly found in fermented food products.  Both are able to survive (and 
thrive) in its absence by using manganese and cobalt instead of iron (8-10).   
Iron Requirements and Dietary Absorption 
The body requires 1-2 mg of iron per day to maintain iron homeostasis (11).  
Although there is no physiologic excretion mechanism to rid the body of iron; about 1-2 
mg per day are lost through bleeding and shedding of cells (12).  Because there is no 
excretion mechanism, the body must tightly regulate iron absorption.  The average daily 
diet contains about 15-25 mg of iron, of which only 1-2 mg are absorbed by the intestine.  
Dietary iron comes in two forms: heme iron found in meat and meat products and 
nonheme iron present in cereals, vegetables, beans and fruit.  Heme iron is 20-30% 
bioavailable, whereas nonheme iron is only 1-10% available.  Other components of the 
diet can either enhance or inhibit the bioavailability of nonheme iron (13).  Iron 
absorption occurs in two steps: (1) uptake by duodenal enterocytes in the small intestine 
and (2) transfer across mucosal cells into the circulation.  Ferric iron appears to require 







reductase (Dcytb, duodenal cytochrome b) is highly expressed on the brush border 
membranes of these cells; this enzyme is up-regulated in conditions which increase 
intestinal iron absorption such as chronic or iron-deficiency anemia induced in hpx mice 
(which lack circulating TF) (14).  Following reduction, iron is transported across the 
apical membrane into the absorptive cell through a divalent metal transporter (DMT1, 
also designated DCT1 and Nramp2) (15).   
The body produces 200 billion new erythrocytes per day; a process which requires 
~20 mg of iron for hemoglobin synthesis (3).  The remainder of iron required for other 
processes is recovered from hemoglobin through macrophage phagocytosis of senescent 
red blood cells (3).  Not surprisingly, the majority of iron is found in heme (66%) (bound 
to hemoglobin, the oxygen transport protein), 10% is bound to myoglobin, (the muscle 
oxygen storage protein) and about 23% is stored in ferritin.  Although essential to iron 
metabolism, less than 1% of iron is transported by TF for storage or delivery to iron 
requiring cells.   
Iron Homeostasis 
Diseases of iron deficiency and overload are among the most common nutritional 
disorders worldwide.  Therefore, systemic iron balance must be highly regulated to 
provide necessary iron while simultaneously preventing iron toxicity associated with 
excess iron.  A 25 amino acid peptide hormone, hepcidin, primarily synthesized in the 
liver, functions as the main sensor of iron in the body (16, 17) and is the dominant 
regulator of dietary iron absorption and iron release from macrophages (18).  Hepcidin 







triggering its internalization and degradation in lysosomes (19, 20).  Ferroportin is the 
only known iron exporter from the intestinal epithelium to the plasma.  Removal of 
ferroportin from the cell surface prevents the export of iron and increases cytosolic iron 
stored in ferritin (15, 21).  Export of iron to the plasma through the basolateral membrane 
of enterocytes by ferroportin requires the oxidation of Fe2+ to Fe3+ by the membrane 
bound, multi-copper ferroxidase, hephaestin.  In the absence of hephaestin, iron remains 
within the mucosa and cannot be exported (15).  The exported iron is then chelated by 
apo TF in the plasma.  Similarly, during iron recycling from senescent red blood cells, 
iron export through ferroportin requires oxidation by the ferroxidase, ceruloplasmin in 
macrophages.   
The expression of hepcidin is influenced by various proteins involved in iron 
homeostasis including hemojuvelin (HJV), bone morphogenic protein (BMPs), 
transferrin receptor-2 (TFR-2), TF, and the hereditary hemochromatosis protein (HFE); 
all of which are related to iron overload disorders.  The intricate process by which these 
proteins regulate hepcidin expression has recently been reviewed (15, 22, 23).  In 
summary, increased hepcidin expression leads to decreased ferroportin levels and 
decreased plasma iron.   
In addition to these mechanisms, iron balance is controlled through the iron 
regulatory element/iron regulatory protein (IRE/IRP) system.  Several proteins involved 
in iron metabolism are regulated in this manner.  They contain IREs in either the 3’ or 5’ 
untranslated regions (UTR) of their mRNA.  Proteins with a 5’ IRE include ferritin, 5-







mitochondrial aconitase.  Proteins with 3’ IREs include transferrin receptor-1 (TFR-1), 
DMT-1 and human cell division cycle protein 14A (24).  The location of the IRE dictates 
whether the regulation by IRP binding is positive or negative.  Ferritin contains a 5’ IRE 
and binding of an IRP blocks the assembly of the ribosomal machinery thus inhibiting 
ferritin synthesis when iron storage is unnecessary (25).  TFR-1 contains a 3’ IRE and 
binding of IRP-1 stabilizes the message increasing translation of TFR-1 under low iron 
conditions.  There are two IRPs, 1 and 2; IRP-1 can accommodate an Fe-S cluster under 
high iron conditions.  When this occurs, IRP-1 functions as an aconitase, interconverting 
citrate and isocitrate, and is unable to bind the IRE, thus leading to degradation of the 
mRNA.  IRP-2 does not contain an Fe-S cluster and is regulated under high iron 
conditions by rapid proteosomal degradation (22, 24).  Mice lacking both IRP-1 and IRP-
2 die at an early age, however single knockout mice (of either IRP) survive indicating 
that the two IRPs may be somewhat redundant in function (26-29).  In summary, under 
low iron conditions, IRPs bind to both TFR-1 and ferritin mRNA, causing an 
upregulation of TFR-1 synthesis and downregulating ferritin synthesis.  Conversely, 
under excess iron conditions, the IRPs do not bind to the IREs resulting in degradation of 
the TFR-1 mRNA and promotion of ferritin synthesis by allowing the ribosomal 
machinery to assemble on the message.  These two major regulatory systems, the 
hepcidin/ferroportin and the IRE/IRP systems must communicate to maintain cellular and 







Iron and Transferrin Associated Diseases 
Iron Deficiency: Anemias 
Iron deficiency is the most common nutritional deficiency in Western countries, 
affecting up to 11% of women and 4% of men in the United States (30).  The three most 
common types of anemia are: anemia of iron deficiency, anemia of chronic disease (also 
known as anemia of inflammation) and anemia of critical illness (31, 32).  The primary 
form is anemia of iron deficiency caused by a lack of iron for heme synthesis which 
results in smaller than normal red blood cells (mycrocytic) containing a reduced amount 
of hemoglobin (hypochromic) (33).  Blood loss is the most common source of iron 
deficiency and is nearly always due to occult bleeding from the gastrointestinal (GI) tract.  
The leading cause of GI bleeding worldwide is hookworm infection.  In premenopausal 
women, menstrual blood loss is the most common cause of iron deficiency.  Typically, 
iron deficiency is treated with oral administration of a ferrous sulfate tablet.  Anemia of 
chronic disease and anemia of critical illness are alleviated by treatment of the underlying 
disease with occasional blood transfusions and/or iron supplementation (32).      
Iron Overload: Hereditary Hemochromatosis 
Iron overload disorders occur when the amount of iron absorbed by the body 
exceeds the capacity of TF.  Patients with hereditary hemochromatosis (HH) present with 
iron stores up to ten times the normal level.  This overload causes iron accumulation in 
parenchymal tissues and can lead to severe tissue damage, liver cirrhosis and fibrosis and 
multi-organ failure.  HH is the most common autosomally inherited genetic disorder in 







which are recessive and one which is dominantly inherited.  The result of types 1-3 
(recessively inherited) is inadequate production of hepcidin.  Type 1 HH is caused by 
mutations in HFE and is the most prevalent form of HH.  The penetrance ranges from 
1:400 to 1:10,000 and is much higher in men than in women (34).  The most common 
mutation in HFE is C282Y which prevents the association of HFE with β2-microglobulin 
(β2m) and trafficking of the complex to the membrane.  A second mutation, H63D is 
sometimes associated with iron overload, especially in conjunction with C282Y (15).  
Type 1 HH typically leads to liver cirrhosis, fibrosis and diabetes.  Type 2 HH is caused 
by mutations in HJV causing juvenile hemochromatosis which is often fatal by the third 
decade.  Juvenile hemochromatosis presents with cardiac and endocrine dysfunction, 
rather than liver disease.  Type 3 HH is caused by mutations in TFR-2 and is the slowest 
progressing form of HH.  Lastly, type 4 HH is dominantly inherited and is caused by 
mutations in ferroportin.  The defect results in either poor trafficking to the cell 
membrane causing iron accumulation in macrophages and low TF saturation or resistance 
to hepcidin-induced internalization leading to iron accumulation in hepatocytes and high 
TF saturation (21, 35-37).  HH is generally treated by phlebotomy or through iron 
chelation therapy such as subcutaneous infusions of deferoxamine (or more recently oral 
iron chelators such as deferiprone).  Desferrioxamine B (DFO) is a stronger iron 
chelating agent than hTF, however the half-life of iron removal from hTF by DFO is ~1 










Atransferrinemia (also referred to as congenital hypotransferrinemia) is an 
extremely rare recessive inherited disease characterized by low or undetectable levels of 
TF in the plasma.  It was first described in 1961 and has only been documented in 11 
patients from 9 different families.  The molecular basis of this disease has only been 
characterized in four of the patients (39 and references therein).  The age of onset is 
typically infancy to early childhood.  Accumulation of toxic levels of iron in tissues is the 
underlying pathology of the disease (40).  Iron accumulation is found in the liver, thyroid, 
heart and kidneys.  Individuals suffering from atransferrinemia have severe hypochromic, 
mycrocytic anemia, suffer from pallor and fatigue, and do not respond to iron therapy 
(41).  Individuals absorb iron quite well from the diet, however it is taken up by cells as 
non-TF bound iron which is inefficient compared to uptake through the TF/TFR cycle 
(42).  A spontaneous mutation identified in mice resembles human atransferrinemia.  The 
almost complete lack of iron in these hypotransferrinemic mice (Trf hpx/hpx) is the 
consequence of a spontaneous mutation resulting in a splice site of the Trf mRNA 
(encoding for TF) with a 27 base-pair in frame deletion (43, 44).  These mice also have 
the highest levels of iron absorption of any mouse model (45).  Atransferrinemia is lethal 
in these mice if they are not treated immediately with serum, exogenous TF, or red blood 
cell transfusions (44).   If treatment is stopped after 4 weeks of age, the mice can survive, 
but are small and pale compared to littermate controls.  Mice sacrificed at 8 to 9 months 







model highlights the importance of a functional TF cycle to effectively deliver iron to 
cells.    
The Transferrins 
Discovered over half a century ago, the transferrins (TFs) are a class of bilobal 
glycoproteins found in a variety of fluids in both invertebrates and vertebrates (46-48).  
TF-like proteins have been identified in primitive vertebrates such as lamprey, hagfish, 
and frogs and in invertebrates such as crab, tarantula and some insects (49, 50).  The two 
major functions of the TFs are iron transport and sequestration.  Members of the TF 
family are responsible for transporting iron from sites of absorption (small intestine) to 
sites of utilization in cells of virtually all tissues; effective iron delivery is essential for 
normal erythroid development (51).  The ability of the TFs to tightly bind Fe3+ (Kd = 10-
22 M) thereby keeping it soluble in aqueous solution has been extensively studied (52).  
TF family members share a high degree of sequence and structural homology; notably, 
the iron binding ligands are conserved throughout species and within family members 
(49).  Iron is coordinated in an octahedral geometry by two tyrosines, one histidine, one 
aspartic acid and two oxygen atoms from the synergistic anion, carbonate, which is 
anchored in place by an arginine residue.  The residues involved in iron release are less 
conserved lending to different iron release properties between closely related family 
members.  Table 2 shows a sequence alignment of key residues in each lobe in the three 
main family members including serum transferrin (sTF), ovotransferrin (OTF) and 
lactoferrin (LTF).  It is believed that the TFs all evolved from a common ancestor, an 







bilobal nature of TF is believed to have arisen from a gene duplication and fusion event 
of an ancient monolobal TF ~314 million years ago (53).  However, a recent evaluation 
of the phylogenetic tree suggests that the duplication producing ancestral TF and 
melanotransferrin occurred earlier than the branching of the urochordates (>570 million 
years ago) (54).  Although quite similar, the family members differ in their affinity for 
iron, mechanism of iron release, and their ability to bind to specific TFRs on the cell 
surface.   
Serum Transferrin 
 
Human serum transferrin (hTF, siderophilin) is the second most abundant protein 
in the plasma and circulates at a concentration of ~25-50 µM.  The hTF present in the 
plasma is only ~30% saturated with iron with a distribution of 27% diferric, 23% 
monoferric N-lobe, 11% monoferric C-lobe, and 40% apo (55, 56).  It was first isolated 
over 50 years ago and shown to be the major iron carrying protein in the plasma (46).  
hTF is synthesized by hepatocytes and secreted into the blood stream (57-59).  hTF can 
bind two molecules of Fe3+ with high affinity at neutral pH (10-22 M (52)).  Obviously 
this binding must be reversible for hTF to deliver iron to cells.  Although the primary 
function of hTF is to bind iron absorbed from the gut and deliver it to cells, hTF has other 
functions.  Its role is to protect Fe3+ from hydrolysis, thus preventing it from reacting 
with molecular oxygen and damaging cells through Fenton reactions. All dividing cells 
require iron; iron delivery by hTF is needed to sustain the activity of ribonucleotide 
reductase, the only enzyme that converts ribonucleotides to deoxyribonucleotides (the 







Table 2.  Sequence alignment of key residues in hTFa, OTF and LTF 
 
Function hTF OTF LTF 
 
N-lobe 
Asp63 (NI)b Asp60 Asp60 
Tyr95 (NII) Tyr92 Tyr92 
Tyr188 (NII) Tyr191 Tyr192 
Iron Binding 
Ligands 
His249 (NII) His250 His253 
    
Synergistic Anion 
Anchor Arg124 (NII) Arg121 Arg121 
    
Lys206 (NII) Lys209 Arg210cDilysine Trigger 
Motif Lys296 (NI) Lys301 Lys301 
 
C-lobe 
Asp392 (CI) Asp395 Asp395 
Tyr426 (CII) Tyr431 Tyr435 
Tyr517 (CII) Tyr524 Tyr528 
Iron Binding 
Ligands 
His585 (CII) His592 His597 
    
Synergistic Anion 
Anchor Arg456 (CII) Arg460 Arg465 
    
Lys534 (CII) Gln541 Lys546 
Arg632 (CI) Lys638 Asn644 Triad Motif 
Asp634 (CI) Leu640 Asn646 
 
a hTF refers to human serum TF. 
b Subdomain of hTF in which each residue is located is indicated in parentheses. 











 Additionally, hTF is capable of binding other metal ligands and because it is 
~30% saturated with iron, the opportunity to coordinate other metals is possible.  hTF has 
been shown to bind the main group metals, Bi3+, Ga3+, In3+, Al3+ and Tl3+; transition 
metals, Mn2+, Cu2+, Ni2+, Zn2+ and Ru3+ and lanthanide ions such as La3+, Ce3+, Nd3+, 
Sm3+ and Gd3+.  hTF can also bind Cr3+, Co2+ and Cd2+ (60 and references therein).  
Binding and transport of these other metals may ultimately serve as a therapeutic 
(delivery of Ru3+, Ti4+ or Pt2+ as anticancer drugs) or as a diagnostic tool since Al3+ 
toxicity has been observed in the brains of Alzheimers Disease patients and TF may be 
responsible for trafficking it across the blood brain barrier (60-62) although this idea 
remains controversial. 
Ovotransferrin 
First isolated over 50 years ago from avian egg white, OTF, was initially called 
conalbumin because it binds tightly to albumin (63, 64).  Further ethanol fractionation 
procedures were required to separate it from albumin (65).  OTF, synthesized by the 
oviduct, is the second most abundant protein in egg white comprising ~15 % of total 
protein (64).  OTF is a product of the avian sTF gene; however it differs from sTF in its 
carbohydrate content and regulation of expression (66, 67).  OTF plays a protective role 
by serving as an antioxidant and antimicrobial agent by sequestering iron thus making it 
unavailable for invading microbes which require iron for proliferation (68, 69).  Despite a 
high degree of structural and sequence homology with hTF (52% identical and 66% 








LTF is found in exocrine secretions such as milk, tears and mucus as well as 
intracellularly in leukocytes.  This member of the TF family possesses antibacterial, 
antimycotic, antiviral, antineoplastic and anti-inflammatory activity (70).  LTF acts 
primarily as an antimicrobial agent by sequestering iron with a higher affinity and 
retaining it at pH values much lower than hTF (pH 3.0-4.0 for LTF vs. pH 5.0-6.0 for 
hTF).  The bacteriostatic role of LTF is evident in human milk; breast-fed infants are less 
susceptible to infections than formula fed infants due to the high concentration of LTF 
(50).  Although all three molecules (hTF, OTF and LTF) are structurally similar, LTF 
does not appear to play a significant role in iron transport (71-76).  Both hTF and LTF act 
in concert with each other to sequester iron in two different environments; hTF functions 
in the serum, lymph and cerebrospinal fluid and LTF functions in exocrine secretions.  
The cationic nature and extremely high isoelectric point (pI ~9) allow LTF to bind DNA 
and possibly function in transcriptional regulation (77-80).  Despite ~44% homology with 
hTF, the residues involved in iron release from the N- and C-lobes (see below) are not 
conserved in LTF (Table 2), thus maintaining its role as an iron sequestering agent and 
not as an iron transport protein (81).   
Melanotransferrin 
 
Melanotransferrin (MTF) is a member of the TF family that was first identified 
almost 30 years ago as a cell surface marker of melanoma and termed melanoma tumor 
antigen p97 (82).  Since its discovery, MTF expression has been observed in the liver, 







capable of binding only one ferric ion in its N-lobe (86).  Hence, MTF does not appear to 
play an essential role in iron metabolism and its exact function remains unknown (87-90).  
Suggestions for MTF function include a role in chondrogenesis, angiogenesis, cell 
migration, invasion, metastasis, tumorigenesis and the regulation of plasminogen 
activation (83).  A Zn(II) binding motif has been identified in the inter-lobe region of 
MTF (91).  Unlike other TFs, MTF is a membrane bound protein (92).  Interestingly, 
increased levels of a soluble MTF have been reported in the plasma of patients with 
Alzheimers disease (93).     
Other Transferrin-like Molecules 
Additional members of the TF superfamily have been identified that share 
sequence and possible structural homology to the TFs, but do not appear to play a role in 
iron metabolism (49, 54).  For example, a TF family member called saxiphilin was 
identified in bullfrogs and functions to transport a neurotoxin called saxitoxin (94).  
Additionally, an inhibitor of carbonic anhydrase (ICA) was identified (95); as its name 
implies, it inhibits certain carbonic anhydrase (CA) isoforms.  The presence of ICA 
(indicated by CA inhibitory activity) has been detected in the serum of mice, rats, rabbits, 
cats, dogs, sheep and pigs (96).  A specific gene encoding ICA has been found in pigs, 
mice, rats, cows and dogs, but not in marsupials, monotremes, avians or fish (96).  
Interestingly, in humans and apes, the gene encoding ICA contains a premature stop 
codon and has been annotated as a pseudogene (97).  Through strategic site-directed 
mutagenesis, the iron binding capability of the N-lobe of mouse ICA (mICA) was 







mICA is structurally similar to hTF.  Additionally, the CA inhibitory activity of this 
mutant was not disrupted, strongly indicating that the C-lobe is responsible for inhibition 
of CA, as further demonstrated by limited trypsin proteolysis experiments with pig ICA 
(96).  Other TF family members include the major yolk protein of sea urchins, pacifastin 
in crayfish and triplicated TF-1 in algae (54).  
Transferrin in the Body 
Transferrin Synthesis and Regulation 
The TF gene is located on human chromosome 3, which also contains the genes 
for other proteins involved in iron metabolism including, LTF, MTF and the TFR.  The 
first exon of TF encodes a signal peptide which is necessary for the secretion of TF out of 
hepatocytes and into the plasma (98, 99) and is cleaved to the mature protein which is 
found in circulation.  Glycosylation of TF takes place in the endoplasmic reticulum prior 
to secretion (100).  TF is also synthesized in other tissues such as Sertoli cells in the 
testes (101), and behind the blood brain barrier (in oligodendrocytes, choroid plexus cells 
and the cerebellum (102-104)).  Additionally, TF synthesis has been documented in 
placenta, stomach, spleen, heart, kidney and lactating mammary glands (104, 105).  
Peripheral blood mononuclear lymphoid cells have also been shown to express TF (106, 
107).  TF synthesis is regulated by various factors; for example, when iron is limited to 
newly hatched chicks, there is an increase in both transferrin mRNA and protein 
synthesis (58).  These levels return to control levels upon administration of iron saturated 
ferritin (58).  Estrogen treatment increases the rate of TF synthesis in the liver.  When 







increase TF mRNA synthesis 3.2 fold (57).  Other mechanisms affecting liver TF 
synthesis include cell density, dexamethasone, human growth hormone, retinoids, and 
temperature (50).   
The Transferrin Cycle 
In order for cells to utilize the iron bound to TF in the plasma; TF undergoes 
clathrin dependent receptor mediated endocytosis (Figure 1).  At the extracellular pH 
(7.4), diferric hTF binds to the TFR with nM affinity (108).  The complex is engulfed in a 
clathrin coated pit which fuses with an endosome.  Through a mechanism involving a 
proton pump, the pH within the endosome is lowered to ~5.5 (109, 110).  The acidic 
environment of the endosome results in protonation of the synergistic anion and of key 
residues within the iron binding cleft releasing iron to as yet unidentified chelator.  Apo 
hTF remains bound to the TFR (with nM affinity) at low pH and is recycled back to the 
cell surface where it dissociates from the TFR back into circulation to bind more Fe3+ 
(111, 112).  The entire cycle takes 2-3 minutes and TF goes through 100-200 endocytic 
cycles in its lifetime (113).  Upon the release of Fe3+ from hTF, it must be reduced to Fe2+ 
for export by endosomal DMT1.  Recently, the ferrireductase, STEAP3 was identified in 
the endosomal membrane of erthyroid cells.  It appears that STEAP3 is the enzyme 
responsible for the reduction of Fe3+ to effectively transport iron out of the endosome 
through DMT1 (114, 115).  Alternatively, it has recently been documented that in the 
monoferric C-lobe hTF/TFR complex, the reduction potential of the bound iron is raised 










Figure 1. Receptor Mediated Endocytosis 
 
TF binds to the TFR at pH 7.4 and undergoes clathrin dependent endocytosis.  The pH 
within the endosome is lowered to ~5.6 upon which iron is released, the iron is likely 
reduced and exported out of the vesicle through DMT-1 where is it utilized by the cell or 














feasible (116).    Following release and reduction, the iron must travel to the 
mitochondria where it is utilized in the biosynthesis of heme by ferrochelatase.  This is 
the final and rate limiting step (obtaining Fe2+ from hTF) in the heme biosynthetic 
pathway (117).  The protein, mitoferrin, in the mitochondria is responsible for iron 
import.  It has been suggested that the endosome may physically contact the mitochondria 
and pass off the iron (117, 118) although this transfer has not been definitively shown.  
This recycling endosomal system (in which apo TF remains bound to the TFR) is unique.  
It is more common for ligands such as asialoorosomucoid and insulin to dissociate from 
their respective receptors and get targeted to lysosomal vesicles (111).  Thus the intact 
complex recycles back to the cell surface and TF escapes degradation within a lysosome 
and is used again to deliver more iron (112). 
Transferrin Structure 
General  
The primary structure of TFs is comprised of ~700 amino acids (~80 kDa) divided 
into two homologous lobes that share 40% identity and 50% similarity.  Each lobe, N- 
and C-lobe, can be further broken down into subdomains (NI, residues 1-92 and 247-331; 
NII, residues 93-246; CI, residues 339-425 and 573-679; CII, residues 426-572 (hTF 
numbering) (76)) which form a deep iron binding cleft within each lobe (Figure 2).  The 
two lobes are connected by a short peptide linker (residues 332-338).  A common feature 
of all TF family members is the large conformational change(s) that take place upon the 
binding and release of iron in each lobe.  A crystal structure of apo hTF was recently 
solved highlighting lobe opening (Figure 3).  The two subdomains of the N-lobe pivot 







iron binding cleft (73, 76, 119).  Structural studies of the N-lobe indicate that it undergoes 
a twist and a bend around the hinge upon iron binding (120).  The C-lobe also undergoes 
a large conformational change opening 49.5o upon removal of iron.  The C-lobe hinge 
region is longer than the hinge found in the N-lobe.  Unlike the N-lobe hinge, which lies 
adjacent to an anti-parallel β-sheet, the strands nearest the hinge region in the C-lobe are 
unstructured, and one of them is completely missing (76).  In combination with the 
greater number of disulfide bonds in the C-lobe (11 disulfides compared to 8 in the N-
lobe), opening of the cleft in the C-lobe would be predicted to involve a more rigid 
motion of the CI and CII subdomains than observed for the N-lobe. 
Spectral Characteristics 
Iron bound TF is characteristically salmon pink in color with a visible absorption 
maximum centered around 470 nm.  This visible maximum occurs as a result of a ligand 
to metal charge transfer (LMCT) band between the Fe3+ and the phenolate groups of the 
two liganding tyrosine residues (121).  Original evidence of a LMCT complex with 
phenolate groups came from Raman scattering studies (122).  Raman and electronic 
spectrum of diferric hTF were similar to standard spectra of Fe(EDDHA)- which contains 
two phenolate groups, providing evidence of the involvement of two tyrosine residues in 
the iron binding site (122).  This LMCT causes a disruption of the π to π* transition 
energy of the liganding tyrosine residues which results in an increase in the UV 
absorbance that extends and overlaps the intrinsic tryptophan fluorescence (123, 124).  
Disruption of iron coordination (through mutagenesis of the binding ligands) alters the 








Figure 2. Diferric Serum Transferrin 
   
Structure of pig serum TF (PDB ID: 1H76).  The subdomains are colored as follows: NI 
(red), NII (blue), CI (yellow), CII (green).  The Fe3+ ions are represented by orange 








 Figure 3. Apo Serum Transferrin 
 
Structure of human serum TF (PDB ID: 2HAU).  The subdomains are colored as follows: 
NI (red), NII (blue), CI (yellow), CII (green).  The degree of domain opening is indicated 







The intrinsic parameters, λmax and the ratio of the A280/Amax, are typically measured and 
indicate the degree of iron saturation and/or iron coordination to provide a quick 
assessment of possible alterations in the iron binding center as a result of an introduced 
mutation.  The intrinsic fluorescent properties of hTF arise from eight tryptophan 
residues (three in the N-lobe, five in the C-lobe) with some contribution from one or 
more of the Tyr residues.  The bound iron quenches the Trp fluorescence by overlapping 
with the absorption band produced by the metal-protein interaction.  The Trp residues in 
iron bound hTF are quenched 70% compared to apo-hTF (123).  Upon iron removal, TF 
undergoes large conformational changes which release the iron and alter the environment 
surrounding the Trp residues resulting in an increase in the intrinsic fluorescence signal 
(123).  We have recently determined the relative contribution of each of the Trp residues 
in hTF to the iron release signal (124, 126).  Both a decrease in absorbance and an 
increase in fluorescence have been used to monitor iron release from TF (124, 127-134). 
Iron Binding Ligands  
The amino acid ligands that bind iron are well dispersed in the primary sequence 
of TF making it impossible to accurately predict precisely which residues were involved 
in the interaction.  The crystal structure of diferric LTF was solved just over 20 years ago 
and provided the definite answer to this long standing question (71).  Although it was 
widely suggested that the coordination to the iron involved tyrosine, histidine, and 
possibly tryptophan residues, it was not until this crystal structure that the aspartic acid 
ligand was identified and the involvement of any tryptophan residue was ruled out.  The 







comparison to other metalloproteins in which the liganding residues are typically close in 
sequence (135).  The requirement for a synergistic anion, carbonate, to achieve iron 
binding to hTF was established by Bates and coworkers more than 30 years ago (136).  
As shown in Figure 4 and Figure 5, the ligands are identical in the two lobes of hTF; 
Asp63 from NI (Asp392 from CI), Tyr95 from the edge of the NII subdomain (Tyr426 
from the edge of the CII), Tyr188 from NII (Tyr517 from CII), His249 from hinge 
bordering NI (His585 from hinge bordering CI) and two oxygen atoms from the 
synergistic carbonate anion which is anchored in place by Arg124 from NII (Arg456 
from CII).  Although there are structures of human iron bound N-lobe, the crystal 
structure of full-length diferric hTF has not been solved.  The only structure of the human 
C-lobe with iron bound in the cleft is an unrefined 3.3 Å structure (137).  Therefore, the 
diferric structure of the homologous pig TF (71% sequence identity) has been used to 
model the iron binding site of the human C-lobe (75).  These liganding residues are 
completely conserved between hTF, LTF and OTF (Table 2) (71, 72, 75, 137).  Mutation 
of any of these residues in the isolated N-lobe disrupts the iron binding properties of hTF.  
In the hTF N-lobe, substitution of Asp63 by Ser, Glu, Asn or Ala resulted in significant 
blue shifts in UV-vis λmax indicating altered/weakened interactions in the iron binding 
center.  This is also observed by faster rates of iron release from these mutants (138, 
139).  As purified, the mutants were yellow in color (characteristic of a missing ligand), 
however the samples became pink in color upon addition of NTA, which can substitute as 







 Figure 4. N-lobe Iron Binding Site 
 
Amino acid residues involved in iron coordination are shown in green.  The synergistic 
anion, carbonate (which is anchored by an Arg) (salmon) completes iron coordination.  
Iron is represented by a red sphere.  Figure generated using Pymol (125) from the iron 







 Figure 5. C-lobe Iron Binding Site 
 
Amino acid residues involved in iron coordination are shown in green.  The synergistic 
anion, carbonate (anchored by an Arg) (salmon) completes iron coordination.  Iron is 
represented by a red sphere.  Figure generated using Pymol (125) from the iron bound pig 







The two liganding tyrosine residues are inequivalent; Tyr188 is absolutely essential for 
iron binding, whereas Tyr95 exhibits weakened iron binding, but is not abolished (140).  
Both the characteristic spectroscopic properties and iron release kinetics were altered (but 
not abolished) in Y95F compared to the wild type hTF N-lobe.  The Y188F hTF N-lobe 
mutant was incapable of binding iron at all as exhibited by lack of any color and of a 
detectable λmax.  Lastly, mutation of His249 resulted in altered spectral and iron binding 
properties similar to the Asp63 mutants.  N-lobe hTF mutants of His249 exhibit 
characteristics of loss of a liganding residue, but NTA can fill the coordination sphere 
around the iron and substitute as a ligand.  In summary, Tyr188 is essential for iron 
binding and mutation of His249 leads to greater destabilization of the iron binding cleft 
than mutation of Asp63 or Tyr95.   
The equivalent iron binding residues have been studied in the C-lobe of hTF 
(133).  These studies were carried out in two full length constructs to specifically monitor 
iron release from the C-lobe; a recombinant monoferric C-lobe construct (FeC hTF) and a 
recombinant diferric construct with iron locked in the N-lobe (LockN hTF).  (To date, 
several attempts to produce isolated C-lobe have either failed completely or produced 
very small amounts of protein (141, 142)).  As reported by Mason et al. (133), mutation 
of Asp392 or His585 resulted in altered spectral properties; in fact the visible maximum 
was so broad it could not be determined accurately.  Additionally, iron release from both 
the D392S and H585A mutants was enhanced relative to the appropriate control 
constructs at both pH 5.6 and 7.4.  No indication of iron binding was observed for the 







Tyr426 mutant (equivalent to Tyr95 in the N-lobe), no signature iron binding visible 
maximum was observed (133).   
Many of the studies discussed above also analyzed the immediate iron 
environment by electron paramagnetic resonance (EPR) studies which provides a 
characteristic EPR signature for hTF.  Studies on mutants of the iron binding residues 
revealed striking differences in the EPR spectrum compared to the wild-type lobe 
indicating a disruption of the coordination and the local environment surrounding the 
iron.   
Second Shell Residues 
The iron binding ligands interact through an intricate hydrogen bonding network 
with other amino acids, termed the “second-shell” (73, 119, 143).  As shown in Figure 6 
and Figure 7, each of the ligands is further stabilized by the second-shell residues.  The 
second shell residues in the N-lobe are Gly65, Glu83, Tyr85, Arg124, Lys206, Ser248 
and Lys296.  The homologous residues in the C-lobe are Glu410, Tyr412, Arg456, 
Lys534, Arg632 and Asp634.  Mutation of any of these residues generally has profound 
effects on iron release (144-148).  Mutation of Tyr85 to Phe results in much faster release 
of iron from the isolated N-lobe of hTF (147).  This second-shell mutation results in loss 
of a hydrogen bond between Tyr85 and Lys296.  Tyr85 is also hydrogen bonded to 
Glu83, and loss of Glu83 by mutation to alanine causes His249 to move away from the 
iron binding cleft (147).  Specifically, Glu83 forms a hydrogen bond with His249 placing 







 Figure 6. N-lobe Second Shell Residues 
 
Second shell residues in the hTF N-lobe (PDB ID: 1A8E).  Second shell residues shown 
in green with the dilysine trigger highlighted in orange.  The iron binding ligands are 
shown in white for reference.  Iron is represented by an orange sphere.  Hydrogen bond 







 Figure 7. C-lobe Second Shell Residues 
 
Second shell residues in the pig TF C-lobe (PDB ID: 1H76), human numbering indicated.  
Second shell residues shown in green with the triad highlighted in orange.  The iron 
binding ligands are shown in white for reference.  Iron is represented by an orange 








The synergistic carbonate anion is anchored in place by Arg124 in the N-lobe (Arg456 in 
the C-lobe).  It was determined that neither the anion nor the metal bound tightly to hTF 
or LTF in the absence of the other (136, 149).  All mutants of Arg124 feature accelerated 
iron release rate constants (129, 146, 150, 151).  Crystallographic studies have shown that 
Arg124 and the bound carbonate can adopt two different conformations, termed near and 
far (73).  By mutating Tyr45ÆGlu or Leu66ÆTrp, the Arg can be forced into the far or 
near positions, respectively; crystal structures and kinetic studies of these mutants reveal 
the importance of Arg124 in anion binding to TF (152).  When Arg124 is forced into the 
far conformation (Y45E), the rate of iron release is enhanced 30-fold compared to wild 
type because of stabilization of a water channel that provides access to protons to the 
carbonate and chelator access to the iron thereby destabilizing the carbonate interaction 
with iron.  Conversely, when Arg124 is forced into the near conformation (L66W), the 
bulky Trp side chain projects into the water cavity restricting access to the carbonate 
anion; iron release is 20-fold slower than wild type (152).  Ser248 is located in the hinge 
region of the N-lobe and appears to be involved in the pivoting when the cleft opens or 
closes.  Mutation to Ala (S248A) results in a sluggish rate iron release which is explained 
by the restricted domain rotation (153). 
The most important residues comprising the second shell network in both the N- 
and C-lobes are the dilysine trigger in the N-lobe (Lys206 and Lys296, Figure 6) and a 
triad of residues in the C-lobe (Lys534, Arg632 and Asp634, Figure 7).  These residues 
are involved in the mechanism of iron release and their differences largely account for the 







al. in OTF, Lys206 and Lys296 (hTF numbering) share a low-barrier hydrogen bond at 
neutral pH (154).  In order for this to occur, one of the lysines must be deprotonated 
much below its natural pKa ~10.  Molecular modeling studies suggest that Lys206 has a 
low pKa and Lys296 has a high pKa (155).  These residues are 2.3 Å apart in the iron 
bound structure of hen OTF (3.04 Å apart in the iron bound hTF N-lobe structure) and 
reside in opposite subdomains (NI and NII).  They are stabilized in a hydrophobic 
environment through cation-π interactions with neighboring tyrosine residues (154).  It is 
believed that protonation of one or both lysines at the low pH within the endosome 
(where iron is released from TF) results in a repulsion between the two and begins the 
process of cleft opening.  Many mutagenesis studies have probed the dilysine pair (148, 
156-158).  Mutation of Lys206 to Glu (K206E) produces a construct which locks iron in 
the N-lobe by forming a salt bridge between Glu206 and Lys296.  This construct is 
termed LockN hTF and is useful in biochemical studies to monitor iron release from the 
C-lobe when the N-lobe is in a closed conformation (131, 133, 157). 
In the C-lobe of hTF the dilysine pair is replaced by a triad of residues, Lys534-
Arg632-Asp634 (154).  Unlike the dilysine pair in the N-lobe, Lys534 (equivalent to 
Lys206) and Arg632 (equivalent to Lys296) appear to be too far apart in the iron bound 
pig TF structure to share a hydrogen bond; they are bridged by hydrogen bonding with 
Asp634 (Figure 7).  Mutation of Lys534 or Arg632 to alanine results in extremely slow 
iron release from the C-lobe of hTF (131).  Given that the negative charge on Asp634 
would be predicted to stabilize the positive charges on Lys534 and Arg632, we originally 







constant for iron release.  However, as determined by time-based steady state 
fluorescence, we reported that the D634A mutant exhibits an extremely slow rate of iron 
release, (even in the presence of the sTFR) (81, 131).  This will be further discussed in 
Chapter 3.  Although this triad is conserved in many other sTFs, it is not conserved in 
OTF and LTF (Table 2).  The lack of a dilysine trigger in the N-lobe and the triad in the 
C-lobe partially explains the differences between hTF and LTF in their iron binding and 
release properties.  LTF binds iron with higher affinity and does not release it as readily.  
As such, its primary function is iron sequestration and not transport.  The dilysine trigger 
is conserved in the N-lobe of OTF, but the triad is not conserved in the C-lobe.  To 
investigate the importance of the charge and geometry of the amino acids at these 
positions in the C-lobe, the triad from LTF (Lys-Asn-Asn) and from OTF (Gln-Lys-Leu) 
was substituted into hTF (81).  As a result, iron release from the LTF triad mutant was 
dramatically slowed compared to hTF, however, rate of iron release from the OTF triad 
mutant was similar to the hTF control.  
Interestingly, immediately preceding Lys296 in the N-lobe and Arg632 in the C-
lobe is a structurally unusual γ-turn which may orient these residues to provide the most 
efficient trigger mechanism.  The turn consists of Leu-Leu-Phe (residues 293-295 and 
629-631) and has been identified in all TF structures to date.  The middle Leu in each of 
these turns falls into the disallowed region of a Ramachandran plot making it an 









Kinetically Significant Anion Binding Sites (KISAB) 
It is well established that the presence of salt affects the iron release properties of 
each lobe.  Specifically, residues termed kinetically significant anion binding (KISAB) 
sites (159) have been identified in each lobe of hTF.  In the N-lobe, Arg124, as well as 
the dilysine pair (Lys206-Lys296) have been identified as KISAB sites.  Of the pair, 
Lys296 is the primary binding residue while Lys206 has a secondary role (148, 150).  In 
the C-lobe, studies showed that a positive charge in the middle position of the triad is 
responsible for anion binding, thus identifying Arg632 as a KISAB site (81).  It is 
probable that several other, as yet to be identified, residues may serve as KISAB sites and 
a recent molecular modeling study has provided some insight into potential sites in the N-
lobe of hTF (160).       
Glycosylation 
hTF contains two conserved asparagine-linked glycosylation sites in the C-lobe 
(Asn413 and Asn611).  The primary structures of the glycans are: 1) of the N-
acetyllactosaminic type, 2) either biantennary or triantennary and 3) are fully sialyated 
and not fucosylated (161).  Three variants are present in normal serum as either having 
two biantennary glycans, two triantennary glycans or one of each at either site.  The 
majority (80-84%) of TF in the serum has two biantennary glycans (162).  There is no 
evidence that the carbohydrate variants affect function.  No apparent role for 
glycosylation of hTF has been determined and several studies have reported that 
enzymatically deglycosylated or recombinantly produced nonglycosylated hTF binds iron 







pathologies linked with TF glycosylation, carbohydrate-deficient TF (one or two 
isoforms of TF which lack their terminal trisaccharide) is used as a marker of alcoholism 
(166).  Because TF is synthesized and excreted by the liver and the liver is the primary 
organ affected by alcohol abuse, the enzymes responsible for carbohydrate synthesis are 
affected by over consumption of alcohol.  It has been suggested that acetaldehyde (the 
product of ethanol metabolism by alcohol dehydrogenase in the liver) mediated inhibition 
of the enzymes responsible for glycosyl transfer is the underlying mechanism related to 
this TF abnormality (166).  
The location and number of glycan groups differ among family members.  LTF 
has two carbohydrates; one in the N-lobe (Asn138) and one in the C-lobe (Asn479) (167) 
and OTF contains only a single carbohydrate in the C-lobe (Asn473) (168).   
Disulfides 
There are 38 cysteine residues in TF, all of which are engaged in disulfide bonds 
(Table 3).  Both rabbit and human TF N-lobes contain 8 disulfides while the C-lobes have 
11.  Interestingly, TF from pig has 7 disulfides in the N-lobe and 11 in the C-lobe.  LTF 
and OTF have only 6 disulfides in the N-lobe with 10 and 9 in the C-lobe, respectively 
(135).  The large number of disulfide bonds make the structure of TF rigid.  Additionally, 
recombinant production of TF in bacteria is challenging because bacteria lack the 
reducing environment needed to form disulfide bonds and do not express folded, 
functional protein.  We have developed and optimized a mammalian expression system 







Table 3. Disulfide bonds 
 




Cys9 (NI) --- Cys48 (NI) 
2 Cys19 (NI) --- Cys39 (NI) 
3 Cys118 (NII) --- Cys194 (NII) 
4 Cys137 (NII) --- Cys331 (linker) 
5 Cys158 (NII) --- Cys174 (NII) 
6 Cys161 (NII) --- Cys179 (NII) 
7 Cys171 (NII) --- Cys177 (NII) 
8 Cys227 (NII) --- Cys241 (NII) 
  
9 Cys339 (linker) --- Cys596 (CI) 
10 Cys345 (CI) --- Cys377 (CI) 
11 Cys355 (CI) --- Cys368 (CI) 
12 Cys402 (CI) --- Cys674 (CI) 
13 Cys418 (CI) --- Cys637 (CI) 
14 Cys450 (CII) --- Cys523 (CII) 
15 Cys474 (CII) --- Cys665 (CI) 
16 Cys484 (CII) --- Cys498 (CII) 
17 Cys495 (CII) --- Cys506 (CII) 
18 Cys563 (CII) --- Cys577 (CII) 







The Transferrin Receptor 
The TFR is essential to the iron delivery process.  As described above, diferric 
hTF binds to the TFR on the cell surface, the complex is internalized in a clathrin coated 
pit, and iron is released from TF to be utilized by the cell.  Two isoforms of TFR have 
been identified, TFR-1 and TFR-2.  TFR-1 (henceforth be referred to as TFR) is the 
primary receptor involved in iron uptake and is critically involved in erythropoiesis and 
neuronal development (169).  Knockout mice missing both TFR alleles (TFR-/-) died 
before embryonic day 12.5 (169).  TFR-2 is involved in iron homeostasis and sensing 
body iron levels as mentioned above and is described in further detail below.   
Gene Regulation  
The gene encoding the TFR has been mapped to chromosome 3 (170).  Rapidly 
dividing cells, especially reticulocytes (which require large amounts of iron for 
hemoglobin synthesis) exhibit high levels of TFR expression on the cell surface.  Non-
replicating cells typically have low levels of the TFR at the cell surface and mature red 
blood cells which lack nuclei have no TFR.  The expression of the TFR gene is regulated 
in an iron dependent manner.  The TFR mRNA contains multiple IRE stem-loop 
structures in the 3’ UTR.  As described above, IRP-1 can incorporate an Fe-S cluster 
which acts as an iron sensor.  When the Fe-S cluster is complete (high iron conditions), 
IRP-1 cannot bind to the IRE and it functions as a cytoplasmic aconitase.  In this situation 
TFR expression is down regulated (22).  Under low iron conditions, IRP-1 binds to the 








Structural Features           
The TFR is a 760 amino acid, ~180 kDa homodimeric class II membrane receptor 
(171).  Each monomer is composed of three domains; a cytoplasmic N-terminal domain 
(residues 1-61), a membrane spanning region (residues 62-88) and a large extracellular 
ectodomain (residues 89-760); residues 89-121 form a stalk that separates the large, 
globular extracellular portion from the membrane.  The structure of the butterfly-shaped 
extracellular domain is shown in Figure 8 (172).  The ectodomain itself is comprised of 
three domains; a helical domain (responsible for dimerization, residues 607-760), a 
protease-like domain (residues 122-188 and 384-606) and an apical domain (189-383) 
(172).  The TFR undergoes many posttranslational modifications on its journey to the cell 
surface, including: acylation with palmitate, phosphorylation of Ser24, N-linked 
glycosylation at Asn251, Asn317 and Asn727, as well as attachment of an O-linked 
glycan at Thr104.  Additionally, two intermolecular disulfide bonds form between Cys89 









Figure 8. Transferrin Receptor 
 
Structure of the ectodomain of the TFR (PDB ID: 1CX8).  Domains are colored as 
follows: apical (green), protease-like (blue) and helical (orange).  The stalk region has 

















The TFR contains only one O-linked glycosylation site, Thr104 near the 
transmembrane domain (175, 176).  Although the function of the glycan at this site is 
unknown, elimination of Thr104 did not lead to any significant abnormalities in 
transferrin binding or cellular distribution (177).  It is possible, however, that lack of 
glycosylation at this site may play a role in the generation of a soluble TFR found in 
plasma (177) (see below). 
The three N-linked glycans have been identified and appeared to be similar in 
both TFR isolated from placenta and TFR expressed in mouse NIH-3T3 cells; the 
Asn251 site showed a complex triantennary, trisialyated carbohydrate with a fucose core, 
the Asn317 site featured a sialyated hybrid oligosaccharide and the Asn727 site had a 
high mannose type carbohydrate (178, 179).  However, the precise composition of the 
oligosaccharide typically differs between cell types and species (165).  The function of 
each of these sites has been studied in vivo and in vitro (134, Appendix A).  
Contradictory results have been obtained regarding the function of Asn251; in one study 
it was shown to be important in protection against proteolysis of TFR to the soluble TFR 
(180), however in another study no proteolysis upon elimination of Asn251 was observed 
(181).  Both in vivo and in vitro studies show no involvement of Asn251 in TF binding 
and dimerization (134, 180).  The absence of carbohydrate at Asn317 revealed a possible 
role in the interaction between the TFR and the C-lobe of hTF at low pH in vitro.  The 
mutant lacking carbohydrate at this position clearly showed weaker binding affinity and 







the sTFR reveals that Asn317 is located near a hydrophobic patch (comprised of Trp641 
and Phe760) that has been shown to be involved in the interaction with hTF at low pH 
and to partake in receptor stimulated iron release (132).  Lastly, previous studies showed 
that glycosylation of Asn727 is critical to proper folding and transport of TFR to the 
plasma membrane (181, 182).  However, in vitro studies utilizing the recombinant 
soluble portion of the TFR (sTFR, described below) reveal no significant biochemical 
differences in a mutant lacking Asn727 in regards to dimerization, hTF binding or 
receptor stimulated iron release (134).   
Interaction with TF 
Although there is no high resolution x-ray crystal structure of the TF/TFR 
complex, a lower resolution cryo-electron microscopy (cryo-EM) model (7.5 Å) provides 
some insight into the interaction between these two proteins (183).  This model was built 
by first placing the crystal structure of the sTFR into the density map (172).  The two iron 
bound lobes of the TF molecule were modeled separately using structures of the iron 
bound hTF N-lobe and the iron bound C-lobe of rabbit serum TF (Figure 9) (73, 75).  
However, docking of the two lobes required a 9 Å shift of the N-lobe with respect to the 
C-lobe in order to fit into the density map.  Because no crystal structures of any diferric 
or apo-TF family member have revealed this shifted conformation, it was postulated that 







 Figure 9. Cryo-EM Model of the TF/TFR Complex 
 
TFR domains colored as in Figure 7.  hTF N-lobe (red), rTF C-lobe (yellow).  The 
orientation of the complex is shown with TF on the right and left of the sTFR dimer and 








From the model, the NI subdomain interacts with the helical domain of the TFR and the 
NII subdomain interacts with the protease-like domain and is situated between the TFR 
and the membrane.  The specific residues postulated to be important in the interaction are 
shown in Figure 10 and Table 4.  Both ionic and hydrophobic interactions between the N-
lobe and the TFR are predicted from the model.  As shown in Figure 11, the CI 
subdomain interacts with the helical domain of the TFR dimer while the CII subdomain 
does not make any contacts leaving it free to move unrestricted.  A network of salt 
bridges between the C-lobe of TF and the TFR are likely involved in complex formation 
(132, 183).  As shown in Table 4 and Table 5, many of the residues identified are 
conserved in other TFs which are known to bind to the human TFR and are not conserved 
in those that cannot bind the human TFR, further substantiating their importance in the 
interaction between hTF and the TFR (76).  The residues highlighted in purple are under 
active investigation by our laboratory (Chapter 4).  It is believed that the primary 
recognition site in hTF is in the C-lobe, however both lobes contribute to the binding 
energy and are necessary for high affinity binding and iron delivery to cells (133, 141, 
142, 184, 185).  Several independent studies indicate that the majority of the binding 
interaction takes place with the C-terminal helical domain of the TFR.  These studies 
include X-ray hydroxyl radical footprinting (186), site-directed mutagenesis of the TFR 
and SPR binding studies (187), use of chicken/human TFR chimeras (188) and 











Figure 10. N-lobe/TFR Interaction 
 
Close up of the residues identified in the cryo-EM model to be involved in the interaction 
between the N-lobe and the TFR.  TFR (gray), TFR protease-like domain (blue), N-lobe 
of hTF (red).  Residues on the TFR proposed to interact with the N-lobe (cyan).  Residues 
in the NII subdomain proposed to interact and actively being investigated in our 











Table 4. Potential residues in the N-lobe involved in the interaction with the sTFRa 
 
 NI NII 
Residueb 71 72 73 74 142 143 144 145 



















rTF G L T P P R K P 
pTF G L A P P R K P 
 



















cOTF G L A P I E S G 
hLTF G L A P P P E P 
 
a Table adapted from (76) 
b These residues were identified in the cryo-EM model of the TF/TFR complex (183). 
c (h) human, (r) rabbit, (p) pig, (b) bovine, (c) chicken 
d The residues in bold are conserved 
e The residues in purple are being actively investigated (Chapter 4) 








Figure 11. C-lobe/TFR interaction 
 
Close up of the residues identified in the cryo-EM model to be involved in the interaction 
between the C-lobe and the TFR.  TFR (gray), TFR helical domain (orange), C-lobe of 
hTF (yellow).  Residues on TFR proposed to interact (cyan).  Residues in the CII 
subdomain proposed to interact and actively investigated in our laboratory (purple).  













Table 5. Potential residues in the C-lobe involved in the interaction with the sTFRa
  
Residueb  350     355     360     365     370   
Bind human TFR 
hTFc Hd,e H E R L K C D E W S V N S V G K I E C V S A E
rTF H H E R L K C D E W S V T S G G L I E C E S A E 
pTF H E E T Q K C D A W S I N S G G K I E C V S A E 
Do Not Bind human TFRf
bTF H Q E R T K C D R W S G F S G G A I E C E T A E 
cOTF K D E K S K C D R W S V V S N G D V E C T V V D 
hLTF E Q E L R K C N Q W S G L S E G S V T C S S A S 
 
a Table adapted from (76) 
b These residues were identified in the cryo-EM model of the TF/TFR complex (183). 
c (h) human, (r) rabbit, (p) pig, (b) bovine, (c) chicken 
d The residues in bold are conserved 
e The residues in purple are being actively investigated (Chapter 4) 







A hydrophobic patch on the TFR (Trp641/Phe760) is important in receptor stimulated 
iron release and interaction with apo hTF at low pH.  Specifically, this patch interacts 
with His349, which was identified in the cryo-EM model as a potentially important 
residue in the interaction (132, 183, 187).  In summary, the precise molecular details of 
the interaction remain to be elucidated, but several studies have identified the helical 
domain of the TFR and the CI subdomain of TF to be of great importance to complex 
formation. 
The TFR differentially recognizes the four forms of TF (diferric hTF, monoferric 
N-lobe, monoferric C-lobe, and apo hTF) in a pH dependent manner (190).  Several 
different techniques have been used to analyze the affinity between these two proteins 
including cell binding experiments (with the intact TFR), surface plasmon resonance 
(SPR) and isothermal titration calorimetry (ITC), both utilizing the sTFR.  Briefly, the 
TFR binds diferric hTF with nM affinity at pH 7.4 and each monoferric hTF about 10-
fold weaker (132, 191).  At neutral pH, apo hTF does not compete for binding (133) 
however, at pH 5.6, apo hTF binds to the TFR with nM affinity (111, 112).  Binding of 
the isolated lobes of hTF has also been attempted.  At pH 7.4, the C-lobe alone binds 
weakly and the N-lobe does not bind at all (141, 142, 184).  This is further indication of 
the cooperativity between the lobes since both lobes are necessary to achieve high 
affinity binding.  Affinity studies at pH 5.6 utilizing SPR or ITC have been difficult to 
carry out most likely because the solubility of the sTFR at low pH is poor (unpublished 








Interaction with HFE 
In addition to interacting with TF, the TFR also interacts with HFE.  HFE is 
related to the class I major histocompatibility complex proteins (MHC) and must interact 
with β2m to be directed to the cell surface.  The C282Y mutation eliminates a disulfide 
bond in the α3 domain of HFE which prevents its interaction with β2m and cell-surface 
expression in a cell culture model (192).  The exact function of HFE in iron homeostasis 
is unknown, however, formation of a complex with TFR-2 regulates hepcidin mRNA 
levels.  The crystal structure of HFE bound to the TFR reveals information about the TF 
binding site (193).  The formation of the HFE/TFR complex is pH dependent; the 
complex forms with high affinity at neutral pH and not at all at pH 6.0 (194, 195).  
Binding of HFE to the TFR does not alter the structure of HFE, however it appears that 
there is a rearrangement in the helical domain of the TFR.  It was postulated that this 
binding event might be propagated across the membrane to the cytoplasmic tail of the 
TFR and communicate the presence of bound HFE (193).  Biochemical studies show that 
HFE and TF can form a ternary complex with TFR (HFE and TF bind on opposite 
monomers of the TF dimer) and that binding of HFE prevents binding of TF (on the same 
monomer) suggesting overlapping binding sites for the two molecules only at neutral pH 
(194-197).  The association of HFE with the TFR decreases the affinity of the TFR for 
TF (196).  
Transferrin Receptor-2 
A second isoform of the TFR (designated TFR-2) is primarily expressed in liver 







have been identified in TFR-2 which result in decreased hepcidin expression and type 3 
HH; thereby firmly establishing its role in iron metabolism (199).  The TFR-2 
ectodomain is 45% identical and 66% similar to the TFR-1 ectodomain, however their 
internalization signals differ and they share no sequence similarities in their cytoplasmic 
domains (198).  TFR-2 can bind diferric TF at neutral pH and apo TF at acidic pH, but 
with 30-fold lower affinity than TFR-1 (200, 201).  The binding of diferric TF to TFR-2 
increases the half-life of TFR-2 3.5 fold but the mRNA levels remain unchanged; an 
affect which appears to be hepatocyte specific (202, 203).  As described above, TFR-2 
also interacts with HFE, however in a study using the soluble forms of both TFR-2 and 
HFE no binding was detected.  In a cell culture study with full length membrane bound 
components, TFR-2 and HFE exhibited a strong affinity for one another suggesting a 
mechanism for iron sensing between TFR-2, HFE and diferric TF (200, 204).  Co-
expression of HFE and TFR-2 in TRVb-CHO cells (which lack endogenous HFE and 
TFR) led to increased affinity for diferric TF and increased iron uptake from TF (205). 
Soluble Transferrin Receptor  
A soluble form of the TFR has been identified in plasma.  This was first identified 
through reaction with monoclonal TFR antibodies and, significantly, the concentration of 
the soluble TFR appeared to correlate with the rate of erythropoiesis (206, 207).  The 
soluble TFR is generally released from tumor cells, reticulocytes and erythroblasts (208-
211) and is generated through proteolytic cleavage near the cell surface to release the ~85 
kDa extracellular fragment containing residues 101-760 (212).  Studies have found that 







TFR giving rise to the soluble TFR (177).  Additionally, treatment of cells with 
neuraminidase, to remove sialic acid residues, increases the cleavage of the TFR (213).  
The soluble fragment is found circulating in the plasma bound to TF (214).  As 
determined by studying a variety of human red blood cell disorders, the concentration of 
the soluble TFR increases in iron deficient conditions (214, 215).  Specifically, patients 
with iron-loading anemias and ineffective erythropoiesis showed an increase in the 
concentration of soluble TFR compared to healthy controls (216).        
Mechanism of Iron Release 
The in vivo process of iron release via receptor mediated endocytosis has been 
described in detail above.  Iron release from hTF is a very complex process that is 
influenced by a variety of factors including pH, ionic strength, chelator, lobe-lobe 
interactions and the interaction between hTF and the TFR.  Obviously, it is difficult to 
measure each of these parameters separately as they are all interrelated.  In an effort to 
understand how this process works at the molecular level, a number of groups over many 
years have attempted to determine how each of these factors independently affects iron 
release. 
pH Effects 
The transferrin cycle and delivery of iron to cells is a pH dependent process.  Iron 
binds tightly to TF at neutral pH and is readily released at the acidic pH encountered in 
an endosomal vesicle (~5.6).  Much experimental data shows that the rate of iron release 
increases with decreasing pH (131, 139, 156, 217, 218).    Additionally, one study 







mechanisms above and below this transition point and was different for the two 
monoferric species (219).  Critical to the iron release process are protonation events that 
occur at low pH to initiate cleft opening and iron release.  It is believed that protonation 
of the synergistic carbonate anion is the first step in iron release (73, 152, 220).  
Additionally, protonation of the dilysine “trigger” in the N-lobe drives the N-lobe into an 
open conformation facilitating the release of iron to a chelator (154).  The triad of 
residues present in the homologous position in the C-lobe is also likely protonated which 
disrupts the hydrogen bond bridging network and induces a more open conformation in 
the C-lobe, facilitating attack by an incoming chelator (131). 
There is a complicated correlation between pH and ionic strength (described 
below) on the iron release process.  At pH 7.4, iron release from the isolated N-lobe is 
retarded with increasing concentrations of salt.  The opposite is observed at pH 5.6 where 
there is a hyperbolic increase in the rate of iron release with increasing salt.  Interestingly, 
at the intermediate pH 6.1, the rate of iron release increases at lower concentrations of 
salt and then decreases at the higher concentrations of salt (150).  It was suggested that at 
low salt concentration, iron release is accelerated because the protein has ample ability to 
bind anion, but at higher concentrations of salt, the chloride dominates and competes with 
the chelator for binding to the protein, thus decreasing the rate of iron release (150).   
Anion Effects 
The anion effect on iron binding and release from TF has been the subject of 
much investigation.  The effect of increasing anion concentration varies in a lobe and pH 







synergistic.  Synergistic anions are defined as those which participate in and support high 
affinity iron binding.  The synergistic anion, carbonate, is essential for high affinity iron 
binding as it donates two oxygen atoms as ligands.  In the absence of carbonate (or a 
suitable substitute), Fe3+ will not bind to TF (136).  It was determined that the synergistic 
anion must contain a carboxylic acid group which interacts with the protein and another 
functional electron donating group that lies within 6.3 Å of the iron and is able to 
coordinate it (136).  Additionally, the carbonate anion is the first to be protonated upon 
lowering the pH and initiates cleft opening and iron release.  Although carbonate is the 
natural synergistic anion, oxalate can also promote iron binding however, due to the 
bidentate nature of the interaction with iron, release of iron from hTF is difficult and 
uptake of iron by cells is slowed or abolished when carbonate has been substituted with 
oxalate (221).  
Nonsynergistic anions affect iron release possibly by inducing conformational 
changes which are necessary for iron release (222).  The absolute requirement of anion 
binding for iron release to occur was reported by Raymond and coworkers (223).  In the 
absence of iron, the binding of nonsynergistic anions to TF can be observed by a variety 
of spectroscopic techniques including EPR, NMR and UV difference spectra.  
Equilibrium constants for binding of several different anions to TF have been determined 
by these techniques and is well summarized in a review from the Sadler laboratory (60).  
In iron bound TF (in the absence and presence of the TFR), nonsynergistic anions bind to 







concentrations of salt at pH 5.6.  In the absence of salt, little iron release is observed 
(223).   
Role of Chelators in Iron Release 
In the absence of chelator, iron release from hTF at pH 5.6 has a half life greater 
than 3 hours (and is even slower at pH 7.4).  Given that the time frame for iron release for 
one cycle of endocytosis is 2-3 minutes, a chelator must be present to overcome this 
discrepancy.  Although a chelator within the endosome has not been definitively 
identified, candidates include citrate, pyrophosphate and ATP.  The rate at which iron is 
released from TF is dependent on the chemical nature of the chelators used.  Studies 
using a variety of chelators to either donate iron to TF or remove iron from TF were 
initiated by Bates and colleagues (224-227).  Since these initial experiments, several 
different types of natural (siderophores) and synthetic chelators have been studied.  These 
include EDTA, NTA, citrate, acetohydroxamic acid (AHA), pyrophosphate (PPi) and 
phosphonates, as well as hydroxymates, catecholates, hydroxycarboxylates and 
terephthalamide based chelators (135, 153 and references therein).  The relative affinity 
of the chelator for iron and not the size of the chelator appears to be what confers its 
ability to remove iron from TF or donate iron to it.  The chelators listed above acquire 
iron from TF through either a first order linear pathway, a hyperbolic saturation pathway 
or a dual pathway that follows saturation kinetics at low concentration of chelator and is 
linear at higher concentrations of chelator (153).  It has been proposed that a 
conformational change in the protein is the rate limiting step in chelator mediated iron 







EDTA, for example) exists during the process independent of chelator concentration.  
However, due to the complexity of the iron release profiles with other chelators, 
especially PPi, a dual pathway is necessary to fit the data (228).  A recent paper discusses 
the effect of ligand structure on the pathway of iron release and summarizes the 
prevailing kinetic models addressing saturation, first-order and combined pathways 
(229). 
Lobe-Lobe Interactions 
One of the most important and complicated aspects of iron release from TF is the 
cooperativity between the N- and C-lobes.  Iron release from either lobe is influenced by 
the iron status of the opposite lobe.  It has been shown that iron release from the C-lobe is 
enhanced when metal is bound in the N-lobe, but that the iron status of the C-lobe has 
only a small effect on the rate of iron release from the N-lobe at pH 7.4 (127, 128).  
However, these effects change depending on pH and chelator used (128).  Interactions 
between the two lobes of LTF and OTF are also well documented indicating 
cooperativity throughout the TF family (72, 230, 231).  Several different techniques have 
been used to show this cooperative effect including NMR of hTF (232), calorimetric 
studies of hTF and OTF (233), absorption spectra of OTF (234), urea gel analysis (235, 
236) and chemical relaxation studies (237, 238).  Helix 12 in the C-lobe has been 
implicated by several of these studies to participate in lobe-lobe interactions (52, 239).  
However, based on crystal structures, this helix does not undergo any significant changes 
between apo, monoferric and diferric forms (76).  This is probably due to the absence of 







and aids in the communication between them.  The interface between the two lobes is 
largely hydrophobic however, two possible salt bridges between the lobes were identified 
in the apo structure (Asp240--Arg678 and Arg308--Asp376) (76).  Differences in rate 
constants using Co(III) “locked” constructs (240) and more recently authentic “locked” 
constructs (Chapter 3) in the presence and absence of the TFR reveal unequivocally that 
there is cooperativity between the lobes during iron release.  We have recently shown that 
at pH 5.6, iron release from the C-lobe is unaffected by the iron status of the N-lobe 
while iron release from the N-lobe is altered when iron is locked in the C-lobe (Chapter 
2) (236).  Additionally, the conformation of an iron free N-lobe is stabilized when the C-
lobe contains iron (241).  Analyzing cooperativity between the lobes in the presence of 
the sTFR adds another level of complexity to the interpretation of the data.     
The Role of Receptors 
As described earlier, the TFR is critical for iron delivery to cells.  The four 
species of hTF bind to the receptor with different affinities in a pH dependent manner.  
Many studies have shown the stimulatory effect that the TFR has on iron release from the 
C-lobe (81, 132, 134, 240, 242).  Although previous studies suggested that the TFR has 
very little impact on the rate constant for iron release from the N-lobe (240, 242, 243), 
more recent data suggests that the TFR actually slows the rate of iron release from the N-
lobe making it more equivalent to that of the C-lobe so that iron release from Fe2 hTF 









Models of Iron Release 
The details of the mechanism of iron release from the N-lobe have been studied 
more extensively than the C-lobe, however a similar series of events likely takes place in 
the C-lobe.  It has been suggested that the first step of iron release involves protonation of 
the carbonate anion with simultaneous movement of Arg124 (73).  This movement 
initiates cleft opening allowing protons access to the dilysine pair comprising the trigger.  
Upon protonation of the dilysine trigger, the two residues repel each other to open the 
cleft allowing a chelator to enter.  A molecular dynamics study of the hTF N-lobe by 
Rinaldo and Field highlights the importance of protonation of the dilysine trigger, but 
states that the repulsion between the lysines may not be sufficient to trigger cleft opening.  
Instead, they propose that Lys206 becomes protonated which repels Lys296, which then 
transfers a proton to liganding Tyr188 and weakens the hold on the iron (155).  
Investigation of the iron release mechanism from the C-lobe has more recently been 
investigated (81, 131).  As described above, the dilysine trigger is not conserved in the C-
lobe, instead a triad of residues is found in the homologous position (154).  Again, 
disruption of this hydrogen bond network may trigger cleft opening and allow chelator 
access to the iron binding center.  The triad differs between hTF, OTF and LTF leading to 
the hypothesis that some of the differences in iron release properties between these 
family members results from differences in the triad residues.  The three family members 
(hTF, OTF and LTF) have also been studied and compared by chemical relaxation 
techniques (218, 237, 238).  It was shown that both hTF and OTF take up a similar 







rates.  However, LTF differed mechanistically from hTF and OTF in the steps leading to 
iron release.  
Protein Expression and Purification 
Recombinant Production of hTF and the sTFR 
 Recombinant expression of hTF is challenging due to the 19 disulfide bonds 
which must be properly joined to yield functional protein.  Attempts at producing the N-
lobe of hTF in E.coli were largely unsuccessful and properly folded protein was not 
obtained (244).  The N-lobe of hTF has been successfully expressed and characterized in 
a baculovirus system (maximum expression 20 mg/L) (245) and in the methylotrophic 
yeast, Pichia pastoris (maximum expression 230 mg/L) (246).  Although all three of 
these systems have been used, production in bacterial systems has yielded very little 
functional protein.  Additionally, for unknown reasons attempts to produce full-length 
hTF in the yeast system have not been successful (247).  The most successful system is a 
mammalian expression system, optimized by our laboratory, in which the cDNA for the 
N-lobe of hTF was first placed in the eukaryotic expression vector, p-NUT, for 
expression in baby hamster kidney (BHK) cell culture (244, 248).  The construct in the p-
NUT vector is under the control of the mouse metallothionein promoter and contains the 
natural signal peptide of hTF.  The p-NUT vector contains a mutated dihydrofolate 
reductase gene which has a 270-fold lower affinity for the competitive inhibitor 
methotrexate (MTX) making selection with MTX possible (249).  The robust production 
of the hTF N-lobe (55-120 mg/L) (250) has laid the groundwork for extensive research to 







studies have provided insight into the residues involved in iron binding and release as 
well as interactions with the sTFR.  The addition of a hexa-His tag on either the N- or C-
terminus of full length hTF was investigated (251) and both glycosylated and 
nonglycosylated hTFs have been expressed and characterized (165).  Since the early 90’s, 
full length diferric hTF, monoferric hTFs, locked hTFs and authentic apo hTF and 
numerous mutants have been expressed (131, 251, 252).  Although expression of the 
isolated N-lobe has been very successful, expression of the isolated C-lobe has not.  It 
appears that the C-lobe requires the presence of the N-lobe to pull it through the 
translational machinery and to properly fold.  A new approach with an engineered 
tobacco etch virus protease cleavage site in the hinge region connecting the two lobes has 
provided promising preliminary results.   
Until a few years ago, full length, membrane bound TFR was isolated from 
placenta (~2-6 mg/placenta) and required the use of detergent to maintain solubility 
(253).  Recombinant sTFR has been successfully produced in a baculovirus/insect cell 
system (~14 mg/L) (197), far exceeding the previously reported expression in Chinese 
hamster ovary cells (2 mg/L) (172).  We have expressed an N-terminal hexa-His tagged 
sTFR in our BHK cell system at levels comparable to the baculovirus system (>12 mg/L) 
(134).  The ability to produce and purify the sTFR in large quantities has allowed an 
exponential growth of knowledge regarding the function of hTF and the interaction with 
the sTFR.  We are able to elucidate how the two proteins interact and how the sTFR 







To produce these proteins, BHK cells are grown in Dulbecco’s Modified Eagle’s 
Medium, Ham F-12 (DMEM) with 10% fetal bovine serum (FBS) and are subsequently 
transfected with 10 µg of the appropriate plasmid DNA by the calcium phosphate 
precipitation method (255).  After 24 hours, selection with 500 µM MTX begins.  
Plasmid containing cells survive MTX selection and are initially grown in 100 mm 
dishes, passaged to T150 flasks using trypsin and Versene with final passage into 1750 
cm2 expanded surface roller bottles.  Medium, DMEM F-12 containing 10% FBS is 
changed twice at two day intervals.  The final three batches are grown in DMEM F-12 
containing the serum substitute Ultroser G (UG) at a level of 1% and 1 mM butyric acid 
(BA); this medium is changed three times at two to three day intervals.  It has been 
shown that UG and the addition of BA increases recombinant protein production (252).  
To assess the quantity of protein secreted to the medium, a competitive solid phase 
immunoassay is used.  Originally carried out as a radioimmunoassay (165, 256), 
biotinylated hTF has been substituted for radiolabeled hTF.  Briefly, removawells are 
coated with rabbit anti-mouse IgG.  After several washes, a dilution of the appropriate 
monoclonal antibody (specific to the N-lobe, C-lobe or TFR) is added to all wells except 
those used to determine nonspecific binding.  The wells are incubated and then washed.  
Biotinylated hTF or sTFR is added in the presence and absence of unlabeled standards 
and samples and a standard curve is generated by the competition between the 
biotinylated and unlabeled hTF or TFR.  After another incubation and washing, avidin-
HRP conjugate, which binds to the biotinylated samples, is added to the wells and 







system.  This reaction is quenched by the addition of 1 N phosphoric acid and the A450 is 
determined using a Molecular Dynamics plate reader (247).  Typical production levels 
range from 20-50 mg/L for Fe2 hTF, FeC hTF, FeN hTF, the sTFR and mutants thereof. 
Purification of Recombinant Proteins  
Almost all of the full length hTF and the sTFR constructs produced contain an N-
terminal hexa-His tag for ease of purification.  The constructs contain a factor Xa 
cleavage site for removal of the His-tag if needed.  To begin purification, the medium 
containing the secreted recombinant protein is filtered through a cotton plug to remove 
cell debris and then concentrated and exchanged using a tangential flow device with a 
cartridge which has a 30 kDa molecular weight cutoff membrane.  The volume is 
typically reduced from 1-4 liters to ~200 mLs in 1 hour.  The sample is brought to 1X 
with respect to start buffer (50 mM TRIS, pH 7.4, 300 mM NaCl, 20 mM imidazole, 10% 
glycerol and 0.05% NaN3) for purification over a Ni-NTA column.  The hexa-His tagged 
sample is pumped onto a Ni-NTA column at 2 mL/min using a Biocad Sprint system and 
eluted with start buffer containing 250 mM imidazole.  Fractions (3 mL) are collected 
and the peak is pooled, concentrated and exchanged into 0.1 M ammonium bicarbonate to 
eliminate imidazole, glycerol and other buffer components before passage over a 
Sephacryl S200HR 26-60 (for hTF samples) or S300HR 26-60 (for sTFR) gel filtration 
column.  The final protein is concentrated to a nominal 15 mg/mL using the appropriate 
absorption coefficient for iron bound hTF and mutants thereof as determined by the 
modified Edelhoch method (257).  Complexes of hTF/TFR are generated by incubating a 







HR gel filtration column to separate the TF/TFR complex from the excess unbound TF.  
All complexes are concentrated to 15 mg/mL with respect to hTF (126, 134, 254).     
Techniques to Measure Iron Release 
Steady-State Fluorescence 
Upon transitioning from iron bound (pH 7.4) to apo (pH 5.6), Fe2 hTF undergoes 
a ~400% increase in Trp fluorescence emission (97) as shown in Figure 12.  As described 
above, bound iron is a strong quencher of Trp fluorescence and thus removal of iron 
increases the emission of the Trp residues in hTF (123).  We have recently analyzed the 
steady-state emission profiles of Trp mutants of hTF to determine the contributions of 
each of the individual Trp residues to the increase in the iron release signal (124, 126).  
Aisen and colleagues pioneered a time-based steady state fluorescence assay to monitor 
iron release from hTF over a specific time course in the presence or absence of the TFR 
(258).  This technique has been used in several studies (81, 129, 130, 132-134, 259), but 
limitations exist.  The rates of iron release from mutants which release iron quickly are 
difficult to capture by this method and kinetic assays in the presence of the TFR are both 







 Figure 12. Steady-state Emission Scan of Fe2 hTF 
 
Steady-state emission scan of Fe2 hTF (500 nM) iron bound (red curve) and apo (black 
curve).  Sample was excited at 280 nm and emission was monitored between 300-400 nm 










Although the time-based steady-state technique has provided much insight into 
the iron release process from hTF, as mentioned, it is limited in its ability to capture rapid 
iron release events that are associated with particular mutants and the presence of the 
sTFR, especially when monitoring iron release from the C-lobe of hTF.  To allow capture 
of these fast events and improve our understanding of iron release from hTF and from 
various hTF/sTFR complexes, we have utilized a sensitive stopped-flow fluorescence 
spectrofluorimeter (Applied Photophysics SX.18MV).  This instrument provides data 
with a high signal to noise ratio allowing precise fitting of progress curves and 
observation of kinetic events that have not been observed with the less sensitive steady-
state format.  The basic principles and advantages of the stopped flow technique are: 1) 
rapid mixing of sample with “effector”; 2) 1-2 ms dead time (i.e. can detect fast events); 
3) low concentration of sample needed; 4) small volumes required; and 5) the ability to 
collect multiple data sets sequentially from the same starting material.  In comparison, the 
steady-state technique requires self-mixing of sample with the “effector”, a diffusion 
limited timescale and more sample in a larger volume for a single determination (124, 
134, 243, 254, 260).  The progress curves of iron removal (as monitored by an increase in 
the intrinsic fluorescence) are fit to a single-exponential function (y = A1*exp(-x/t1) + 
y0); double-exponential function (y = A1*exp(-x/t1) + A2*exp(-x/t2) + y0); or triple-
exponential function (y = A1*exp(-x/t1) + A2*exp(-x/t2) + A3*exp(-x/t3) + y0) as 









As described above, a decrease in the absorbance ~470 nm can be monitored as 
iron is released from hTF.  Prior to the availability of the more sensitive fluorescence 
instruments, absorbance was the primary technique used to monitor iron release.  The 
absorbance studies require considerably more protein and the change in absorbance is 
quite small.  We recently used data from stopped flow fluorescence and absorbance 
measurements to specifically assign two events during iron release from the isolated N-
lobe as iron release and a conformational change (124).  Stopped flow absorbance studies 
on full length hTF and hTF in complex with the sTFR have been far more technically 
challenging and to date, not reproducible. 
Urea Gel Electrophoresis 
Over 30 years ago, the serendipitous observation was made that 6 M urea gels 
could be used to distinguish the iron status of the two lobes of hTF (261).  Migration 
through these gels is influenced by the shape, charge and the disulfide content of the two 
lobes.  As shown in Figure 13, Fe2 hTF, migrates the farthest into the gel before being 
denatured by the urea; because this is the most compact form of hTF.  The least compact 
form, apo hTF is denatured soon after exposure to the 6 M urea and remains near the top 
of the gel.  The N- and C-lobes migrate at differing intermediate positions in part due to 
the different number of disulfide bonds, 8 in the N-lobe and 11 in the C-lobe making the 
C-lobe more rigid and somewhat less susceptible to denaturation when it is open (as in 
FeN hTF).  Since their discovery, many studies have used urea gels to monitor the effect 







 Figure 13. Urea Gel Standards of the Four TF Forms 
 
6 M urea gel showing the different migration patterns of the four forms of hTF. 






















We have recently published a study (Chapter 2) utilizing urea gels to qualitatively 
compare how lobe conformation, pH and the sTFR affect iron release from the two lobes 
of hTF (236). 
Verification of the Source of the Iron Release Signal 
The steady-state and stopped flow techniques described above rely on changes in 
the intrinsic tryptophan fluorescence from hTF.  A potential problem arises when 
monitoring iron release from an hTF/sTFR complex is that the Trp residues in the sTFR 
may contribute to the change in fluorescence.  There are 11 Trp residues per sTFR 
monomer making it reasonable to suggest that they might also undergo changes in their 
local environments and contribute to the fluorescent signal.  To address this issue, we 
undertook the challenge of incorporating the tryptophan analog, 5-hydroxytryptophan (5-
HTP) into both FeC hTF and the sTFR (254, Appendix B).  5HTP can be selectively 
excited at longer wavelengths (Excitation at 315 nm vs. 280 nm for native Trp) than Trp 
and thus the 5-HTP signal can be completely distinguished from the native Trp signal.  
Although complete incorporation was not achieved, we were able to convincingly 
selectively excite the two molecules.  Making complexes of FeC hTF/sTFR, 5-HTP FeC 
hTF/sTFR, FeC hTF/5-HTP sTFR and 5-HTP FeC hTF/5-HTP sTFR we determined that 
the Trp residues in the sTFR do not contribute to the change in fluorescence upon iron 
removal from FeC hTF at pH 5.6.  This important finding substantiates the use of steady-









Other Techniques to Probe Iron Release 
Other techniques are used to monitor iron release from hTF and deserve brief 
mention here.  Chemical relaxation studies by el Hage Chahine and colleagues have 
provided insight into the specific number of protonation events that take place during iron 
removal.  This technique has been used to study and compare hTF to OTF and LTF (as 
well as carrying out these experiments with hTF bound to the TFR).  Although complex, 
the thorough analysis in these studies has allowed identification of the number of 
protonation events that occur in hTF and in the hTF/TFR complex due to the low pH of 
the endosome.  These events take place before the more global conformational changes 
that we monitor (218, 237, 238, 243, 267).   
The dynamics of acid induced conformational changes associated with iron 
release have been investigated using electrospray ionization mass spectrometry (ESI-MS) 
(241, 268, 269).  For example, in the absence of chelators, there is a dissociation of the 
hTF N-lobe-Fe3+-carbonate complex as the pH is decreased and the iron remains bound 
until the pH is lowered to ~4.5 (despite the dissociation of the anion) at which point a 
large portion of the protein is unfolded.  In contrast, in the presence of citrate as a 
chelator, iron release is more facile at higher pH values (closer to endosomal pH 5.6) and 
unfolding is not observed.  Removal of iron from the C-lobe requires a reduction in pH 
below 4.5.   
Changes in mass as a result of hydrogen/deuterium exchange have been used to 
analyze the degree of “openness” of the hTF N-lobe.  Specifically, two mutants of the N-







releases iron slowly), were compared to native apo N-lobe and iron bound N-lobe.  It was 
found that the double mutant was open to an intermediate degree between the apo G65R 
mutant and the native apo N-lobe (270).  Additionally, the presence of NTA was detected 
in the G65R mutant indicating that at least one form of the G65R mutant formed a ternary 
complex (protein-metal-NTA).  The presence of carbonate and bicarbonate ternary 
complexes were also detected indicating the powerful application of ESI-MS to detect the 
precise nature of the ternary complex (270).    
Lastly, although static in nature, crystallographic studies of apo and Fe-bound 
hTF constructs and several mutants thereof have provided insight into the global 
conformational changes that take place upon iron release.  These structures have provided 
information with regard to the degree of cleft opening and about interaction both within 
and between lobes.  A table summarizing these characteristics from structures of hTF, 
LTF and OTF has recently been published (135).            
Purpose and Scope 
Due to its central role in iron metabolism, transferrin has been studied 
extensively.  Although a significant amount of progress has been made in elucidating the 
overall mechanism of iron release, the precise details remain unclear.  The use of 
recombinant technology and site-directed mutagenesis have allowed us to evaluate the 
importance of residues specifically involved in iron binding and those involved in iron 
release.  A variety of techniques including absorbance and fluorescence spectroscopy, 
urea gel analysis and crystallography have been utilized to examine the effects of various 







allowed us to “visualize” events that occur during iron release that were not possible with 
less sensitive instrumentation.  
In this dissertation, we utilize a series of recombinant full length constructs 
including diferric (Fe2 hTF), authentic monoferric constructs (FeN hTF and FeC hTF), 
locked constructs (LockN hTF and LockC hTF) as well as the necessary controls 
(authentic apo hTF and double locked hTF).  In addition to these hTFs we have expressed 
a recombinant form of the soluble portion of the TFR (sTFR).  The constructs listed 
above allow specific analysis of iron release from either the N- or the C-lobe with 
absolute control of the conformation and iron binding/release properties of the other lobe.  
We have investigated how the conformation of one lobe affects the iron release process 
from the opposite lobe (in the presence or absence of the sTFR).  The studies provided 
herein bring together many of the concepts and assertions that have been present in the 
field in a comprehensive manner.  By using these constructs and analyzing iron release 
with urea gels and steady-state fluorescence, we have further probed the cooperativity 
between the lobes and the sTFR, and the anion effect by stopped-flow kinetic analysis.  
This has helped unravel this complex process; by using this sensitive technique, we can 
assign rate constants associated with iron release to anion induced conformational 
changes and interactions between the lobes and with the sTFR.  Models for iron release 
from Fe2 hTF in the presence and absence of the sTFR are provided and include key 
events such as anion binding and conformational changes that result in lobe-lobe 







Preliminary studies of the interaction of hTF with the sTFR are presented; 
investigation of four residues in the N-lobe and three residues in the C-lobe for 
differences in iron release in the absence and presence of the sTFR as well as binding 
affinity studies will reveal more information about the interaction of this central complex 
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Iron release from human serum transferrin (hTF) has been studied extensively; 
however the molecular details of the mechanism(s) remain incomplete.  This is in part 
due to the complexity of this process which is influenced by lobe-lobe interactions, the 
transferrin receptor (TFR), the salt effect, the presence of a chelator and acidification 
within the endosome resulting in iron release.  The present work brings together many of 
the concepts and assertions derived from previous studies in a methodical, uniform and 
visual manner.  Examination of earlier work reveals some uncertainty due to sample and 
technical limitations.  We have used a combination of steady-state fluorescence and urea 
gels to evaluate the effect of conformation, pH, time and the soluble portion of the TFR 
(sTFR) on iron release from each lobe of hTF.  The use of authentic recombinant 
monoferric and locked species removes any possibility of cross contamination by 
acquisition of iron.  Elimination of detergent by use of the sTFR provides a further 
technical advantage.  We find that iron release from the N-lobe is very sensitive to the 
conformation of the C-lobe, but is insensitive to the presence of the sTFR or to changes 
in pH (between 5.6 and 6.4).  Specifically, when the cleft of the C-lobe is locked, the urea 
gels indicate that only about half of the iron is completely removed from the cleft of the 
N-lobe. Iron release from the C-lobe is most affected by the presence of the sTFR and 
changes in pH, but is unaffected by the conformation of the N-lobe. A model for iron 










Human serum transferrin (hTF) is a bilobal 80 kDa iron binding glycoprotein 
responsible for delivering iron to cells by clathrin dependent receptor mediated 
endocytosis. The single chain polypeptide folds into two homologous lobes (N- and C-
lobes) connected by a short peptide linker.  Each lobe is further divided into two 
subdomains (NI, NII and CI, CII) that come together to form the metal binding cleft.  The 
iron binding ligands are identical in the two lobes (a histidine, an aspartic acid, two 
tyrosines as well as two oxygen atoms from the synergistic anion, carbonate).  However, 
the mechanism and rate(s) of iron release differ between the N- and C-lobes,  due in large 
part to differences in the amino acids surrounding the liganding residues, termed the 
“second shell”  ((131) and references therein).  In healthy individuals, hTF is present in 
the serum at a concentration of 25-50 µM, but is only approximately 30% saturated with 
iron.  The distribution of the pool is 27% diferric, 23% monoferric N-lobe, 11% 
monoferric C-lobe, and 40% apo (55, 56).  The source of this uneven distribution is not 
completely understood.  At pH 7.4, diferric hTF preferentially binds to the hTF receptor 
(TFR) with nM affinity, the two monoferric species bind approximately 40 fold weaker 
(although each lobe contributes equally to the binding energy of the interaction with the 
TFR), and apo hTF does not compete for binding (133).  However, at the putative 
endosomal pH of 5.6, apo hTF remains bound to the TFR and is recycled back to the 
plasma membrane.    
The precise details of the steps by which iron is released from the two lobes of 







progress, some controversy exists with regard to the relative importance of various 
factors, which minimally include pH (protonation of various key residues in each lobe is 
an initial step within the endosome), ionic strength (anions or inert salt must be present 
for iron release to occur), the identity of a chelator (critical to extraction of the iron in the 
physiologically observed time frame of <3 min), and the TFR (111, 153).  The bilobal 
composition of hTF adds complexity by introducing cooperativity (negative or positive) 
between the lobes (127, 235, 271). What is clear is the crucial role of the second shell 
residues in the release of iron from each lobe. Thus, in the N-lobe, two lysine residues, 
Lys206 and Lys296 (residing on opposite sides of the binding cleft) comprise the 
“dilysine trigger”.  These two lysine residues share a hydrogen bond at neutral pH which 
is protonated at low pH and triggers cleft opening (148, 154).  Likewise in the C-lobe, 
Lys534 and Arg632 are found in positions that are homologous to Lys206 and Lys296 
(81, 131).  Mutation of Lys206 to glutamate in the N-lobe or Arg632 to alanine in the C-
lobe completely prevents iron release from that lobe on a relevant timescale allowing 
targeted measurement of iron release from the opposite lobe. 
In transitioning from a “closed” iron bound state to an “open” iron free state, the 
N- and C-lobes each undergo large conformational changes upon iron release (75, 76).  
The intrinsic tryptophan fluorescence of hTF increases dramatically upon iron removal 
and can be used to monitor iron removal from hTF (258).  Some of the eight tryptophan 
residues in hTF (3 in the N-lobe and 5 in the C-lobe) are strongly quenched by the bound 
Fe3+ through radiationless transfer of electronic excited-state energy (123). This energy is 







by the metal-tyrosine interaction.  Of course, tryptophan fluorescence is also sensitive to 
changes in the local environment around each residue, so it is possible to monitor 
conformational changes before and/or after iron release (272).  As an example, we have 
reported the contribution of each of the three tryptophan residues in the isolated N-lobe to 
the change in fluorescence when iron is released (124).  Similarly, we have described the 
role of each of the five tryptophan residues in the C-lobe (in the absence and presence of 
the sTFR) to the increase in fluorescence as a result of iron release at pH 5.6 (126).  
 Over 30 years ago, the serendipitous observation was made that 6 M urea gels 
could be used to distinguish the iron status of the two lobes of hTF (261).  Migration 
through these gels is influenced by the shape, charge and the disulfide bond content of the 
two lobes.  Thus diferric hTF, which is the most compact form of hTF, migrates the 
farthest into the gel before being denatured by the urea.  The least compact apo form 
(both lobes open) is denatured soon after exposure to the 6 M urea and stays near the top 
of the gel; in part due to the fact that the N-lobe has 8 disulfide bonds and the C-lobe has 
11, the two monoferric species migrate at differing intermediate positions.  Since their 
discovery, many studies have used urea gels to monitor the effect of a variety of factors 
on the iron status of hTF (52, 55, 165, 235, 262-266). 
In the present study, we have substantiated much previous work in a concise and 
semi quantitative manner using a unique combination of urea gels and steady-state 
fluorescence measurements to examine hTF and a complex of hTF bound to the soluble 
portion of the TFR (sTFR) as a function of lobe conformation, pH and time to qualitatively 







previously been limited by the availability of TFR from natural sources and the need for 
detergent to keep the TFR in solution (242, 253).  Availability of non-glycosylated 
recombinant diferric hTF (Fe2 hTF), authentic monoferric TFs (designated FeN hTF and FeC 
hTF), and constructs with either N-and/or C- “locked” lobes (designated LockN hTF and 
LockC hTF), as well as the sTFR allow a comprehensive assessment of the contributions of 
pH, the TFR and the conformation of each lobe to the release of iron.  As shown in Scheme 
1, use of these constructs allows a rational and precise assessment of pathway(s) available 
to transition from fully iron loaded, to monoferric, to fully iron free hTF.  The quality of 
the results obtained from commercially available urea gels is improved by the absence of 
carbohydrate in the recombinant hTF samples (the Asn linkage sites at positions 413 and 
611 in the C-lobe are mutated to Asp).  A model of iron release from diferric hTF is 
provided. The current work foreshadows our more quantitative work on this system by 
providing concepts and end points to generate the models we are developing by analysis 
of kinetic data from stopped flow fluorescence studies.  
Experimental 
Materials  
Dulbecco’s modified Eagle’s medium-Ham F-12 nutrient mixture (DMEM-F12), 
antibiotic-antimycotic solution (100X) and trypsin solution were from the GIBCO-BRL 
Life Technologies Division of Invitrogen.  Fetal bovine serum (FBS) was obtained from 
Atlanta Biologicals (Norcross, GA).  Ultroser G (UG) is a serum replacement from Pall 
BioSepra (Cergy, France).  Ni-NTA resin was purchased from Qiagen.  Corning 







from Fisher Scientific.  The Hi-Prep 26/60 Sephacryl S-200HR and S-300HR columns 
were from Amersham Pharmacia.  Amicon Ultra-4 (30 kDa cutoff) ultrafiltration 
concentrators were from Millipore.  Novex 6% TBE-Urea gels, 2X TBE Urea gel sample 
buffer and 5X TBE-Urea gel running buffer were from Invitrogen.  All other chemicals 
and reagents were of analytical grade.   
Protein production and purification   
The DNA manipulations used to generate Fe2 hTF, FeN hTF, FeC hTF, LockN 
hTF, LockC hTF (see abbreviations for detailed description of the residues that have been 
mutated to produce these constructs) and the sTFR have been described in detail 
previously (131, 134, 165, 252).  Briefly, to produce recombinant hTF and all of the 
mutants, baby hamster kidney (BHK) cells transfected with the pNUT plasmid containing 
the appropriate cDNA sequence are placed into two to four expanded surface roller 
bottles.  Adherent BHK cells are grown in DMEM-F12 containing 10% FBS.  This 
medium is changed twice at two day intervals, followed by addition of DMEM-F12 
containing the serum substitute UG (1%) and 1 mM butyric acid (BA).  The presence of 1 
mM BA has been shown to increase the production of recombinant protein from BHK 
cells (252).  The amount of protein produced is determined using a competitive 
immunoassay (247).  The His6-tagged recombinant protein from the tissue culture 
medium is captured by passage over a Ni-NTA column followed by final purification on 
a gel filtration column (S-200HR for hTF constructs and S-300HR for sTFR).  
Polyacrylamide gel electrophoresis in the presence of SDS was used to verify the 







concentration of 15 mg/mL using the published absorption coefficients determined by the 
modified Edelhoch method (257).  
Complexes of hTF/sTFR are prepared by combining sTFR with a small molar 
excess of hTF (Fe2 hTF, FeN hTF, FeC hTF, LockN hTF and LockC hTF) and isolated by 
passage over an S-300HR column (134).  Complexes were adjusted to a nominal 
concentration of 15 mg/mL with respect to hTF.   
Urea Gel Analysis 
The iron-binding status of the hTF constructs as a function of pH or time were 
examined by urea gel electrophoresis using Novex 6% TBE-urea mini-gels, run in 90 
mM Tris–90 mM borate, pH 8.4, containing 2 mM EDTA.  For pH titrations, samples (1 
µg/µL) were incubated for 15 minutes in 100 mM MES buffer ranging from pH 5.6-6.4 
(in increments of 0.2 pH units), also containing 300 mM KCl and 4 mM EDTA.  The 
reaction was stopped by addition of 2X TBE-Urea gel sample buffer (final concentration 
of sample 0.5 µg/µL).  The composition of the 2X sample buffer was  45mM Tris and 45 
mM borate, containing 1mM EDTA, 6% Ficoll  400,  0.005% Bromophenol Blue,  
0.025% Xylene cyanol and 3.5 M urea.  For time-based experiments, sample (1 µg/µL) 
was added to pH 5.6 iron removal buffer (100 mM MES, pH 5.6 containing 300 mM KCl 
and 4 mM EDTA) and incubated for the designated times (0, 3, 6, 12 and 15 minutes) at 
room temperature (note that time zero is the construct in sample buffer).  At each time 
point, the iron removal process was stopped by the addition of sample buffer as stated 
above and the sample was placed on ice (final concentration of sample 0.5 µg/µL).  This 







flow kinetic experiments (unpublished results).  Approximately 2.5 µg of sample was 
loaded per lane and the gels were electrophoresed for 2.25 h at 125 V.  Protein bands 
were visualized by staining with Coomassie blue.    
Steady State Fluorescence  
Steady-state fluorescence spectra were obtained for each sample using a 
Quantamaster 6 spectrofluorimeter from Photon Technology Int (South Brunswick, NJ).  
Iron bound protein (500 nM) was added to a cuvette (1.8 mL final volume) containing 
100 mM HEPES, pH 7.4.  An identical amount of sample was incubated for at least 15 
minutes in the appropriate pH iron removal buffer (as above) to generate apo protein.  
Samples were excited at 280 nm and emission was monitored between 300 – 400 nm.  
Slit widths of 1 nm (excitation) and 6 nm (emission) were used with a 320 nm cut-on 
filter in front of the emission monochromator.  All emission spectra were corrected for 
Raman scattering by subtraction of a buffer blank (124). 
Results 
Iron Release as a function of pH 
 To elucidate the pathway of iron release as a function of pH, each of the hTF 
constructs described below was incubated in 100 mM MES containing 300 mM KCl and 
4 mM EDTA at pH values ranging from 5.6 to 6.4.  In all cases, iron removal was 
evaluated by electrophoresis on 6 M urea gels that specifically show bands corresponding 
to apo, each monoferric and Fe2 hTF conformations.  More globally, steady state 
emission scans monitor the increase in the intrinsic Trp fluorescent signal as a function of 







spectra (Figure 1-3).  (Note that the source spectra from which the bar graphs are derived 
are provided as Supplementary Material).  It is important to recognize that Fe2 hTF with 
iron bound in both lobes at pH 7.4 should be maximally quenched and that the same 
sample at pH 5.6 should be maximally unquenched.  Accordingly, at pH 7.4 diferric 
LockN hTF and LockC hTF would also both be quenched to the same extent as Fe2 hTF, 
but would only reach a value that is approximately half of the maximally unquenched 
state (the monoferric species).  Likewise, the two monoferric constructs (FeN hTF and 
FeC hTF) would start at this intermediate value of fluorescence intensity and upon iron 
removal reach the unquenched apo state. 
Studies evaluating iron release from the diferric hTF  
As shown by the urea gel in Figure 1a, at pH 5.6, the majority of the iron was 
removed from Fe2 hTF as indicated by the band corresponding to the apo form of hTF.  
Additionally, equal amounts of monoferric C-lobe, monoferric N-lobe and diferric were 
observed.  At pH 6.4, approximately half was diferric hTF and half was monoferric C-
lobe.  At the intermediate pH values, there was a pH dependent decrease in apo and 
monoferric N-lobe and a corresponding increase in monoferric C-lobe and diferric, 
indicating that at higher pH values iron removal from the N-lobe of Fe2 hTF was favored 
(Figure 1a).  At pH 5.6, the steady-state data indicated a substantial increase (368%) in 
the fluorescence intensity relative to the diferric form at pH 7.4 (Figure 1b).  Collectively, 









Studies evaluating iron release from the N-lobe  
 To systematically evaluate iron release from the N-lobe, constructs in which the 
C-lobe was completely open or was locked in a closed conformation were used (Scheme 
1).  These constructs are designated: FeN hTF, which is recombinant monoferric N-lobe 
hTF with the two Tyr ligands disabled by mutation (Y426F and Y517F) thereby 
precluding iron binding in the C-lobe, and LockC hTF, which is recombinant diferric hTF 
with the arginine at position 632 mutated to alanine to effectively lock iron in the C-lobe.   
As shown by the urea gel in Figure 2a, following a 15 minute incubation iron 
removal from FeN hTF was nearly complete and was equivalent regardless of the pH (5.6 
up to 6.4).  The steady state data indicated a 74% increase in the fluorescent signal at pH 
5.6 relative to pH 7.4 (iron bound) (Figure 2b).  As would be predicted from the urea gel 
results, there were minimal differences in the fluorescence intensity at the intermediate 
pH values (Figure 2b) indicating nearly equivalent iron removal at each pH after 15 
minutes.   
In contrast, as shown by the urea gel in Figure 2c, it appears that only about half 
of the iron was removed from the N-lobe of LockC hTF, although again, the results did 
not seem to be very sensitive to the pH.  At pH 5.6, the steady state data indicated a 106% 
increase in the fluorescence emission intensity relative to pH 7.4 (iron bound) (Figure 
2d). In contrast to the urea gel results,  the intensity at λmax at pH 5.6 after the 15 minute 
incubation appears to be consistent with complete iron removal from the N-lobe (in this 
construct which retains iron in the C-lobe) (compare Figure 2d, pH 5.6, LockC hTF to 







explanation for the discrepancy between the results from the urea gel and the steady state 
fluorescence is that in the steady state experiment the low pH and excess chelator 
promote and result in irreversible iron release. In contrast, in the urea gel format, addition 
of the pH 8.4 sample buffer to the sample to “quench” iron release could result in 
rebinding of some portion of the iron. We suggest that this potential experimental 
anomaly is strongly and uniquely promoted by the locked C-lobe which restricts the 
opening of the N-lobe allowing a ternary complex (protein/metal/EDTA) to persist (see 
discussion).   As observed for FeN hTF, there was very little difference in the 
fluorescence intensity at the intermediate pH values.  Collectively, we conclude that iron 
release from the N-lobe is relatively insensitive to pH and that considerably more iron is 
completely removed from the N-lobe when the C-lobe is open than when the C-lobe is 
locked (compare Figure 2a and 2c).   
Studies evaluating iron release from the C-lobe  
To systematically evaluate iron release from the C-lobe, constructs in which the 
N-lobe was completely open or was locked in a closed conformation were used (Scheme 
1). These constructs are designated:  FeC hTF, which is recombinant monoferric C-lobe 
hTF with the two Tyr ligands disabled by mutation (Y95F and Y188F) thereby 
precluding iron binding in the N-lobe, and LockN hTF, which is recombinant diferric hTF 
with the lysine at position 206 mutated to a glutamate to effectively lock iron in the N-
lobe.   
As shown by the urea gel in Figure 3a, after a 15 minute incubation at pH 5.6 all 







of the iron is removed (Figure 3a).  There is a pH dependent decrease in iron removal 
between pH 5.6 and 6.4.  At pH 5.6, there is a 71% increase in the steady-state 
fluorescence emission relative to pH 7.4 (iron bound) (Figure 3b).  At the intermediate 
pH values, there is a gradual pH dependent decrease in the fluorescence intensity with 
increasing pH, which more quantitatively illustrates the sensitivity to pH of iron removal 
from the C-lobe when the N-lobe is open (Figure 3b). 
LockN hTF is similar to FeC hTF, in that at pH 5.6 almost all of the iron is 
removed from the C-lobe, while at pH 6.4 none of the iron is removed (Figure 3c).  
Again, there is a pH dependent decrease in iron removal between pH 5.6 and 6.4 after a 
15 minute incubation.  At pH 5.6 there is a 194% increase in the steady-state fluorescence 
emission relative to pH 7.4 (iron bound) (Figure 3d).  As observed for FeC hTF, there is a 
substantial pH dependent decrease in the fluorescence intensity.  Thus, iron release from 
the C-lobe is pH sensitive (compare Figure 3a and c), but is completely insensitive to 
whether the N-lobe is open or locked.   The steady-state data reinforces both of these 
conclusions (Figure 3b and d) as indicated by the substantial differences in endpoint 
intensity as a function of pH.   
Iron Release as a Function of Time and the sTFR  
 To elucidate the pathway of iron release as a function of time and to determine the 
effect of the sTFR on each lobe, the various hTF constructs alone and in complex with 
the sTFR were incubated in 100 mM MES containing 300 mM KCl and 4 mM EDTA at 
pH 5.6.  In all cases, iron removal was specifically evaluated by electrophoresis on 6 M 







Studies evaluating iron release from the diferric hTF  
As shown by the urea gel in Figure 4a, iron removal from Fe2 hTF was time 
dependent with all four species visible at the 3 minute time point. Additionally, there is a 
time dependent increase in apo hTF such that at the 15 minute time point, the 
predominant species was apo with an approximately equal distribution of the other three 
species (Figure 4a).  In the presence of the sTFR, apo and monoferric N-lobe were the 
only species present (Figure 4b).   In the presence of the sTFR, iron removal from the C-
lobe was complete within the first 3 minutes. Thus, the sTFR reverses the order of iron 
release strongly favoring removal from the C-lobe. 
Studies evaluating iron release from the N-lobe  
As shown by the urea gel in Figure 5a and 5b, almost all of the iron was removed 
by the 3 minute time point from the N-lobe of FeN hTF with an open C-lobe.  In addition, 
there is little time dependence following the initial iron release and the sTFR had no 
effect.   
As shown by the urea gel in Figure 5c, by the 3 minute time point only about half 
of the iron was removed from the N-lobe of LockC hTF with no further time dependent 
increase in the absence or presence of the sTFR (Figure 5c and d).  We note that there 
was a small amount of apo present at the 6 minute time point (Figure 5d) which was not 
observed in the absence of the sTFR.  In conclusion, it appears that more iron was 
removed from the N-lobe when the C-lobe is open than when it is locked (compare 







hTF or LockC hTF in the presence of the sTFR is equivalent to iron removal in the 
absence of the sTFR (compare Figure 5a to 5b and Figure 5c to 5d).   
Studies evaluating iron release from the C-lobe  
As shown by the urea gel in Figure 6a, iron removal from the C-lobe of FeC hTF 
(with an open N-lobe) was time dependent as indicated by an increase in apo hTF.  
However, complete iron removal was not observed at the 15 minute time point.  In 
contrast, in the presence of the sTFR, all of the iron was removed by the 3 minute time 
point (Figure 6b). 
Iron removal from the C-lobe of LockN hTF was time dependent as indicated by 
an increase in the monoferric N-lobe band on the urea gel in Figure 6c, although 
complete iron removal was not observed at the 15 minute time point (Figure 6c).  In the 
presence of the sTFR, iron removal was nearly complete by the 3 minute time point, with 
a further increase as a function of time (Figure 6d).  Thus, a similar amount of iron is 
removed from the C-lobe whether the N-lobe is open or locked in the absence of the 
sTFR (compare Figure 6a and c).  The presence of the sTFR drives iron release from the 
C-lobe of FeC hTF to completion within the first 3 minutes (compare Figure 6a and b).  
Similarly, almost all of the iron is removed from the C-lobe of LockN hTF in the presence 
of the sTFR (compare Figure 6c and d), although complete iron removal is not achieved 








In the current study, we have analyzed iron release from a variety of recombinant 
hTF constructs at different pH values, including the putative endosomal pH of ~5.6.  The 
use of authentic monoferric constructs unable to bind iron in one lobe, of diferric 
constructs with iron locked in one lobe and the soluble portion of the specific TFR, have 
allowed us to more thoroughly dissect the system. This work provides the most 
comprehensive and unambiguous assessment of the effect of pH, the sTFR, and lobe-lobe 
interactions on iron release that has been carried out to date. The use of urea gels 
combined with the data for the increase in the fluorescence intensity (as a result iron 
removal), allows direct visualization of the global effects of iron release.  As detailed 
below it solidifies many of the prevailing “truths” gathered in a less systematic fashion.  
The studies described herein definitively demonstrate that iron release from the 
N-lobe is highly dependent on the conformation of the C-lobe.  We clearly show that 
there is a difference in iron removal from the N-lobe as a function of the conformation of 
the C-lobe (240). Thus when the cleft of the C-lobe is locked, we observe by urea gels 
that the N-lobe appears to be unable to  undergo the conformational changes needed to 
assure irreversible iron removal (either in the absence or presence of the sTFR) at pH 5.6 
(Figure 5c and d).  This apparent incomplete removal of iron from the N-lobe of LockC 
hTF is independent of pH (Figure 2c), time (Figure 5c) and salt concentration (data not 
shown, see below).  In agreement with previous work (266), when the C-lobe is in an 
open conformation, nearly all of the iron is removed from the N-lobe (Figure 2a and 







Contrary to iron release from the N-lobe, iron release from the C-lobe is 
independent of the conformation of the N-lobe (open or locked), but highly dependent on 
pH (Figure 3), time (Figure 6a and c) and salt concentration (data not shown).  As 
reported previously (240),  
the presence of the sTFR greatly accelerates iron release from the C-lobe (Figure 6)  
In the case of Fe2 hTF, pH, time and the sTFR affect iron removal (Figure 1 and 
Figure 4).  As in numerous studies, we show that iron is first released from the N-lobe 
and then the C-lobe of Fe2 hTF (Figure 4a) (218, 266).  In agreement with previous work, 
at low pH the presence of the sTFR switches the order of iron release from N-lobe then 
C-lobe, to C-lobe then N-lobe (Figure 4b) (240, 266).  These results are not in accord 
with chemical relaxation studies monitoring iron release which suggest that iron is 
released from the N-lobe before the C-lobe of diferric hTF whether alone or in a complex 
(243).  In this work more drastic changes in the pH were used and the TFR was isolated 
from placenta requiring detergent to maintain solubility.  Whether micelles could 
interfere with the iron release process is unknown.   
We suggest that the apparent restriction of iron release from the N-lobe of LockC 
hTF is due to a conformational effect of the C-lobe that disrupts the cooperativity 
between the lobes.  Iron release is a highly dynamic process which requires that both 
lobes are capable of undergoing the necessary conformational changes that ultimately 
result in the release of iron to a chelator.  It is well established that the transition from pH 
7.4 to pH 5.6 involves a series of protonation events which allow each cleft to open and 







transferrin structure suggests that most of the movement is restricted to the NII and CII 
subdomains, since the NI and CI subdomains closely align in the two structures.  The N- 
and C-lobes undergo rotations of 59.4o and 49.5o, respectively, upon cleft opening (76).  
X-ray scattering studies of the N-lobe indicate that a two step process leads to cleft 
closure; a 20o rigid-body twist of the NII subdomain followed by a 50o hinge-bend (120).  
Assuming that each lobe of hTF undergoes a similar process (in reverse) to open the cleft 
at pH 5.6, we suggest a possible model to explain our results.  Fe2 hTF (Figure 7, upper 
panel, A) is shown in a fully iron bound conformation with a chelator approaching to 
remove the iron from the N-lobe as the pH is lowered to 5.6.  Protonation events as well 
as the interaction of anions and the chelator with the N-lobe (B) result in a 
conformational change, possibly the 50o hinge-bend (B, blue star), which is 
communicated to the C-lobe, thereby changing its conformation (B, green triangle).  The 
chelator enters the iron binding cleft of the N-lobe and extracts the iron inducing the 
second conformational change in the N-lobe, the 20o hinge-twist (C, two blue stars).  
Simultaneously, anions and the chelator attack the more rigid C-lobe, triggering its 
equivalent hinge-bend motion (green star) and allowing entry of the chelator.  Following 
iron removal from the N-lobe and complete elimination of the iron bound to the chelator, 
the N-lobe is able to adopt its final apo conformation (D, three blue stars).  Subsequently, 
the iron is extracted from the C-lobe by the chelator as a result of an equivalent hinge-
twisting motion (D, two green stars).  Lastly (E), the iron bound to the chelator is 







When iron is locked in the C-lobe, the chelator interacts with the N-lobe and 
induces the first conformational change, the hinge-bend.  This change is communicated to 
the C-lobe, but because it is locked, it cannot undergo the necessary conformational 
change to promote complete iron release (including departure of the iron bound to the 
chelator) from the N-lobe.  The C-lobe communicates back to the N-lobe that it is unable 
to undergo this change, thereby preventing full opening and complete iron/chelator 
release from the N-lobe (possibly by restricting the hinge-twist motion).  Thus, the locked 
C-lobe restricts the movement of both lobes and partially disrupts their communication 
with each other. In the steady state format the dilute sample, excess chelator and 
invariable pH promote complete iron removal from the N-lobe,  in spite of the restrictions 
imposed by the locked C-lobe.  In the urea gel format we suggest that the ternary 
complex is not fully resolved and some of the iron rebinds to the N-lobe when the pH 8.4 
sample buffer is added. As described in the Results, this is uniquely promoted by the 
locked C-lobe. It is curious and not obvious as to why this occurs in approximately half 
of the sample.   
A previous study, designed to identify a chelator that would be effective at pH 
7.4, showed that iron release from the N-lobe critically depended on a closed C-lobe 
(235).  In this work, it is suggested that at pH 7.4, an open C-lobe blocks an anion 
binding site in the N-lobe necessary for iron release.  As described above, at pH 5.6 iron 
release from the N-lobe appears to be partially inhibited by locking the C-lobe closed 
with no dependence on salt strongly indicating that lobe-lobe communication and 







We provide further unequivocal evidence for the requirement of the sTFR for 
complete iron release from the C-lobe regardless of whether the N-lobe can release iron 
(Fe2 hTF), has no iron (FeC hTF) or has iron locked in (LockN hTF)  (Figure 4b and  
Figure 6b and d).  Iron release from the N-lobe of FeN hTF and LockC hTF is unaffected 
by the presence of the sTFR.  The time based patterns are identical to those observed for 
these samples in the absence of the sTFR, i.e., iron removal from the N-lobe of FeN hTF 
is complete and iron removal from the N-lobe of LockC hTF is restricted  (Figure 5) .  
However, iron release from the N-lobe of Fe2 hTF bound to the sTFR is partially 
inhibited as indicated by the presence of the monoferric N-lobe species on the urea gel 
(Figure 4b).     
Although the C-lobe binds iron with higher affinity, considerably more 
monoferric N-lobe is present in the serum than monoferric C-lobe (23% vs. 11%, 
respectively) (55).  Our studies provide support for the suggestion (266), that this 
monoferric N-lobe comes from Fe2 hTF that has been taken into the cell through receptor 
mediated endocytosis.  Preferential release of iron from the C-lobe could result in the 
return of the monoferric N-lobe/TFR complex to the serum. 
In summary, iron release from the N-lobe is highly dependent on the 
conformation of the C-lobe, but independent of changes in pH and time.  In contrast, iron 
release from the C-lobe is dependent on pH and time and independent of the 
conformation of the N-lobe.  Importantly, iron release from Fe2 hTF is not a simple 
combination of FeC hTF and FeN hTF.  Fe2 hTF can undergo all of the dynamic 







complete communication and cooperativity between the lobes.  The significance and 
complexity of the bilobal structure of hTF is indicated by the different iron release 
properties observed when the lobes are altered (to prevent iron binding or to lock iron in a 
lobe).  Although the two lobes are homologous, their differences are further evidenced by 
their responses to conformation and changes in pH.           
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Figure 2.  Effect of lowering pH on iron release from Fe2 hTF    
 
a) 6M Urea gel. All samples were incubated for 15 minutes in iron removal buffer before 
loading on the gel (2.5 µg/lane);  b) Bar graph of steady-state emission intensity at λmax 
for each spectra.  Note that the emission spectra from which the end points shown in the 
bar graph were obtained are provided as Supplementary Material.   All samples were 
incubated for 15 minutes in iron removal buffer (100 mM MES pH 5.6, 300 mM KCl, 4 
mM EDTA),  before monitoring the emission. Samples were excited at 280 nm and 
emission was monitored between 300-400 nm using a 320 nm cut-on filter. As an 
important control, we analyzed a construct with iron locked in both lobes and observed 
that at pH 5.6, no iron was removed and that the fluorescence intensity at pH 5.6 was 








Figure 3. Effect of lowering pH on iron release from the N-lobe of hTF  
 
a) 6M Urea gel of FeN hTF;  b) Bar graph of steady-state emission intensity;  c) 6M Urea 
gel of LockC hTF;  d) Bar graph of steady-state emission intensity. All samples were 
prepared as described in the legend to Figure 1.  (The appearance of a double band in 2C 
is ascribed to the extreme sensitivity of urea gels to charge heterogeneity. We have 
observed that this heterogeneity seems to increase as a function of the age of the sample 









Figure 4. Effect of lowering pH on iron release from the C-lobe of hTF  
 
a) 6M Urea gel of  Fec hTF; b) Bar graph of steady-state emission intensity;  c) 6M Urea 
gel of LockN hTF;  d) Bar graph of steady-state emission intensity. All samples were 
prepared as described in the legend to Figure 1. (See the legend of Figure 2 for 
explanation of the appearance of the double band in 3c in the bands corresponding to the 









Figure 5. Influence of the sTFR on time based iron release from Fe2 hTF at pH 5.6.   
 
a) Fe2 hTF, alone; b) Fe2 hTF / sTFR complex.  All samples were incubated for the 
designated time courses in 100 mM MES pH 5.6, 300 mM KCl, 4 mM EDTA.  Iron 









Figure 6. Influence of the sTFR on time based iron release from the N-lobe at pH 5.6.   
 
a) FeN hTF;  b) FeN hTF /sTFR complex; c) LockC hTF; d) LockC hTF/ sTFR complex.  
All samples were incubated for the designated time courses in iron removal buffer (100 
mM MES pH 5.6, 300 mM KCl, 4 mM EDTA).  Iron release was quenched by the 
addition of sample buffer. (See the legend of Figure 2 for explanation of the appearance 









Figure 7. Influence of the sTFR on time based iron release from the C-lobe at pH 5.6.   
 
a) FeC hTF;  b) FeC hTF /sTFR complex; c) LockN hTF; d) LockN hTF/ sTFR complex.  
All samples were incubated for the designated time courses in 100 mM MES pH 5.6, 300 
mM KCl, 4 mM EDTA.  Iron release was quenched by the addition of sample buffer. 
(See the legend of Figure 2 for explanation of the appearance of the double band in 6c 









Figure 8. Model of iron release from Fe2 hTF.   
 































Supplemental Figure 1. Fluorescence emission scans 
  
Maximum fluorescence emission from Fe2 hTF, FeN hTF, FeC hTF, LockC hTF and 
LockN hTF at pH 7.4 (100 mM HEPES) and pH 6.4-5.6 (100 mM MES, 300 mM KCl, 4 
mM EDTA).  All samples were incubated at least 15 minutes to try to assure complete 
iron removal.  Samples were excited at 280 nm and emission was monitored between 
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The bilobal human serum protein, transferrin (hTF), has been extensively 
investigated; however, some of the molecular details related to the mechanism of iron 
release remain uncertain.  The process of iron release is complicated by the active 
participation of the transferrin receptor (TFR), salt, a chelator, pH (as a result of 
acidification of the endosome) and lobe-lobe interactions.  In the present work,  previous 
uncertainties due to sample and/or technical limitations has been overcome by the use of 
authentic monoferric and locked species (completely precluding the acquisition or release 
of iron from one lobe or the other in a predictable manner).  Use of a sensitive stopped 
flow spectrofluorimeter allows the accurate and reproducible capture of kinetic events 
reported by the substantial increase in the intrinsic fluorescent signal.  Although our data 
is consistent with much of the previous work, our integrated and thorough approach 
provides more detailed insight into many of the prevailing beliefs, particularly regarding 
the relative effect and importance of the various participants.  We can confidently assign 
rate constants to the individual lobes and accurately measure the effect of one lobe on the 
other, as well as the influence of salt and the TFR.  (Use of the recombinant soluble 
portion of the TFR (sTFR) precludes the use of detergent in our assays).  We present a 
comprehensive model of iron release from the Fe2 hTF/sTFR complex.  It is completely 
clear that a critical function of the TFR is to balance iron release from each lobe so that 











Human serum transferrin (hTF)1 is a bilobal ferric-iron binding glycoprotein.  The 
homologous N- and C- lobes are connected by a short peptide linker and are further 
divided into subdomains (NI/NII and CI/CII).  The subdomains come together to form a 
deep iron binding cleft within each lobe (75, 76).  Diferric hTF preferentially binds to 
specific hTF receptors (TFR) on the cell surface at neutral pH (133).  The complex 
undergoes clathrin dependent receptor-mediated endocytosis during which the clathrin 
coated pit fuses with an endocytic vesicle.  The pH within the endosome is lowered to 
~5.6 resulting in protonation of the synergistic anion and the iron binding residues to 
loosen the cleft and facilitate iron release to an, as yet, unidentified chelator.  At the low 
pH within the endosome, apo hTF remains bound to the TFR and is recycled back to the 
cell surface.  Upon exposure to the neutral pH of the serum, the complex dissociates and 
hTF is free to bind more iron and continue the cycle.  The entry of hTF into the cell, 
removal of iron from hTF and return to the surface is complete in ~2-3 minutes (111, 
273).   
Ferric iron (Fe3+) is coordinated in an octahedral geometry by identical ligands in 
each lobe of hTF: two tyrosines, one histidine, one aspartic acid and two oxygen atoms 
from the synergistic carbonate anion, which is anchored by a highly conserved arginine 
residue (71).  Although the iron binding ligands are identical, the precise steps leading to 
iron release from each lobe differ, due largely to differences in the “second-shell” 
residues (73, 119, 143).  These amino acids do not directly coordinate the iron, but 








ligands.  Two lysine residues that lie on opposite sides of the iron binding cleft, Lys206 
(which resides in the NII subdomain) and Lys296 (located in the NI subdomain), are 3.04 
Å apart in the iron-bound isolated hTF N-lobe structure and 9 Å apart in the apo structure 
of the isolated hTF N-lobe; these residues comprise the “dilysine trigger” (73, 119, 154).  
They share a hydrogen bond at neutral pH which is protonated at low pH and literally 
triggers the opening of the cleft.  In the C-lobe, Lys534 (in the CII subdomain) and 
Arg632 (found in the CI subdomain) are found in homologous positions to Lys206 and 
Lys296, respectively (154).  Mutation of Lys206 to glutamate in the N-lobe or Arg632 to 
alanine in the C-lobe completely prevents iron release from that lobe on a relevant 
timescale and allows targeted measurement of iron release from the opposite lobe (81, 
131). 
 It is well established that the presence of salt affects the iron release properties of 
each lobe of hTF.  Iron release requires binding of a non-chelating anion, such as Cl-, to 
an anion binding site that appears to be distinct from the synergistic anion binding site.  
Specifically, residues termed kinetically significant anion binding (KISAB) sites (159) 
have been identified in each lobe of hTF.  In the N-lobe, Arg124, as well as the dilysine 
trigger (Lys206-Lys296) have been identified as KISAB sites.  Of the pair, Lys296 is the 
primary anion binding site while Lys206 appears to play a secondary role (148, 150).  
Studies of the C-lobe show that a positive charge in the middle position of the triad is 
responsible for anion binding, indicating that Arg632 is one KISAB site (81).  It is highly 








completely eliminates the effect of salt.  Furthermore, the anion binding requirement for 
iron release is preserved when hTF is in complex with the TFR (258).     
 The rate of iron release from hTF can be measured by an increase in the intrinsic 
Trp fluorescence (with some contribution from Tyr residues) that occurs upon iron 
removal.   Human TF has eight Trp residues, three in the N-lobe and five in the C-lobe.  
Ferric iron within each binding cleft is a strong quencher of Trp fluorescence through 
radiationless transfer of electronic excited-state energy (123).  This energy is transferred 
to an absorption band that overlaps the Trp fluorescence and is created by the metal-Tyr 
interaction (122).  This absorption band between the iron and the liganding tyrosine 
residues is responsible for the visible maximum (~470 nm) of hTF (121).  Additionally, 
the charge transfer band results in a disruption of the π to π* transition energy of the 
liganding Tyr residues which results in an increase in the UV absorbance that overlaps 
the intrinsic Trp fluorescence (123).   The decrease in absorbance (at 470 nm) or the 
increase in the fluorescent signal, have both been utilized to derive iron release rate 
constants.  The recovery of the intrinsic fluorescent signal can be monitored because the 
quenching effect of iron on the Trp (and Tyr) residues is released.  Additionally, the large 
conformational changes associated with iron removal impact specific Trp residues which 
are extremely sensitive to alterations in their local environment (274, 275).  Thus, the 
increase in the intrinsic Trp signal is ascribed to a combination of unquenching by loss of 
iron, which triggers the large conformational changes in hTF and more localized changes 
in the immediate environment of the Trp residues.  Recent studies from our laboratory 








(124, 126).  We have also established that the increase in Trp fluorescence observed 
when monitoring iron release from a complex of FeC hTF with the recombinant soluble 
portion of the TFR (sTFR) is derived solely from the Trp residues in hTF with no 
contribution from the 22 Trp residues in the sTFR dimer (254). 
Initial studies by Aisen and colleagues measured iron release to the chelator 
pyrophosphate by precipitation of 59Fe with 20% polyethylene glycol allowing distinction 
between 59Fe-still bound to hTF and 59Fe-pyrophosphate.  Obviously, a discrete number 
of time points to define iron release rather than a continuous progress curve are provided 
by this protocol.  Additionally, the monoferric constructs utilized were made from hTF 
isolated from serum.  There is always a concern in such experiments that the iron free 
lobe might acquire iron.  Additionally, mixed metal TFs with kinetically inert Co3+ in one 
lobe and Fe3+ in the other lobe were used as “locked” constructs. Although this is 
certainly a valid approach assuring that the correct metal is in the designated lobe is 
technically challenging.   In studies monitoring iron release from an hTF/TFR complex, 
full length, membrane bound TFR was isolated from placenta requiring detergent to 
remain in solution.  The relatively poor yield of TFR from placenta, the formation of 
micelles and its instability at pH 5.6 all present difficulties in such experiments.  In spite 
of these technical challenges these initial studies contributed a great deal to understanding 
the role of the TFR in iron release.  They provided the first data showing that in the 
absence of the TFR: 1) iron is released from the N-lobe followed by the C-lobe and that 
2) binding to the TFR induces a switch in this order (240, 242, 266).  A time-based 








intrinsic Trp fluorescence from the hTF constructs described above was pioneered by 
these same investigators (258).  This was a significant achievement because it allowed 
observation of a continuous progress curve and provided a more accurate determination 
of rate constants (as long as the kinetic events being measured were within a suitable time 
frame).  
 The laboratory of el Hage Chahine has carried out a large number of chemical 
relaxation studies which allow specific assignment of kinetic rate constants to protonation 
events from hTF alone and in complex with the sTFR during the process of iron release 
(218, 243).  Since this work also uses TFR purified from placenta and monoferric FeC 
hTF generated from apo-transferrin, the same challenges and limitations apply.   In some 
instances extremely low pH values are needed to drive the reactions.  The analysis of the 
data from these studies is complex and it is sometimes difficult to understand the source 
of the various parameters that were reported.  Nevertheless, knowledge of the number of 
protonation events occurring in both TF (± the TFR) on a time scale preceding the more 
global conformational changes and/or actual iron release steps that we observe is 
extremely valuable.    
We have exploited recombinant technology and site-directed mutagenesis to 
produce authentic monoferric and locked constructs, as well as the soluble portion of the 
TFR (sTFR, eliminating the need for detergent) to allow unambiguous assignment of 
events related to iron release from hTF.  The use of a sensitive stopped-flow 
spectrofluorimeter provides data with a high signal to noise ratio allowing precise fitting 








sensitive steady-state format.  In addition to iron release, we are able to assign rate 
constants to conformational changes as a function of salt, to communication between the 
two lobes of hTF, and to interactions with the sTFR.  Building on our recent qualitative 
study of iron release from these constructs and a model presented for iron release from 
Fe2 hTF in the absence of the sTFR (236), we now present a more comprehensive model 
for iron release from Fe2 hTF in the presence of the sTFR to more fully describe this 
complicated system.  We provide irrefutable evidence that a critical role of the sTFR is to 
balance iron release from each lobe so that removal occurs efficiently from both lobes 




Fetal bovine serum (FBS) was purchased from Atlanta Biologicals (Norcross, 
GA).  Ultroser G (UG), a serum replacement, was from Pall BioSepra (Cergy, France).  
Dulbecco’s modified Eagle’s medium-Ham F-12 nutrient mixture (DMEM-F12), 
antibiotic-antimycotic solution (100X) and trypsin solution were from the GIBCO-BRL 
Life Technologies Division of Invitrogen.  Corning expanded surface roller bottles and 
Dynatech Immunolon 4 Removawells were obtained from Fisher Scientific.  Ni-NTA 
resin was purchased from Qiagen.  The Hi-Prep 26/60 Sephacryl S-200HR and S-300HR 
columns were from Amersham Pharmacia.  Amicon Ultra-4 (30 kDa cutoff) 
ultrafiltration concentrators were from Millipore.  All other chemicals and reagents were 








Protein production and purification  
The DNA manipulations used to generate Fe2 hTF, FeN hTF, FeC hTF, LockN 
hTF, LockC hTF and the sTFR have been described in detail previously (131, 134, 165, 
236, 252).  Briefly, to produce recombinant hTF, baby hamster kidney (BHK) cells 
transfected with the pNUT plasmid containing the appropriate cDNA sequence are placed 
into two to four expanded surface roller bottles.  Adherent BHK cells are grown in 
DMEM-F12 containing 10% FBS.  This medium was changed twice at two day intervals, 
after which DMEM-F12 containing the serum substitute UG (1%) and 1 mM butyric acid 
(BA) was used instead.  UG and BA have both been shown to increase production of 
recombinant hTF and sTFR from BHK cells (252).  The amount of protein produced was 
usually determined using a competitive immunoassay (247).  The hexa-His tagged 
recombinant protein from the tissue culture medium is captured by passage over a Ni-
NTA column followed by final purification on a gel filtration column (S-200HR for hTF 
constructs and S-300HR for sTFR).  Polyacrylamide gel electrophoresis in the presence 
of SDS was used to verify the homogeneity of the all of the recombinant TFs which were 
brought to a nominal concentration of 15 mg/mL.  Absorption coefficients for each 
construct were determined by the modified Edelhoch method (257).  
Complexes of hTF/sTFR are prepared by combining sTFR with a small molar 
excess of hTF (Fe2 hTF, FeN hTF, FeC hTF, LockN hTF and LockC hTF) and isolated by 
passage over an S-300HR column (134).  Complexes were adjusted to a nominal 
concentration of 15 mg/mL with respect to hTF.   








The kinetics of iron release from all hTF constructs, in the absence and presence 
of the sTFR, were monitored at pH 5.6 on an Applied Photophysics SX18.MV stopped-
flow spectrofluorimeter (134).  One syringe contained protein (375 nM) in 300 mM KCl 
and the other syringe contained 200 mM MES buffer, pH 5.6, 300 mM KCl, and 8 mM 
EDTA (our “standard conditions”).  Samples were excited at 280 nm and the 
fluorescence emission was monitored using a high-pass 320 nm cut-on filter.  For KCl 
titrations, one syringe contained protein in either: 50, 150, 300 or 600 mM KCl, the other 
contained 200 mM MES buffer, pH 5.6, 8 mM EDTA and an equivalent concentration of 
KCl.  Rate constants were determined by fitting the change in fluorescence intensity-
versus-time using Origin software (version 7.5) to a single-exponential function (y = 
A1*exp(-x/t1) + y0); double-exponential function (y = A1*exp(-x/t1) + A2*exp(-x/t2) + 
y0); or triple-exponential function (y = A1*exp(-x/t1) + A2*exp(-x/t2) + A3*exp(-x/t3) + 
y0).  The goodness of the fit was determined by analysis of the residuals of each fit.  Note 
that in the case of the sTFR complexes the initial quench in the fluorescent signal (the 
first 0-2 sec) was not included in the fits.  All iron release curves shown are an average of 
at least 4 separate experiments.  The average curves are generated using Origin software 
(version 7.5). 
Results and Discussion 
General characteristics of kinetic curves  
 The kinetic curves for each authentic monoferric construct at pH 5.6 under our 
“standard conditions” (100 mM MES, pH 5.6, 300 mM KCl and 4 mM EDTA) are 








chosen to simulate the putative endosomal pH.  Since it is well established that salt 
affects the process we arbitrarily chose a salt concentration (although as detailed below 
we assessed the effect of different concentrations of salt on the kinetic process).  The 
chelator EDTA was selected due to its stability at pH 5.6 and its high affinity for ferric 
iron. The concentration of EDTA was selected to provide a large excess allowing us to 
maintain pseudo first order conditions in all experiments.   It is immediately obvious that 
there are striking differences with regard to the shape of the three curves, the changes in 
the fluorescence intensity and the time course for completion. As previously described 
(126), a short lag is observed in the kinetic curve for FeC hTF (red curve); this lag is not 
present in the curves for FeN hTF (blue curve) or Fe2 hTF (black curve).  It is attributed to 
communication between the two lobes.  Ordinarily, iron release from the N-lobe (which 
clearly precedes iron release from the C-lobe) is communicated to the C-lobe.  In the 
monoferric construct, the lack of iron in the N-lobe results in a lag since the pH induced 
conformational change still occurs but is fluorescently silent.  The two constructs with 
iron locked into either the N-or C-lobe show similar differences to the monoferric 
constructs.  Again, iron release from the C-lobe of LockN hTF (green curve) is preceded 
by a short lag that is not observed in LockC hTF.  In this case the delay is caused by the 
fact that the iron cannot be released from the N-lobe.  Additionally, iron release from 
each locked construct required 2-5 times longer to reach the plateau compared to iron 
release from the same lobe in a construct lacking iron in the other lobe.  Of great interest 
is the effect that the sTFR has on the iron release process (Figure 1C and D).  As 








from all complexes (compared to the construct in the absence of the sTFR).  This 
decrease is attributed to the greater initial fluorescence due to the presence of the sTFR 
resulting in a muting of the net change in the fluorescent signal (since the sTFR does not 
contribute to it) (254).  Iron release from the C-lobe of FeC hTF is enhanced and occurs 
on a timescale that is 10 times faster than in the absence of sTFR (Figure 1C, red curve).  
Although it occurs on the same timescale, the presence of the sTFR also impacts the 
kinetics of iron release from FeN hTF (Figure 1C, blue curve), as described in more detail 
below.  Likewise, iron release from the locked constructs occurs on a timescale that is 5 
times faster than in the absence of the sTFR (Figure 1D, pink and green curves).  Iron 
release from Fe2 hTF in the presence of the sTFR occurs on a timescale that is 2.5 times 
faster with a different effect on each lobe.  Although significant differences are obvious 
from a visual comparison of the progress curves for the various constructs, obviously 
more detailed and precise information can be derived from analysis of the kinetic fits of 
these curves. 
Illustration of the Advantage of Stopped-Flow 
In the C-lobe of hTF, it had been suggested that Asp634 forms hydrogen bonds 
with both Lys534 and Arg632 creating a “triad” of residues that may serve as a pH 
sensitive motif similar to the dilysine trigger in the N-lobe (154).  Given that the negative 
charge of Asp634 was predicted to stabilize the positive charges on Lys534 and Arg632, 
we had hypothesized that mutation of this residue to alanine (D634A) would result in 
faster iron release.  However, as measured by time-based steady-state fluorescence, the 








the sTFR) (81, 131).  We found this result very puzzling and could provide no rationale 
explanation for it.  Consequently, we reanalyzed iron release from this mutant using our 
stopped-flow instrument.  We now report that the D634A mutant yields three rate 
constants (kobs1 = 54.1 ± 1.6 min-1, kobs2 = 8.1 ± 0.88 min-1 and kobs3 = 1.2 ± 0.31 min-1).  
When bound to the sTFR even faster rate constants are observed (kobs1 = 88.5 ± 11.3 min-
1, kobs2 = 12.2 ± 0.68 min-1 and kobs3 = 2.1 ± 0.76 min-1).  This example perfectly 
illustrates the technical and experimental limitations of steady-state measurements for 
mutants that release iron fast (i.e,. events can be completely missed).     
Kinetic Assessment of iron release and conformational changes in the absence of the 
sTFR 
The model shown in Figure 2A (red arrows), is based on our kinetic data that will be 
discussed in detail below.  Under our standard conditions (100 mM MES, pH 5.6 in the 
presence of 300 mM KCl and 4 mM EDTA), and in the absence of the sTFR, iron is 
released first from the N-lobe, then from the C-lobe.  By using authentic locked and 
monoferric constructs (indicated below the arrows), we are able to specifically determine 
rate constants for each kinetic event (k1N and k2C).  Iron release from Fe2 hTF occurs first 
from the N-lobe (k1N = 21.37 ± 6.84 min-1) as confirmed by analysis of kobs1 from the 
LockC hTF construct (18.99 ± 2.09 min-1) (Table 1A).  Iron release from the C-lobe 
follows (k2C = 0.65 ± 0.06 min-1) as confirmed by iron release from FeC hTF (kobs1 = 0.60 
± 0.07 min-1).  We suggest that the additional kinetic events for LockC hTF (kobs2 = 3.09 ± 
1.44 min-1 and kobs3 = 0.36 ± 0.07) are comprised of conformational changes and 








release.  As described below, we believe that kobs2 is a conformational event that is 
influenced by increasing concentrations of KCl and that kobs3 is reporting a 
conformational change that results from communication with the C-lobe.  The opening of 
the N-lobe is restricted by the locked C-lobe (236), and this impaired communication 
impacts kobs3.  The rate constants determined for the LockN hTF and FeN hTF constructs 
provide support for the proposed order of iron release.  If the alternative pathway (Figure 
1A, black dashed arrows) was followed, then the rate constant for iron release from 
LockN hTF would be faster than the rate constant for FeN hTF and would be similar to 
that observed with LockC hTF.  The LockN hTF construct, provides the rate constant for 
iron release from the C-lobe (kobs = 0.39 ± 0.07 min-1), which is very similar to the rate of 
iron release from FeC hTF and k2C from Fe2 hTF.  Likewise, FeN hTF provides the iron 
release rate constant(s) for the N-lobe.  This data is best fit by three exponentials and the 
rate constants derived are similar to the rate constants assigned to iron release and 
conformational events in LockC hTF.  Thus, there is an initial fast step ascribed to actual 
iron release from FeN hTF (kobs1 = 22.70 ± 5.91 min-1) followed by two slower 
conformational events (kobs2 = 4.94 ± 1.80 min-1 and kobs3 = 1.03 ± 0.09 min-1).  Although 
the rate of iron release from the N-lobe and the salt induced conformational change are 
equal for LockC hTF and FeN hTF, the final event is ~3 times slower for LockC hTF 
compared to kobs3 from FeN hTF.  This is attributed to ineffective communication between 
the lobes due to the restricted opening of the N-lobe imposed by the locked C-lobe.  









Under our standard conditions, the kinetic data for iron release supports much previous 
work (240, 242, 266) suggesting that the sTFR induces a switch in the order of iron 
release, such that the C-lobe first releases iron followed by the N-lobe (Figure 1B, red 
arrows).  Analysis of the data in Table 1B completely reinforces and corroborates this 
assertion.  The Fe2 hTF/sTFR complex yields two rate constants representing iron release 
from the C-lobe and then the N-lobe (k1C = 5.53 ± 1.53 min-1 and k2N = 1.34 ± 0.26 min-
1).  Analysis of both the locked and monoferric constructs in complex with the sTFR 
confirms this assignment.  Iron release from the C-lobe of LockN hTF occurs with a rate 
constant of, kobs1= 5.11 ± 0.81 min-1 (equal to k1C from Fe2 hTF).  Iron release from the 
N-lobe of FeN hTF occurs as the second observable event (kobs2 =1.21 ± 0.13 min-1) and is 
similar to k2N from Fe2 hTF.  Iron release from LockN hTF is followed by a second event 
that may be an sTFR induced conformational change in the C-lobe (kobs2 = 1.20 ± 0.66 
min-1) perhaps compensating for the lack of iron release from the N-lobe.  FeN hTF 
undergoes a salt and sTFR induced conformational change prior to iron release as 
indicated in Table 1B and further described below, (kobs1 = 23.44 ± 2.09 min-1).  The 
assignment of iron release from the C-lobe followed by the N-lobe in the presence of the 
sTFR is further substantiated by analysis of the kinetic data the LockC hTF/sTFR and FeC 
hTF/sTFR complexes.  Iron release from the N-lobe of the LockC hTF/sTFR complex 
yields a single rate constant which is equal to k2N from Fe2 hTF (kobs1 = 1.36 ± 0.12 min-
1).  Iron is released from FeC hTF with a rate constant of 7.31 ± 0.99 min-1 which is very 
similar to k1C from Fe2 hTF.  As for FeN hTF, this event is preceded by a KCl and sTFR 








 In the presence of the sTFR, there is an 8-fold increase in the rate constant for 
iron release from the C-lobe of Fe2 hTF (kobs1,complex = 5.53 min-1 vs. kobs2, alone = 0.65 min-
1).  Furthermore and significantly, the data indicate a 16 fold decrease in the rate constant 
for iron release from the N-lobe of Fe2 hTF compared to Fe2 hTF alone (kobs2,complex = 
1.34 min-1 vs. kobs1, alone = 21.37 min-1).  These differences are completely consistent with 
the rate constants that we have determined for iron release from the monoferric and 
locked constructs.  Importantly, the two rate constants for iron release from each lobe of 
Fe2 hTF are closer to each other in the presence of the sTFR than in its absence.  For 
example, iron release from the N-lobe is 32 times faster than iron release from the C-lobe 
in the absence of sTFR; however in the presence of the sTFR, iron release from the C-
lobe is only 4 times faster than the N-lobe.  Thus the sTFR balances the rate of iron 
release from the two lobes; in this scenario release of iron from the C-lobe is 
communicated to the N-lobe which then releases its iron.  Although it was reported that 
the sTFR had little effect on iron release from the monoferric N-lobe (266), this earlier 
study captured only a global single event.  Subsequently a small decrease in the rate of 
iron release from the N-lobe of hTF with Co3+ bound in the C-lobe was reported (240).  
In our work, even though it appears that kobs1 from FeN hTF alone and in complex with 
the sTFR are equal, as described above, they can be confidently assigned to different 
events.   
Salt effects explain the rate constants in the absence of the sTFR 
As shown in Table 2A, the rate constants for iron release and conformational changes 








concentrations of salt.  The changes observed for iron release from the N- and C-lobes of 
Fe2 hTF are consistent with the changes observed for the respective locked and 
monoferric constructs.  Interestingly, for both FeN hTF and LockC hTF, a new event 
intermediate between the two other events is detected at concentrations of KCl greater 
than 150 mM.  The decision to fit the data to a triple-exponential (versus a double-
exponential) is determined by consideration of the residuals of the fit (Supplemental 
Figure 1).  Both urea gels and steady-state fluorescence experiments revealed that the 
total amount of iron that was removed from FeN hTF and LockC hTF appeared insensitive 
to salt concentration (data not shown), but here we clearly observe a kinetic effect.  This 
strongly indicates that the rate at which iron is removed and the conformational events 
occurring in FeN hTF are sensitive to salt concentration.  LockC hTF (lacking the putative 
KISAB site Arg632) actually shows an increase in the rate of iron release with increasing 
salt similar to iron release from FeN hTF.  Obviously the KISAB site (or lack thereof) in 
the C-lobe does not influence iron release from the N-lobe.  In contrast, FeC hTF and 
LockN hTF exhibit a strong correlation between the amount of iron removed and the 
concentration of salt, as shown here kinetically (as well as by urea gels and steady-state 
fluorescence, data not shown).    
Salt effects explain the rate constants in the presence of the sTFR 
As indicated in Table 2B, similar effects of salt are observed in the presence of the sTFR 
although the enhancements are smaller than in its absence.  Again, for the Fe2 hTF/sTFR 
complex, the enhancement in the rate constant of iron release from the N- and C-lobes 








constructs.  In the presence of the sTFR, iron release from each monoferric construct is 
preceded by a salt induced conformational change in the complex (perhaps priming each 
lobe for iron release).  Interestingly, in the case of the FeC hTF/sTFR complex, this 
occurs only at high salt concentrations and the rate constant for iron release is completely 
insensitive to salt.  The same is not true for iron release from the C-lobe of the LockN 
hTF/sTFR complex; in this case two kinetic events are observed at all salt concentrations 
and both show a 2-fold increase.  Additionally, the rate of the conformational event 
which precedes iron release from the FeN hTF/sTFR complex decreases with increasing 
salt while the rate of iron release increases.  Likewise, the rate of iron release from the N-
lobe of the LockC hTF/sTFR complex also decreases with increasing salt.      
Model for iron release from the Fe2 hTF/sTFR complex 
We previously proposed a model for iron release from Fe2 hTF in the absence of 
the sTFR (236).  In the current paper, we expand the model to address the impact of the 
sTFR on iron release from Fe2 hTF under our “standard conditions”.  When the pH is 
lowered to ~5.6, the C-lobe of Fe2 hTF/sTFR undergoes a fast conformational change 
induced by anion binding and an incoming chelator (A, green star).  This initial 
conformational change may be the result of anion binding to the KISAB site, Arg632, 
which causes loosening of the cleft by displacing the hydrogen bond with Asp634.  Upon 
protonation of the iron binding and the second shell triad residues (further disrupting the 
hydrogen bond network), the C-lobe undergoes a second conformational change allowing 
iron to be released to a chelator (B, two green stars).  Simultaneously, anions bind to 








inducing a conformational change and priming it for iron release (B, blue star).  KISAB 
sites in the N-lobe include Arg124 and Lys296; binding of anion first to Arg124 would 
induce cleft opening.  Similar to the C-lobe, the iron binding ligands and the dilysine 
trigger (which includes Lys296) are protonated inducing a second conformational change 
and allowing approach and attack of the chelator (C, two blue stars).  Once the dilysine 
trigger has been protonated, a Cl- ion can bind to Lys296 helping to maintain an open 
cleft by interfering with the re-formation of the dilysine trigger.  The iron is removed by 
the chelator and the protein is in an open, apo conformation (D).  The apo hTF remains 
tightly bound to the sTFR (E) until it is released back to the plasma to continue the cycle.  
Throughout this process, the sTFR also undergoes compensatory conformational changes 
(represented by a lengthening of the sTFR in the model) to accommodate the opening of 
the two lobes.  Extensive mutagenesis of the sTFR in combination SPR binding affinity 
studies at both pH 7.4 and 6.3, clearly identified a number of residues in the sTFR that 
are involved in interaction with hTF.  The pH dependence implies that conformational 
changes expose or bury specific residues involved in the interaction (187).  Furthermore, 
it has been shown that TFR (in the absence of TF) undergoes a pH induced 
conformational change (276).  In summary, the sTFR increases the rate of iron release 
from the C-lobe of Fe2 hTF 8 fold and decreases the rate of iron release from the N-lobe 
of Fe2 hTF, 16 fold.   
Impact of the sTFR on the Two Monoferric and Locked Species 
A discussion of the impact of the sTFR on each of the monoferric and locked 








presence of the sTFR is explained by the introduction of a salt induced conformational 
change at high salt which precedes iron release and causes the enhancement of the rate of 
iron release (12 fold, kobs2, complex = 7.31 min-1 vs. kobs, alone = 0.60 min-1).  The two rate 
constants for iron release from the FeC hTF/sTFR complex have recently been discussed 
in detail (126, 254).  The initial conformational change is induced by anion binding and 
loosens the cleft stimulating a conformational change in the C-lobe that is stabilized by 
the sTFR.  Second, through interactions between the sTFR and the C-lobe, the hTF is 
now in a conformation primed for iron release and this iron release step is enhanced by 
the presence of the sTFR.  Additionally, the preceding salt induced conformational 
change is also only observed when the sTFR is present.   
The major impact of the sTFR on FeN hTF is the 19 fold decrease (kobs2, complex = 
1.21 min-1 vs. kobs1, alone = 22.70 min-1) in the rate of iron release and the 5 fold 
enhancement in the kinetic event assigned to anion binding in the FeN hTF/sTFR 
complex (kobs1, complex = 23.44 ± 2.09 min-1 vs. kobs2, alone = 4.94 ± 1.80 min-1).  The final 
conformational change/communication to the C-lobe that occurs in the absence of the 
sTFR to prime the C-lobe for iron release (kobs3, alone) is no longer present because iron has 
already been released from the C-lobe.   
 Similar to the FeC hTF/sTFR complex, the rate constant for iron release from 
LockN hTF is enhanced 12 fold in the presence of the sTFR (kobs1, complex = 5.63 min-1 vs. 
kobs, alone = 0.39 min-1).  The introduction of a second event in the LockN hTF/sTFR 








N-lobe that the C-lobe is open.  In a non-locked hTF (Fe2 hTF) this conformational 
change would prime the N-lobe for iron release.   
The LockC hTF/sTFR complex fits to a single exponential function and the rate of 
iron release is slow (decreased 14 fold, kobs, complex = 1.36 min-1 vs. kobs1, alone = 18.99 min-
1).  The positive salt effect is absent in the LockC hTF/sTFR complex (in fact the rate 
constant for iron release decreases ~3 fold).  Lack of iron release from the C-lobe of 
R632A and the loss of an anion binding site prevents a critical conformational change in 
the C-lobe that is relayed to the N-lobe and primes it for iron release, thus resulting in 
slow iron release from the N-lobe.    
In summary, we have specifically assigned the events describing the iron release 
process from Fe2 hTF by utilizing authentic monoferric and locked constructs to dissect 
the iron release process and elucidate individual steps leading to complete iron removal 
in the absence and presence of the sTFR.  We conclude that at pH 5.6, the sTFR enhances 
the rate of iron release from the C-lobe and slows the rate of iron release from the N-lobe 
making them more equivalent. 
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Tables and Figures 
Table 1A. Iron release rate constants in the absence of the sTFR  
 
Samples are rapidly mixed with 200 mM MES, pH 5.6, 300 mM KCl, 8 mM EDTA and 
excited at 280 nm.  Emission was monitored with a 320 nm cut-on filter. 
 
Construct kobs1 (min-1) kobs2 (min-1) kobs3 (min-1) 
Fe2 hTF 21.37 ± 6.84 0.65 ± 0.06 --- 
FeN hTF 22.70 ± 5.91 4.94 ± 1.80 1.03 ± 0.09 
FeC hTF 0.60 ± 0.07 --- --- 
LockN hTF 0.39 ± 0.07 --- --- 
LockC hTF 18.99 ± 2.09 3.09 ± 1.44 0.36 ± 0.07 
 
Table 1B. Iron release rate constants in the presence of the sTFR  
 
Samples are rapidly mixed with 200 mM MES, pH 5.6, 300 mM KCl, 8 mM EDTA and 
excited at 280 nm.  Emission was monitored with a 320 nm cut-on filter. 
 
Construct kobs1 (min-1) kobs2 (min-1) 
Fe2 hTF / sTFR 5.53 ± 1.53 1.34 ± 0.26 
FeN hTF / sTFR 23.44 ± 2.09 1.21 ± 0.13 
FeC hTF / sTFR 21.03 ± 2.66 7.31 ± 0.99 
LockN hTF / sTFR 5.63 ± 0.87 1.23 ± 0.08 














 Table 2A. The salt effect in the absence of the sTFR 
 
Fold enhancement in rate constants in the absence of the sTFR between 50 and 600 mM 
KCl in the presence of 100 mM MES, pH 5.6 and 4 mM EDTA. 
Construct kobs1 kobs2 kobs3
Fe2 hTF 5.0 2.1 --- 
FeN hTF 4.3 1.5a 1.1b
FeC hTF 2.2 --- --- 
LockN hTF 2.8 --- --- 
LockC hTF 4.2 1.0a 1.0b
 
Table 2B.  The salt effect in the presence of the sTFR 
 
Fold enhancement in rate constants in the presence of the sTFR between 50 and 600 mM 
KCl in the presence of 100 mM MES, pH 5.6 and 4 mM EDTA 
Construct kobs1 kobs2
Fe2 hTF / sTFR 2.2 1.5 
FeN hTF / sTFR (-)2.7c 2.2 
FeC hTF / sTFR 1.2a 1.0b
LockN hTF / sTFR 1.9 1.9 
LockC hTF / sTFR (-)2.9c --- 
 
a This event only occurs at concentrations of KCl greater than 150 mM 
b This enhancement is calculated using the final event from all salt concentrations 
(depending on the fit). 











Figure 1.  Representative stopped-flow fluorescence iron release progress curves   
 
A) Overlay of FeN hTF, FeC hTF and Fe2 hTF, B) Overlay of LockN hTF, LockC hTF and 
Fe2 hTF, C) Overlay of FeN hTF/sTFR, FeC hTF/sTFR and Fe2 hTF/sTFR, D) Overlay of 
LockN hTF/sTFR, LockC hTF/sTFR and Fe2 hTF/sTFR.  In each case, one syringe 
contained protein (375 nM) in 300 mM KCl and the other contained iron removal buffer 
(200 mM MES, pH 5.6, 300 mM KCl and 8 mM EDTA).  Samples were excited at 280 














Figure 2.  Pathways of iron release ± sTFR.   
 
A) Iron release pathways of Fe2 hTF in the absence of the sTFR, B) and the presence of 
sTFR.  Pathway taken indicated by red arrows, alternative pathway indicated by black 
dashed arrows.  The specific constructs used to isolate the rate constants are indicated 










Figure 3.  Model describing iron release from the Fe2 hTF/sTFR complex.   
 

















 Supplemental Figure 1. Double- vs. Triple-Exponential Fit 
 
Fits of FeN hTF with 150 mM KCl to a double and triple exponential.  The residuals of 
the fits are blown up below to show the vast improvement of the fitting when choosing 



















INTERACTION BETWEEN hTF AND THE sTFR 
Investigation of the N-lobe Interaction 
 Residues in both the NI and NII subdomains were identified by the cryo-EM 
model (183) as possible sites of interaction with the sTFR helical and protease-like 
domains, thus situating the N-lobe between the sTFR and the cell membrane.  For a more 
complete discussion and structural locations of these residues see Chapter 1 (Interaction 
with hTF, Figure 9 and Table 4).  Based on sequence homology with TFs that bind to the 
human TFR and lack of homology with those that do not, we chose to produce single 
point mutants of residues in a loop in the NII subdomain comprised of Pro142-Arg143-
Lys144-Pro145.  This region of the N-lobe appears to interact with the helical domain of 
the sTFR (specifically residues Tyr123-Trp124-Asp125).  SPR revealed that mutation of 
any one of these three residues (Y123S, W124A and D125K) in the sTFR resulted in a 5-
20 fold decrease in binding affinity for diferric hTF at pH 7.5 (187).  Interestingly, the 
binding affinity of these mutants for apo hTF at pH 6.3 was unaltered indicating a pH 
dependent effect of this region of the sTFR on binding hTF.    
Experimental 
 
Generation of Mutants and Kinetic Analysis 
 
 Single point mutations of Pro142, Arg143, Lys144 and Pro145 to alanine were 
introduced into two different backgrounds: 1) Fe2 hTF and 2) FeN hTF.  These constructs 
allow analysis of iron release from both lobes (Fe2 hTF) or specifically from the N-lobe 








were generated and stopped flow kinetic experiments in the absence and presence of the 
sTFR, at pH 5.6, were carried out on an Applied Photophysics SX.18MV 
spectrofluorimeter as detailed in previous sections.  End point iron release from each 
mutant in the absence and presence of the sTFR after a 15 minute incubation in pH 5.6 
buffer was analyzed by urea gel electrophoresis as described in detail in Chapter 2.   
Binding Affinity Measurements 
 The binding affinity of the Fe2 hTF mutants and the sTFR was determined by 
isothermal titration calorimetry (ITC) at pH 7.4 on a TA Instruments CSC Model 4200 
Calorimeter.  Attempts to perform these experiments at pH 5.6 have been complicated by 
solubility problems with the isolated sTFR.  In ITC, both hTF and sTFR are free in 
solution, (in SPR one partner is tethered to a chip which may restrict access to the 
binding site).  Additionally, ITC provides a complete thermodynamic profile (∆H, ∆S and 
∆G) of the interaction between hTF and the sTFR to derive an affinity constant (Kd).  The 
most significant limitation of ITC is the relatively large amount of protein required to 
carry out the experiment (~3 mg of each protein per experiment).  
Results and Discussion 
The kinetic data for iron release from each mutant in the Fe2 hTF background is 
presented in Table 1.  In this table, kobs1 refers to iron release from the N-lobe and kobs2 
refers to iron release from the C-lobe.  In the absence of the sTFR, mutation of either 
proline residue (P142A or P145A) has no apparent impact on iron release as the rate 
constants derived from the progress curves are equal to those of the unmutated control, 








that fits to a single exponential function and provides a rate constant which corresponds 
to iron release from the C-lobe.  The other mutant, K144A, fits to a double exponential 
function and the rate constant corresponding to iron release from the N-lobe is extremely 
fast compared to the rate constant for iron release from the N-lobe of Fe2 hTF.  
Interestingly, in the absence of the sTFR, K144A is the only construct that is 
convincingly apo on a urea gel after a 15 minute incubation in pH 5.6 buffer (Figure 1 
and Figure 2).  Based on the salt titrations of Fe2 hTF and the models presented in Figure 
7 (Chapter 2) and Figure 3 (Chapter 3), we suggest that one or both of these sites (Arg143 
and Lys144) are responsive to anions.  In fact, this region of the hTF N-lobe was 
identified by a molecular modeling simulation as potentially containing several KISAB 
sites (160).  Specifically, if Arg143 is an anion binding site, and anion binding helps 
induce a conformational change necessary for iron release from the N-lobe, then mutation 
of this site may slow iron release from the N-lobe and/or not induce the same 
conformational changes to produce a change in the fluorescence intensity upon iron 
removal.  Other evidence from urea gel electrophoresis shows that an equivalent amount 
of iron is removed from the N-lobe as from the control (Figure 1) and steady-state 
emission scans reach the same intensity (λmax) as apo hTF (data not shown); strongly 
suggesting that iron is completely removed from both lobes (or at least to the same 
degree as the control).  The steady-state and urea gel electrophoresis data (Figure 1 and 
Figure 2) represent the end point of iron removal after a 15 minute incubation at pH 5.6 
but do not address the kinetics of the process.  Thus the kinetic data suggest that the first 








It is possible that iron release is slowed by this mutation, but that it still occurs faster than 
the C-lobe and is complete within 15 minutes.  Mutation of the neighboring Lys144 
might enhance anion access to Arg143 resulting in faster iron release.  Additional studies 
are required to determine whether salt has an effect on each of these mutants; we suggest 
that Arg143 may serve as a KISAB site and that access to this site may be enhanced in 
the absence of neighboring Lys144 upon mutation to alanine. 
 Since these residues were proposed to interact with the receptor, we hypothesized 
that if one or more of these residues were important for the interaction, we might observe 
differences in the iron release rate constants (at pH 5.6) from complexes of these mutants 
with the sTFR.  However, only minor differences in iron release rate constants were 
observed from the sTFR complexes (Table 2).  In the presence of the sTFR, kobs1 is the 
rate constant for iron release from the C-lobe, and kobs2 reports iron release from the N-
lobe (Chapter 3).  Because iron is released first from the C-lobe in the complex, and 
because the C-lobe can bind in its native conformation, iron release from the N-lobe is 
minimally affected.  It is significant that loss of a possible anion binding site appears to 
matter only when anion binding is inducing an initial conformational change to promote 
iron release from the N-lobe prior to the C-lobe (i.e., in the absence of the sTFR).   
 The binding affinity of each mutant for the sTFR is ~10-fold weaker than the 
control Fe2 hTF at pH 7.4 (Table 3).  It appears that all four members comprising the loop 
participate equally in the high affinity interaction with the sTFR at neutral pH.  Of most 








monoferric construct.  This suggests that in the absence of any one of these four residues, 
the interaction between the N-lobe and the sTFR is lost.   
 If the four single point mutants in the diferric construct bind as a monoferric 
species, then placement of each mutant into a construct which does not bind iron in the 
C-lobe (FeN hTF) should generate a construct which does not bind to the sTFR at all.  
Again, in the absence of the sTFR (Table 4), iron release rate constants from P142A and 
P145A are similar to the FeN hTF control while those from R143A and K144A are 
different.  As described in Chapter 3, FeN hTF fits to a triple exponential function; kobs1 is 
assigned to iron release, kobs2 is assigned to a salt induced conformational change (that is 
only present at high concentrations of salt) and kobs3 is attributed to a final conformational 
change to the apo conformation.  In contrast to P142A and P145A, both R143A and 
K144A fit best to double exponential functions.  Again it appears that the iron release 
step, kobs1, (possibly initiated by anion binding), is not observed in R143A FeN hTF.  The 
rate of the salt induced conformational change (kobs2 for the control, kobs1 for R143A), is 
the same, as is the final conformational change to apo.  Further studies are needed to 
determine if kobs1 (of R143A) is sensitive to salt in a concentration dependent manner.  
Interestingly, the K144A mutant also fits best to a double exponential function, however, 
the rates associated with it appear to be similar to kobs1 and kobs3 from the control 
indicating the absence of the salt induced kobs2 conformational change.  Obviously 
investigation of the salt effect of both R143A and K144A in the FeN hTF background is 
warranted.  Iron release from the complexes of these four N-lobe mutants in the FeN hTF 








Investigation of the C-lobe Interaction 
There is a significant amount of data indicating that the CI subdomain makes the 
majority of the contacts with the helical domain of the TFR.  Several independent studies 
have identified a region of the CI subdomain that is important for receptor binding; these 
include radiation footprinting (186), monoclonal antibody epitope mapping (185, 256) 
and the structural model based on cryo-EM (183).  Combined, these studies suggest that 
the region from His349-Lys401 is the primary binding area.  Of great interest, the 
isolated C-lobe binds weakly to the TFR (0.8 µM) (187) and the isolated N-lobe does not 
bind at all; thus both lobes are essential to the high affinity interaction (141).  
Interestingly, each monoferric species contributes equally to the binding energy of the 
interaction again indicating that the full length molecule is needed for binding.  What 
remains unclear is exactly which residues in the His349-Lys401 region are involved in 
these interactions.  Of the eleven residues identified in the cryo-EM (Chapter 1, 
Interaction with hTF, Figure 10 and Table 5), we have chosen to focus on four.  Although 
preliminary work has been reported on the important role played by His349 (132) more 
extensive studies are underway in our laboratory and will not be discussed at this time.  A 
careful analysis of the cryo-EM model revealed potential salt bridges between three of 
the residues in this region of CI with the sTFR helical domain.  Specifically, Asp356 
(hTF) is within 3.49 Å of Arg646 (sTFR); Glu357 (hTF) is within 2.06 Å of Arg629 
(sTFR); and Glu372 (hTF) is within 2.44 Å of Arg651 (sTFR) (Chapter 1, Interaction 
with hTF, Figure 10).  In one study, two of these residues in the sTFR (Arg629 and 








pH 7.4 and apo hTF at pH 6.3 (187).  Significantly, mutation of Arg651 resulted in a 
2500 fold decrease in the affinity at pH 7.4 and gave no detectable binding at pH 6.3 
implicating it as a critical component of the hTF/TFR interaction.  Similarly, mutation of 
Arg629 resulted in a 5-6 fold decrease in binding affinity at pH 7.4 and pH 6.3 (187).  
Other residues in this region of the receptor also affected the binding affinity (particularly 
at pH 6.3) indicating the importance of the TFR helical domain in the interaction with 
apo hTF at this pH.  For these reasons we chose to pursue work with Asp356, Glu357 and 
Glu372 for stopped flow kinetic and ITC affinity experiments.    
Experimental 
Generation of Mutants and Kinetic Analysis 
To isolate iron release from the C-lobe, we singly mutated Asp356, Glu357 and 
Glu372 to alanine in the FeC hTF background.  Complexes of each of the FeC hTF 
mutants with the sTFR were generated; stopped flow kinetic experiments at pH 5.6 in the 
absence and presence of the sTFR were carried out on an Applied Photophysics 
SX.18MV spectrofluorimeter as described in previous chapters.  Iron release from each 
mutant in the absence and presence of the sTFR was also analyzed by urea gel 
electrophoresis as described in detail in Chapter 2.   
Binding Affinity Measurements 
Affinity measurements at pH 7.4 were carried out by ITC as described above. 
Results and Discussion 
 The kinetic data for iron release from D356A, E357A and E372A in the FeC hTF 








the control fit to a single exponential function; the rate constant for iron release from 
D356A and E357A are equal to the control.  However, the rate constant for iron release 
from the E372A mutant is ~2.5 times faster than the control suggesting a small 
conformational alteration that affects iron release despite the fact that this residue is ~30 
Å away from the iron binding center.  Curiously, as determined by urea gel 
electrophoresis this is the only mutant that is convincingly apo in the absence of the sTFR 
after a 15 minute incubation at pH 5.6 (Figure 3 and Figure 4).   Nevertheless, the final 
emission intensity for this mutant is slightly lower (~13%) than that of the control (data 
not shown).    
In the presence of the sTFR, the control FeC hTF/sTFR complex fits to a double 
exponential function (as described in Chapter 3) with kobs1 assigned to a salt induced 
conformational change and kobs2 assigned to iron release (Table 6).  Interestingly, the 
D356A/sTFR complex, fits best to a single exponential function with a rate constant that 
is in between kobs1 and kobs2 of the control.  Further studies are required to assign this rate 
constant to a particular event, but urea gel electrophoresis reveals that the all of iron is 
removed from both the control and D356A complexes (Figure 3).   Although iron release 
from the E357A/sTFR complex was not significantly different than the control complex, 
iron release from the E372A/sTFR complex was faster than the control.  The salt induced 
conformational change was ~3 fold faster than that of the control and the rate constant for 
iron release was slightly increased as well.  Further salt titrations will be performed to 








 To investigate whether any of these differences in the kinetics of iron release are a 
result of weaker binding affinity, ITC was performed on each of these mutants and the 
sTFR (Table 7).  The most striking difference is the 10 fold weaker affinity of the D356A 
mutant for the sTFR.  This appears to be consistent with the differences observed for the 
iron release kinetics.  Additionally, the thermodynamic parameters of the D356A mutant 
were significantly different than those of the control.  Interestingly, the E372A mutant 
(which released iron fast) had the same affinity for the sTFR as the FeC hTF control, 
however, the thermodynamic parameters differed significantly.  Both D356A and E372A 
had positive ∆H values indicating that heat was required for the interaction suggesting a 
weak interaction.     
 In summary, it appears that the entire loop in the N-lobe (Pro142-Arg143-Lys144-
Pro145) is involved in the interaction with the sTFR at neutral pH.  However, significant 
differences are not observed when monitoring iron release from these complexes at 
endosomal pH.  The kinetic differences observed for the R143A and K144A mutants in 
the absence of the sTFR require further investigation to confirm whether they might serve 
as potential KISAB sites.  It is possible that mutation of Lys144 disrupts the local 
environment placing the N-lobe in a more open conformation (as indicated by faster iron 
release).  In the C-lobe, all three mutants had rate constants similar to the control with 
only the E372A mutant being slightly faster in the absence of the receptor.  However, in 
the presence of the sTFR, D356A fit only to a single exponential function and displayed 
~10 fold weaker binding affinity.  Additionally, for the E372A/sTFR complex, both the 








the control.  Clearly, additional experiments are required, but these preliminary studies 
provide interesting results regarding the specific residues involved in the TF/TFR 































Tables and Figures 
Table 1.  Iron release rate constants from the Fe2 hTF N-lobe mutants 
 
Protein kobs1 (min-1) kobs2 (min-1) 
Control Fe2 hTFa 16.2 ± 9.5 0.64 ± 0.09 
P142A Fe2 hTF 15.4 ± 0.80 0.64 ± 0.03 
R143A Fe2 hTF --- 0.65 ± 0.01 
K144A Fe2 hTF 58.8 ± 1.3 0.57 ± 0.03 
P145A Fe2 hTF 18.9 ± 0.01 0.62 ± 0.02 
 
a All samples (375 nM) in 300 mM KCl were rapidly mixed with 200 mM MES pH 
5.6/300 mM KCl/8 mM EDTA.  Excitation: 280 nm, emission: 320 nm cut-on filter.  


































Table 2.  Iron release rate constants from Fe2 hTF N-lobe mutants/sTFR complexes 
 
Protein kobs1 (min-1) kobs2 (min-1) 
Control Fe2 hTF / sTFRa 5.7 ± 1.5 1.4 ± 0.26 
P142A Fe2 hTF / sTFR 4.7 ± 0.11 1.8 ± 0.23 
R143A Fe2 hTF / sTFR 4.6 ± 0.33 1.1 ± 0.01 
K144A Fe2 hTF / sTFR 7.1 ± 0.73 2.2 ± 0.20 
P145A Fe2 hTF / sTFR 5.7 ± 0.28 2.1 ± 0.36 
 
a All samples (375 nM) in 300 mM KCl were rapidly mixed with 200 mM MES pH 
5.6/300 mM KCl/8 mM EDTA.  Excitation: 280 nm, emission: 320 nm cut-on filter.  




































Table 3.  Binding affinity between Fe2 hTF N-lobe mutants and the sTFR 
 
Protein n (per sTFR monomer) K (M






Fe2 hTF 1.04 ± 0.01 2.98 ± 1.44 x 108 -37.41 ± 0.23 36.76 ± 1.21 -48.37 ± 1.19 3.4 
FeC hTF 0.92 ± 0.01 3.14 ± 1.70 x 107 -17.41 ± 0.71 85.10 ± 1.51 -42.77 ± 1.34 31.8 
FeN hTF 0.98 ± 0.01 2.78 ± 1.15 x 107 -18.34 ± 0.24 80.97 ± 1.04 -42.47 ± 1.02 36.0 
P142A hTF 0.89 ± 0.01 3.82 ± 2.05 x 107 -27.60 ± 0.71 52.21 ± 1.43 -43.25 ± 1.73 26.2 
R143A hTF 0.96 ± 0.01 5.66 ± 2.40 x 107 -19.89 ± 0.24 81.67 ± 1.18 -44.23 ± 0.97 17.7 
K144A hTF 0.95 ± 0.01 4.27 ± 1.74 x 107 -19.39 ± 0.27 81.00 ± 1.36 -43.53 ± 1.03 23.4 





































Table 4.  Iron release rate constants from FeN hTF N-lobe mutants  
 
Protein kobs1 (min-1) kobs2 (min-1) kobs3 (min-1) 
Control FeN hTFa 15.8 2.7 0.99 
P142A FeN hTF 11.9 2.8 0.59 
R143A FeN hTF --- 5.1 0.86 
K144A FeN hTF 24.2 --- 0.66 
P145A FeN hTF 10.9 4.4 0.61 
 
a All samples (375 nM) in 300 mM KCl were rapidly mixed with 200 mM MES pH 
5.6/300 mM KCl/8 mM EDTA.  Excitation: 280 nm, emission: 320 nm cut-on filter.  




































Table 5.  Iron release rate constants from FeC hTF C-lobe mutants  
  
Protein kobs1 (min-1) 
Control FeC hTFa 0.59 ± 0.07 
D356A FeC hTF 0.66 ± 0.06 
E357A FeC hTF 0.60 ± 0.04 
E372A FeC hTF 1.59 ± 0.11 
 
a All samples (375 nM) in 300 mM KCl were rapidly mixed with 200 mM MES pH 
5.6/300 mM KCl/8 mM EDTA.  Excitation: 280 nm, emission: 320 nm cut-on filter.  






































Table 6.  Iron release rate constants from FeC hTF C-lobe mutants/sTFR complexes 
 
Protein kobs1 (min-1) kobs2 (min-1) 
Control FeC hTF / sTFRa 20.49 ± 3.39 7.00 ± 0.77 
D356A FeC hTF / sTFR 15.31 ± 1.18 --- 
E357A FeC hTF / sTFR 23.49 ± 1.15 7.37 ± 0.01 
E372A FeC hTF / sTFR 57.74 ± 0.61 10.08 ± 1.27 
 
a All samples (375 nM) in 300 mM KCl were rapidly mixed with 200 mM MES pH 
5.6/300 mM KCl/8 mM EDTA.  Excitation: 280 nm, emission: 320 nm cut-on filter.  






































Table 7.  ITC binding affinity between FeC hTF C-lobe mutants and the sTFR 
 
Protein n (per sTFR monomer) K (M







Fe2 hTF 1.04 ± 0.01 2.98 ± 1.44 x 108 -37.41 ± 0.23 36.76 ± 1.21 -48.37 ± 1.19 3.4 
FeC hTF 0.92 ± 0.01 3.14 ± 1.70 x 107 -17.41 ± 0.71 85.10 ± 1.51 -42.77 ± 1.34 31.8 
FeN hTF 0.98 ± 0.01 2.78 ± 1.15 x 107 -18.34 ± 0.24 80.97 ± 1.04 -42.47 ± 1.02 36.0 
D356A  0.82 ±0.05 4.04 ± 1.77 x 106 4.49 ± 0.39 141.54 -37.69 247.5 
E357A 0.90 ± 0.01 3.63 ± 2.14 x 107 -5.12 ± 0.11 127.55 -43.13 27.5 


































Figure 1.  Urea gel analysis of iron release from Fe2 hTF N-lobe mutants   
 
Even numbered lanes contain the sample in urea gel sample buffer.  Odd numbered lanes 
contain the sample after a 15 minute incubation in iron removal buffer (100 mM MES pH 
5.6 / 300  mM KCl / 4 mM EDTA).  Lanes 1 and 2-Fe2 hTF.  Lanes 3 and 4-Fe2 
hTF/sTFR.  Lanes 5 and 6-P142A.  Lanes 7 and 8-P142A/sTFR.  Lanes 9 and 10-R143A.  
































Figure 2.  Urea gel analysis of iron release from Fe2 hTF N-lobe mutants   
 
Even numbered lanes contain the sample in urea gel sample buffer.  Odd numbered lanes 
contain the sample after a 15 minute incubation in iron removal buffer (100 mM MES pH 
5.6 / 300  mM KCl / 4 mM EDTA).  Lanes 1 and 2-Fe2 hTF.  Lanes 3 and 4-Fe2 
hTF/sTFR.  Lanes 5 and 6-K144A.  Lanes 7 and 8-K144A/sTFR.  Lanes 9 and 10-
































Figure 3.  Urea gel analysis of iron release from FeC hTF C-lobe mutants   
 
Even numbered lanes contain the sample in urea gel sample buffer.  Odd numbered lanes 
contain the sample after a 15 minute incubation in iron removal buffer (100 mM MES pH 
5.6 / 300  mM KCl / 4 mM EDTA).  Lanes 1 and 2-FeC hTF.  Lanes 3 and 4-FeC 































Figure 4.  Urea gel analysis of iron release from FeC hTF C-lobe mutants   
 
Even numbered lanes contain the sample in urea gel sample buffer.  Odd numbered lanes 
contain the sample after a 15 minute incubation in iron removal buffer (100 mM MES pH 
5.6 / 300  mM KCl / 4 mM EDTA).  Lanes 1 and 2-FeC hTF.  Lanes 3 and 4-FeC 
hTF/sTFR.  Lanes 5 and 6-E357A.  Lanes 7 and 8-E357A/sTFR.  Lanes 9 and 10-E372A.  










SUMMARY AND FUTURE DIRECTIONS 
 Although hTF was first isolated from plasma over sixty years ago and its central 
role in iron metabolism is well understood, the details pertaining to the mechanism of 
iron release from each lobe of hTF and an understanding of the molecular interaction 
with the TFR have remained more elusive.  In this dissertation we have substantiated 
many of the prevailing beliefs regarding the mechanism of iron release from hTF.  
Importantly, we have been able to separate the iron release process into discrete steps 
from Fe2 hTF Æ apo hTF by utilizing authentic locked and monoferric constructs 
(Chapters 2 and 3).  These recombinant constructs eliminate the possibility of acquisition 
of iron by the open lobe or, alternatively, completely prevent iron release.  Our work has 
provided more details regarding the mechanism of iron release in both the absence and 
presence of the sTFR.  The models we have created to explain the complex process show 
that iron release is accompanied by conformational changes induced by anion binding, 
lobe-lobe interactions and interaction with the sTFR.  
 Briefly, in Chapter 2, we have described the effects of pH, lobe conformation and 
the sTFR on iron release from both the N- and C-lobes of hTF.  The techniques employed 
provided a qualitative measure of iron release after incubation at endosomal pH for 15 
minutes but did not provide information regarding the kinetic pathway followed to reach 
the endpoint.  We found that iron release from the N-lobe was insensitive to changes in 
pH, but was sensitive to the conformation of the C-lobe.   Conversely, we found that iron 








of the N-lobe.  The two lobes differ in their response to the sTFR; iron release from the 
C-lobe is clearly enhanced while iron release from the N-lobe appears unaffected.  Iron 
release from Fe2 hTF occurs first from the N-lobe then from the C-lobe; the presence of 
the sTFR induces a switch in this order. 
 In order to create a more informative model of iron release, a thorough kinetic 
analysis of iron release from each lobe was undertaken (Chapter 3).  The mechanism of 
iron release differs for the two lobes as does the effect of the sTFR.  Iron release from the 
N-lobe includes a salt induced conformational change and a conformational 
communication event with the C-lobe, neither of which are observed during iron release 
from the C-lobe.  In the absence of the sTFR, iron release from the N-lobe is faster than 
iron release from the C-lobe.  However, it appears that a critical role of the sTFR is to 
enhance iron release from the C-lobe while decreasing the rate of iron release from the N-
lobe such that they occur on a time scale relevant to once cycle of endocytosis.  For each 
lobe, there is a salt induced conformational change prior to iron release that is only 
observed in the presence of the sTFR. 
It is critical to identify the specific residues involved in the hTF/TFR interaction 
(as introduced in Chapter 4).  Because diferric hTF binds to the TFR with high affinity, 
and TFR is highly expressed on cancerous cells, which requires large amounts of iron in 
order to proliferate, hTF can provide targeted drug delivery.  In this regard, a 
recombinant double locked hTF construct (containing the K206E/R632A mutations), has 
been developed to increase the dwell time of a TF conjugated to a toxin within a cancer 








would dissociate from the TFR (due to the weak binding affinity of diferric hTF at 
endosomal pH) and would thus not be recycled back to the plasma.  This would increase 
the half life of the drug thereby increasing its ability to kill the cell.  An important caveat 
of this is that if the conjugation of the drug on hTF interferes with the interaction with the 
TFR, then the hTF/drug conjugate might not enter the cancer cells.  It is critical to 
understand the molecular basis of the interaction in order to conjugate a toxin at a 
specific location that would still allow high affinity binding of hTF to the TFR.  Ideally, a 
crystal structure of the hTF/TFR complex at both neutral and endosomal pH will provide 
further insight and evidence of the molecular basis of the interaction to strategically 
design hTFs or conjugate drugs with therapeutic potential to a specific region of hTF.  
In addition to understanding the molecular basis of the TF/TFR interaction, the 
details of the iron release mechanism from both lobes of hTF warrants further 
investigation.  It is highly likely that other KISAB sites exist, and identification of them 
will help understand the salt effects observed when monitoring iron release from hTF.  
By mutating particular candidate residues, and using the fluorescence and urea gel assays 
we can determine whether or not a mutant is responsive to changing concentrations of 
salt.  Our work suggests that Arg143 in the N-lobe might be a KISAB site.  Furthermore, 
mutation of neighboring Lys144 might induce a conformational change that enhances 
access to Arg143 and results in faster rate constants for iron release.     
The exact fate of the iron once it is released from hTF remains unclear.  Although 
several candidates for the endosomal chelator have been proposed (citrate, ATP, PPi), 








iron must be reduced to ferrous iron before exiting the endosome through DMT1, but 
again, the exact details of the process are unknown.  A ferrireductase in the endosomal 
membrane has been identified (114).  Alternatively, reduction of the iron while hTF is 
still bound to the TFR has also been proposed (116).  Lastly, the mechanism of iron 
transfer between the endosomal vesicle and the mitochondria (for incorporation into 
heme by ferrochelatase) is not yet elucidated.  These are some of the questions 
surrounding the fate and pathway of the iron brought into the cell by hTF that remain 
unanswered.   
In summary, we have set out to describe the molecular basis of receptor mediated 
iron release from hTF.  We have clearly demonstrated the complexity of this process, but 
by utilizing constructs in which iron binding and release are controlled, we have 
unambiguously elucidated many details of the iron release mechanism from both the N- 
and C-lobes of hTF.  Assignment of specific anion induced conformational changes as 
well as conformational changes associated with lobe-lobe communication have been 
“visualized”.  Although more work remains to determine the precise interaction between 
hTF and the TFR, much progress has been made.  Since iron deficiency is the number 
one nutritional deficiency worldwide and hereditary hemochromatosis affects 1/250 
people (of European descent), it is critical to understand how the TF iron delivery system 
works at the molecular level.  A clearer understanding may allow hTF to be altered in a 
clinical setting to alleviate complications due to iron deficiency or iron overload.  The 
implications of hTF as a cancer therapeutic are promising, especially utilizing constructs 
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ABSTRACT: Production of the soluble portion of the transferrin receptor (sTFR) by baby hamster kidney
(BHK) cells is described, and the effect of glycosylation on the biological function of sTFR is evaluated
for the first time. The sTFR (residues 121-760) has three N-linked glycosylation sites (Asn251, Asn317,
and Asn727). Although fully glycosylated sTFR is secreted into the tissue culture medium (40 mg/L),
no nonglycosylated sTFR could be produced, suggesting that carbohydrate is critical to the folding, stability,
and/or secretion of the receptor. Mutants in which glycosylation at positions 251 and 727 (N251D and
N727D) is eliminated are well expressed, whereas production of the N317D mutant is poor. Analysis by
electrospray ionization mass spectrometry confirms dimerization of the sTFR and the absence of the
carbohydrate at the single site in each mutant. The effect of glycosylation on binding to diferric human
transferrin (Fe2 hTF), an authentic monoferric hTF with iron in the C-lobe (designated FeC hTF), and a
mutant (designated Mut-FeC hTF that features a 30-fold slower iron release rate) was determined by
surface plasmon resonance; a small (20%) but consistent difference is noted for the binding of FeC hTF
and the Mut-FeC hTF to the sTFR N317D mutant. The rate of iron release from FeC hTF and Mut-FeC
hTF in complex with the sTFR and the sTFR mutants at pH 5.6 reveals that only the N317D mutant has
a significant effect. The carbohydrate at position 317 lies close to a region of the TFR previously shown
to interact with hTF.
Transferrin (TF) is a bilobal metal binding protein that
transports iron to cells. The N- and C-lobes of human TF
(hTF)1 are homologous globular domains that can each bind
one atom of ferric iron (Fe3+) in a cleft formed by two
subdomains. The iron is coordinated by two tyrosines, a
histidine, an aspartic acid residue, and two oxygen atoms
from the synergistic carbonate anion, which is anchored by
a conserved arginine residue (1). Since ferric iron is insoluble
in aqueous solution at physiological pH, binding to hTF is
an absolute requirement for delivery of iron to cells. Diferric
hTF (Fe2 hTF) in the circulation preferentially binds to the
extracellular portion of the transferrin receptor (TFR) on the
cell surface at neutral pH (7.4). Monoferric hTF binds to
the TFR an order of magnitude less tightly than Fe2 hTF,
and apo-hTF does not effectively compete with diferric or
the two monoferric hTF species for binding to the TFR (2,
3). The Fe2 hTF/TFR complex is endocytosed into a clathrin-
coated pit forming an endocytic vesicle. The coat disas-
sembles as the endocytic vesicles fuse within the cell. The
pH within the endosome is lowered to pH 5.6 by a
mechanism involving a proton pump which leads to iron
release (4, 5). Although all of the details related to the release
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1 Abbreviations: WT, wild type; hTF, human serum transferrin that
is glycosylated; hTF-NG, human serum transferrin that is nonglyco-
sylated; Fe2 hTF, diferric human serum transferrin; N-His hTF-NG,
recombinant nonglycosylated human serum transferrin with an N-
terminal hexahistidine tag and a factor Xa cleavage site attached to
the amino terminus of the protein; FeC hTF, N-His Y95F/Y188F hTF-
NG monoferric hTF with iron in the C-lobe; Mut-FeC hTF, slowly
releasing C-lobe mutant (N-His Y95F/Y188F/R632N/D634N hTF-NG);
TFR, transferrin receptor 1; sTFR, recombinant soluble portion of
transferrin receptor 1 with an N-terminal hexahistidine tag, a factor
Xa cleavage site, and residues 121-760 of the TFR; N251D, N317D,
and N727D, sTFR mutants containing Asn f Asp mutations at the
indicated positions; DMEM-F12, Dulbecco’s modified Eagle’s medium-
Ham F-12 nutrient mixture; BHK cells, baby hamster kidney cells; CHO
cells, Chinese hamster ovary cells; UG, Ultroser G; FBS, fetal bovine
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of iron are not clear, it appears that ferric iron may be reduced
by a newly described ferrireductase (6), and the resulting
ferrous iron crosses the endosomal membrane for use by the
cell in a process involving the divalent metal transporter,
DMT-1 (7). Critical to the cycle, apo-hTF remains bound to
TFR at acidic pH and is transported back to the plasma
membrane surface where it is released to bind more ferric
iron. The complete process of iron delivery takes only 2-3
min (8).
The ubiquitous TFR (also known as TFR-1) is an inducible
760 amino acid, membrane-bound protein. A constitutively
expressed TFR, known as TFR-2, has also been identified
(9). TFR is initially synthesized as an 86 kDa protein that
dimerizes shortly after synthesis forming a homodimer held
together by two intermolecular disulfide bonds (Cys89 and
Cys98) (10, 11). After exiting the endoplasmic reticulum
(ER), N-linked glycosylation occurs at three asparagine
residues (Asn251, Asn317, and Asn727) and one O-linked
threonine residue (Thr104), yielding a protein with a mass
of 190 kDa (10, 12). The predicted TFR primary amino
acid sequence (13, 14) led to the identification of three
distinct regions: a globular extracellular portion which binds
hTF (residues 90-760), a hydrophobic membrane-spanning
segment (residues 62-89), and the remaining 61 residues
which lie within the cytoplasm and contain signaling motifs
(15). Residues 89-126 of the TFR comprise a stalk
separating the extracellular domain from the transmembrane
domain.
The crystal structure of a recombinant form of the soluble
TFR (sTFR, comprised of residues 121-760) expressed by
Chinese hamster ovary cells was determined by Lawrence
et al. (11). The structure revealed that the extracellular portion
of the TFR is comprised of three subdomains: a protease-
like domain (resembling amino- and carboxypeptidases), an
apical domain, and a helical domain (Figure 1A). Experi-
mentally, the sTFR is easier to work with since it remains
soluble in the absence of the detergent required to maintain
the full-length TFR in solution. The development of a robust
baculovirus/insect cell expression system by Drs. Snow and
Bjorkman (including the attachment of a hexa-His tag to the
N-terminus for ease of purification) has made recombinant
sTFR available to the research community (16-19). This
expression system also allows production of site-directed
mutants to determine the role of specific amino acid residues
involved in binding of hTF. Parenthetically, the HFE protein
also binds TFR. This protein is defective in individuals
suffering from hereditary hemochromatosis in which there
is an increase in the intestinal absorption of iron leading to
excessive iron stores and iron overload (20). Significantly,
hTF and HFE compete with each other for binding to TFR,
implying that they share recognition sequences on the TFR
(20, 21). The availability of the crystal structure of the HFE/
sTFR complex identified the amino acid residues involved
in binding of HFE to sTFR and, thereby, also provided
information with regard to potential binding region(s) of hTF
(22). An earlier study (23) had identified a conserved Arg-
Gly-Asp sequence at residues 646-648 in the TFR which
is critical to hTF binding and accounts at least in part for
the high-affinity interaction. Extensive mutagenesis and
binding studies by Giannetti et al. (17) identified other
specific residues in the TFR crucial to the binding of HFE
and of hTF. Importantly, this work showed differential
binding affinities of the sTFR for apo-hTF and Fe2 hTF as
a function of pH. In particular, two TFR residues (Trp641
and Phe760) reside in the helical domain and form a
hydrophobic patch (see below).
Earlier work of Aisen and colleagues (initially utilizing
TFR isolated from placenta and more recently the recom-
binant sTFR) was pivotal in establishing the crucial role of
the TFR in facilitating iron release from hTF at the
appropriate time and place (24-27). This group established
techniques that unequivocally showed that TFR inhibits iron
release from hTF at pH 7.4 and accelerates it at the putative
endosomal pH of 5.6. More recently, other approaches to
map the TFR and hTF interface have been reported (28, 29),
complementing the site-directed mutagenesis work from the
Bjorkman laboratory mentioned above (17). The differential
FIGURE 1: Crystal structure of sTFR (PDB code 1CX8) adapted
from Lawrence et al. (11). (A) Asn-linked glycosylation sites are
labeled on one monomer and shown in yellow. The extracellular
portion of the TFR is comprised of three subdomains: a protease-
like domain resembling amino- and carboxypeptidases (residues
121-188 and 384-606 shown in blue), an apical domain (residues
189-383, purple), and a helical domain (residues 607-760, green).
The hydrophobic patch residues Trp641 and Phe760 are in orange.
(B) Close-up of the region indicated in the red box in (A) to
highlight the residues and the proximity of Asn317 (yellow) to the
hydrophobic patch residues Trp641 and Phe760 (orange) involved
in hTF binding. The residue in the upper right-hand corner is
Asn727.
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effect of radiation damage on hTF (or the C-lobe of hTF)
and the TFR individually compared to the hTF/TFR complex
has been determined, providing a “footprint” that identifies
residues in each that are protected by complex formation
(28). A second approach involved construction of an atomic
model obtained by fitting crystal structures of the human
N-lobe and rabbit C-lobe into a map of the sTFR (29). This
cryo-EM study has identified residues in both the sTFR and
hTF involved in complex formation. It is proposed that the
C-lobe makes contact through the C-I subdomain with the
helical region of the sTFR, allowing the C-II subdomain to
move freely. It is further suggested that the N-lobe binds
TFR through both subdomains in contact with the helical
and the protease-like domain on the underside of the TFR,
placing the N-lobe between the TFR and the membrane.
Recent experiments provide additional insight into the
importance of Trp641 and Phe760 from sTFR in the pH-
dependent release of iron from hTF (30). The double mutant
W641A/F760A sTFR was found to bind Fe2 hTF with an
affinity close to that found for wild-type (WT) sTFR at pH
7.4, 6.3, and 5.6. In contrast, apo-hTF binds this mutant sTFR
with a 400-1000-fold lower affinity at pH 6.3 and 5.6,
respectively, compared to WT sTFR. Furthermore, the double
mutant actually slows iron release from the C-lobe of
monoferric hTF by a factor of 2.
As mentioned, TFR has three N-linked glycosylation sites.
As shown in Figure 1A, Asn727 is found in the helical
domain while Asn 251 and 317 both reside in the apical
domain. Of interest is the observation that Asn317 appears
to reside close to the hydrophobic patch of the sTFR
described above (Figure 1B). Extensive work from the
laboratories of Enns, Hunt, and colleagues has established
the importance of glycosylation in the proper folding,
transport, and insertion of full-length TFR into the plasma
membrane (10, 31-36). Protein structure and stability,
intracellular trafficking, and localization as well as protection
from proteolysis and enhanced solubility are known to be
influenced by attachment of carbohydrate (ref 37 and
references cited therein). Additionally, different glycoforms
have different effects on these properties (38).
In the current study we report the development of an
expression system using baby hamster kidney (BHK) cells
to synthesize and secrete a His-tagged soluble TFR construct
similar to that produced previously in insect cells (18). The
rationale for producing this construct in a different expression
system is threefold: (1) to explore the possibility of obtaining
higher yields in a system in which we have extensive
experience; (2) to provide a different target for crystallization
studies since the glycosylation composition is likely to vary
in the two expression systems; and (3) to allow us to pursue
further mutagenesis studies. We have established a competi-
tive immunoassay to measure the expression levels of the
WT and mutant sTFR permitting the optimization of our
expression system. Additionally, we have produced mutants
in which each of the three asparagine residues have been
converted to aspartic acid to prevent glycosylation, and we
have analyzed the composition of these constructs by mass
spectrometry. We report the binding constants for each of
the sTFR glycosylation mutants by using surface plasmon
resonance (SPR). We also report the rate constants for the
release of iron from the C-lobe of a monoferric hTF (FeC
hTF) and a mutant of FeC hTF (designated Mut-FeC hTF)
bound to each sTFR construct. In the case of the FeC hTF/
sTFR complex we are using a newly developed stopped-
flow procedure which provides these rates with greater
precision. For the first time, the effect of glycosylation on
the biological function of the soluble TFR is revealed.
MATERIALS AND METHODS
Materials. Dulbecco’s modified Eagle’s medium-Ham
F-12 nutrient mixture (DMEM-F12), antibiotic-antimycotic
solution (100), and trypsin were from the GIBCO-BRL
Life Technologies Division of Invitrogen. The Escherichia
coli strain MACHI was also purchased from Invitrogen. Fetal
bovine serum (FBS) was obtained from Atlanta Biologicals
(Norcross, GA) and was tested prior to use to ensure adequate
growth of BHK cells. Ultroser G (UG) is a serum replace-
ment from Pall BioSepra (Cergy, France). The QuikChange
mutagenesis kit and pBluescriptII were from Strategene. Ni-
NTA resin and the Qiaquick nucleotide removal kit were
from Qiagen. The Klenow fragment and buffer were from
New England Biolabs. Corning expanded surface roller
bottles and Dynatech Immunolon 4 Removawells were
obtained from Fisher Scientific. The Hi-Prep 26/60 Sephacryl
S-300HR column was from Amersham Pharmacia. Meth-
otrexate from Bedford Laboratories was purchased at a local
hospital pharmacy and used for selection of plasmid-
containing BHK cells. Centricon 30 microconcentrators, YM-
30 ultrafiltration membranes, and spiral cartridge concentrator
(CH2PRS) fitted with an S1Y10 cartridge were from
Millipore/Amicon. Bovine serum albumin (BSA) was from
Sigma. Rabbit anti-mouse immunoglobulin G was from
Southern Biological Associates. Immunopure NHS-LC-biotin
and immunopure avidin-horseradish peroxidase were from
Pierce. The TMB Microwell peroxidase substrate system was
obtained from Kirkegaard and Perry Laboratories (Gaith-
ersburg, MD). Human serum TF was purchased from
Intergen (Purchase, NY) or from Sigma. The A4A6 mono-
clonal antibody to TFR was a generous gift from the
laboratory of Dr. James Cook at the University of Kansas
Medical Center. All other chemicals and reagents were of
analytical grade or better.
Preparation of Plasmids. A full-length human TFR cDNA
clone was kindly provided by Dr. Caroline Enns (Department
of Cell and Developmental Biology, Oregon Health &
Science University). The cDNA was engineered for the
expression of sTFR that contained the signal peptide of hTF,
four amino acids (V-P-D-K) from the N-terminus of hTF,
six histidine residues, a factor Xa cleavage site, and the
N-terminal region of the TFR beginning at residue 121. A
double-stranded synthetic oligonucleotide was formed by
hybridizing two overlapping oligonucleotides (Table 1, oligos
1 and 2); aliquots (10 íL of a 2 íg/íL solution) of both
oligonucleotides were diluted with 20 íL of Klenow buffer
and incubated at 85.0 °C for 30 min, cooled to room
temperature, and placed at 4 °C overnight. The overhanging
ends were filled in by using the Klenow fragment of E. coli
DNA polymerase and 10 mM dNTPs. This double-stranded
oligonucleotide was purified using the Qiaquick nucleotide
removal kit and was used as the forward primer in a PCR
reaction together with an internal TFR primer (Table 1, oligo
3) containing an MfeI restriction site. The resulting PCR
fragment (coding for a hexa-His-tagged N-terminal sequence
and amino acid residues 121-275 of the TFR) was cleaved
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with SmaI and MfeI, made blunt ended with Klenow
fragment and 10 mM dNTPs, and cloned into the SmaI site
of pBluescriptII (pBSSK). Both the full-length TFR construct
and the cloned PCR fragment were digested with MfeI and
XbaI, and the appropriate fragments were isolated by gel
electrophoresis and Qiaquick gel extraction purification. The
two fragments containing MfeI and XbaI overhanging ends
were ligated overnight at 14 °C and used to transform E.
coli strain MACHI. Subsequent DNA sequence analysis
revealed a clone with a plasmid containing the correct
predicted N-terminal sequence of TFR. The cDNA from the
pBSSK clone was cleaved with SmaI and XbaI; the overhang
created by XbaI was made blunt using Klenow fragment and
10 mM dNTPs, purified using the Qiaquick gel extraction
kit, and ligated into the SmaI site of pNUT.
The three N-linked glycosylation sites at positions 251,
317, and 727 in the sTFR in the pNUT vector were mutated
from Asn to Asp using the QuikChange mutagenesis
procedure (39, 40). The mutagenic primers are shown in
Table 1. To make the sTFR mutant lacking all three
glycosylation sites, the N251D sTFR mutant in the pNUT
vector was mutated at position 317 to create a double mutant
which was used as the template for the final mutation at
position 727. In all cases, the presence of the correct mutation
and the absence of unwanted mutations were confirmed by
DNA sequence analysis. Transfection of BHK cells and
selection with methotrexate were carried out as described in
detail previously (40).
The expression and purification of sTFR in the baculovi-
rus/insect cell system at the California Institute of Technol-
ogy have been described in detail previously (41). Briefly,
the gene encoding residues 121-760 of the TFR was fused
3′ to a gene segment encoding the hydrophobic leader peptide
from the baculovirus protein gp67 with a hexa-His tag and
a factor Xa cleavage site.
sTFR Production. The protocol for transferring the trans-
fected BHK cells into expanded surface roller bottles has
been described previously (39, 40, 42). In each production
run, the first three batches contain DMEM-F12-10% FBS
and were not saved. The subsequent batches (4-7) contained
DMEM-F12 with 1% UG + 1 mM butyric acid replacing
the FBS and were pooled following addition of 0.02%
sodium azide (NaN3) and stored at 4 °C until purification.
sTFR Assay. The amount of sTFR in the tissue culture
medium and at various stages of purification was determined
using a specific monoclonal antibody to the TFR in a
competitive solid-phase immunoassay as previously de-
scribed in detail for hTF (39). In the assay, a constant amount
of biotinylated N-His sTFR was mixed with unlabeled N-His
sTFR standards ranging from 16 to 400 ng/well and varying
amounts of sample and added to each well in duplicate. The
amount of sTFR in each sample was determined by com-
parison with the standard curve generated from the unlabeled
standards.
sTFR Purification. The purification of N-His sTFR fol-
lowed a protocol developed for N-His hTF (40) in which
the pooled batches were concentrated and exchanged into 5
mM Tris, pH 8.0, containing 0.02% NaN3 using a Millipore
spiral wound membrane concentrator fitted with an S1Y10
cartridge. Each sample was filtered through a 0.22 ím
Sterivex filter, and Qiagen start buffer (5) was added to
yield a final concentration of 50 mM Tris, pH 7.5, containing
300 mM NaCl, 20 mM imidazole, 10% glycerol, and 0.05%
NaN3. The sample was then loaded onto a Ni-NTA column
(1  10 cm) at a flow rate of 2 mL/min. The column was
attached to a BioCad Sprint system (Applied Biosystems)
to allow continuous monitoring of the absorbance at 280 nm,
the conductivity, and the pH. After being loaded onto the
column and washed with start buffer (1) until the A280 <
0.1, the N-His sTFR was displaced with elution buffer (start
buffer containing 250 mM imidazole). Peak fractions were
pooled, reduced using YM30 Centricon microconcentrators
to less than 2 mL, filtered through a 0.22 ím Millex syringe
filter, and loaded onto a Sephacryl S300HR 26/60 column
equilibrated and run in 0.1 M NH4HCO3 at a flow rate of
1.5 mL/min. Following pooling of appropriate fractions,
aliquots were analyzed on a 10% SDS-PAGE gel to verify
purity. An identical procedure was used to purify the N-His
sTFR obtained from The California Institute of Technology
(15-18). In this case, the recombinant sTFR was secreted
by insect cells into the medium which was shipped to
Vermont.
The sTFR contains 11 tryptophans, 24 tyrosines, and 2
cystines, yielding a calculated millimolar extinction coef-
ficient of 96.51 (43). The calculated mass of the nonglyco-
sylated sTFR (residues 121-760) is 71726 Da, to which is
added 440 Da for the V-P-D-K sequence, 823 Da for the
hexa-His tag, and 456 Da for the factor Xa cleavage sequence
for a total mass of 73445 Da. From the mass spectrometry
results, the monomer mass of the glycosylated TFR is 79760
Da. The concentration (in milligrams per milliliter) for sTFR
can be determined from the A280 by dividing by 1.21. The
production and purification of the recombinant hTF samples,
FeC hTF and Mut-FeC hTF, have been described in detail
elsewhere (40, 44).
Mass Spectrometry. Electrospray ionization mass spectra
of all protein samples were obtained under nondenaturing
conditions using a JMS-700 MStation (JEOL, Tokyo, Japan)
two-sector mass spectrometer equipped with a standard ESI
source. Typically, a 5 íM protein solution in 100 mM
Table 1: Sequences of the Mutagenic Primers Used in This Study
oligo 1: 5′ -AAA CCC GGG AAG ATG AGG CTC GCC GTG GGA GCC CTG CTG GTC TGC GCC GTC CTA GGG CTG TGT CTG GCT
GTC CCT 3′
oligo 2: 5′ TCA GGT CAT CCC AAT ATA AGC GCC TTC CCT CGA TGA ATT CAT GAT GAT GAT GAT GAT GTT TAT CAG GGA
CAG CCA GAC A 3′
oligo 3:a 5′ CAC ACC AAT TGC ATT TAA 3′
N251D:b 5′ TA TAC ACT CCT GTG GAT GGA TCT ATA GTG ATT GTC AGA GC 3′
N317D:b 5′ A TTC CCT TCC TTC GAT CAC ACT CAG TTT CCA CCA TCT CGG 3′
N727D:b 5′ CAA AAT AAC GGT GCT TTT GAT GAA ACG CTG TTC AGA AAC C 3′
a The underlined region represents the MfeI restriction site used in a subsequent cloning step. b The mutagenic base is represented by the bold,
underlined base.
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ammonium bicarbonate was continuously injected into the
source at a flow rate of 5 íL/min. To avoid in-source
oxidation of the protein ions, the spray needle potential was
kept below 1.9 kVa. Acceleration voltage was kept at 5 kV,
and the nominal resolution was set at 1000. All spectra were
recorded by scanning the magnet at a rate of 5 s/decade.
Typically, 80-180 scans were averaged for each spectrum
to ensure an adequate signal-to-noise ratio. Protein denatu-
ation was carried out by buffer exchanging the original
samples into a solution whose pH was adjusted to 2.0 with
glacial acetic acid. ESI MS measurements of acid-denatured
protein samples were carried out using a QSTAR-XL (PE
SCIEX, Framingham, MA) hybrid quadrupole-time-of-flight
mass spectrometer equipped with a standard TurboSpray ESI
source.
Affinity Measurements Using Surface Plasmon Resonance.
A BIACORE 2000 biosensor system (Amersham Bio-
sciences) was used to measure the affinities between the
sTFR and hTF samples as described previously (17, 18).
Binding of injected hTF to sTFR immobilized on the sensor
chip results in changes in SPR that are recorded in real time
as resonance units (RU) (45, 46). An oriented capture method
was used to immobilize the purified sTFR samples on a CM5
sensor chip (Amersham Biosciences) by first immobilizing
approximately 2200 RU of anti-penta-His antibody (Qiagen)
by random amine coupling for all four flow cells. After the
surface was blocked with 1 M ethanolamine, pH 8.0,
approximately 300 RU of sTFR was immobilized per flow
cell, with the exception of flow cell 1 which was used as a
blank. In both experiments, the baseline for the N317D sTFR
mutant decayed slightly during equilibration of the chip
surface in running buffer, possibly accounting for a lower
Rmax relative to other flow cells, but was allowed to stabilize
prior to analyte injection. Two separate CM5 chips were
required to collect data for all five sTFR samples (BHK WT
sTFR, insect cells WT sTFR, BHK N251D, BHK N317D,
and BHK N727D). For each analyte (Fe2 hTF, FeC hTF, and
Mut-FeC hTF), a 2-fold dilution series of 10 concentrations
preceded and followed by buffer blanks were injected over
the flow cells at 70 íL/min at 25 °C in 50 mM Tris buffer,
pH 7.4, 150 mM NaCl, and 0.005% P-20 surfactant. The
chip surface was regenerated between sample injections with
30 íL of 1 M MgCl2 in running buffer. Primary sensorgram
data were preprocessed using the Scrubber software package
(Biologic Software Pty.; http://www.biologic.com.au) and
globally fitted to 2:1 or 1:1 models in Clamp XP, as
previously described (30, 44, 47). Sensorgrams corresponding
to the highest analyte concentration injections were dropped
in the final fitting. The KD values for the 1:1 models were
statistically corrected with a factor of 0.5 such that they may
be directly compared to the KD1 values for 2:1 models.
Complex Formation and Purification. To prepare FeC hTF/
sTFR complexes for iron release studies, two different
protocols were followed. In the first protocol, a molar excess
of FeC hTF or Mut-FeC hTF was added to 1.0-1.5 mg of
WT or mutant sTFR. Following reduction and filtration, the
complex was loaded onto a Sephacryl S300HR 26/60
column, equilibrated, and chromatographed as described
above. The fractions containing the complex (as confirmed
by SDS-PAGE) were pooled and reduced in YM30 Cen-
tricon microconcentrators to a nominal concentration of 15
mg/mL. In the second protocol, FeC hTF/sTFR complexes
were formed by the addition of a slight excess of sTFR and
subsequent reduction using a microconcentrator.
Kinetic Rate Studies. The rates of iron release from Mut-
FeC hTF in complex with sTFR were determined at 25 °C
using a QuantaMaster-6 fluorometer from Photon Technol-
ogy International (PTI), with excitation at 280 nm and
emission at 330 nm. A 3 mL cuvette containing 100 mM
MES, pH 5.6, 300 mM KCl, and 4 mM EDTA in a volume
of 1.8 mL (and a small stir bar to provide mixing) was placed
in the fluorometer, and data collection was initiated to
establish a baseline. Once equilibrated with respect to
temperature, Mut-FeC hTF (500 nM) or the Mut-FeC hTF/
sTFR complex (also 500 nM with respect to Mut-FeC hTF)
was added by using a 25 íL Hamilton syringe through a
port directly above the cuvette. The release of iron was
monitored at 1 s intervals by measuring the increase in
fluorescence. Data for a minimum of four samples were
processed and analyzed using Origin 7.5 software and fitted
to a single exponential linear equation (Y ) p1e-x/p2 + p3 +
p4x), which yielded R2 values between 0.982 and 0.989.
For experiments with FeC hTF, iron release rates were
determined using an Applied Photophysics (AP) SX.18MV
stopped-flow spectrofluorometer fitted with a 20 íL observa-
tion cell with a 2 mm light path and a dead time of 1.1 ms.
A monochromator was used for excitation at 280 nm, and
the fluorescence emission was measured using a high-pass
filter with a 320 nm cutoff. The temperature (25 °C) was
kept constant using a circulating water bath. One syringe
contained 375 nM (with respect to FeC hTF) complex in 1.0
mL of 300 mM KCl (pH 6.8). The other syringe contained
300 mM KCl, 200 mM MES, pH 5.6, and 8 mM EDTA.
Kinetic traces were collected for 50 s intervals a total of six
to eight times and averaged. At least three separate samples
were averaged for each value reported. Data were analyzed
using Origin 7.5 software fit best to a single exponential
linear equation (as above); R2 values varied from 0.996 to
0.999.
RESULTS
sTFR Production. WT sTFR (residues 121-760) and three
single point mutants (N251D, N317D, and N727D) were
expressed in BHK cells and secreted into the tissue culture
medium. Each construct had four amino acids from the
N-terminus of hTF and an N-His tag as well as a factor Xa
cleavage site. As determined by a competitive immunoassay,
the WT and mutant sTFR samples were expressed in this
BHK system (Table 2). The results clearly show that
production of WT sTFR and the N251D and N727D mutants
is comparable, reaching a maximum of 30-40 mg/L, while
the N317D mutant was approximately half of this value.
Significantly, attempts to express a completely nonglycosy-
lated sTFR construct (the N251D/N317D/N727D triple
Table 2: Production of Recombinant sTFR and the Glycosylation




N-His sTFR WT 34.4 ( 6.1, n ) 4
N-His sTFR N251D 39.5 ( 8.5, n ) 4
N-His sTFR N317D 15.5 ( 1.6, n ) 4
N-His sTFR N727D 30.9 ( 0.9, n ) 2
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mutant) were unsuccessful. Both Western blot analysis and
our competitive immunoassay confirmed the absence of any
secreted sTFR. These results suggest either that glycosylation
and secretion are intimately connected or that the secreted
product is insoluble.
Following reduction and buffer exchange, the BHK cell
medium containing recombinant sTFR was loaded onto a
Ni-NTA column to capture the His-tagged constructs. After
elution from the nickel column with 250 mM imidazole, final
purification involved chromatography using an S300HR 26/
60 gel filtration column. In each case, the main protein peak
was preceded by a shoulder. Analysis of selected fractions
on a 10% SDS-PAGE gel indicated that this shoulder
contained a species with a higher molecular mass, as would
be expected from the elution profile (see below). On the basis
of the assay of the starting material, the yield of the
recombinant sTFR constructs was 60%; this yield is similar
to our previously reported recoveries for recombinant hTF-
NG (40).
Mass Spectrometry. The results of ESI MS analyses of
various sTFR samples are summarized in Table 3. Since these
experiments were carried out under near-native conditions,
formation of multiple adducts resulted in significant broaden-
ing of the protein ion peaks in ESI mass spectra (see Figure
2 and Supporting Information) and resulted in rather modest
mass measurement precision (ranging from 1.2 to 4.0 kDa
for the major species, dimer). Nevertheless, the achieved
precision is sufficient to confirm the predicted absence of
glycosylation at a single site for each mutant when compared
to the WT sTFR with glycans attached to all three sites. For
each of the analyzed sTFR samples, the main peak from the
S300HR column was always composed of a sTFR dimer,
with a small amount of a tetrameric species also observed
in all four sTFR preparations (Figure 2A). The presence of
the tetrameric species in the mass spectra is not surprising,
since such low-abundance oligomers are often observed in
ESI MS under native conditions and are usually attributed
to oligomerization stimulated by increased protein concentra-
tion in solution in the ESI interface (48). Although sTFR
dimers were also observed in the shoulders of the N251D
and N317D mutant peaks, a major species in each case had
a significantly higher mass than the dimer but lower than
the tetramers (Figure 2B). Such species were also observed
in the WT sTFR shoulder peak and were only slightly less
abundant than the sTFR dimer. Although the measured
masses of these species are reasonably close to that of a
putative sTFR homotrimer, the limited resolution and ac-
curacy of measurements in the high m/z range make it
impossible to assign the species solely on the basis of mass.
For example, a putative heterotrimer composed of a sTFR
dimer and a single TF molecule would have a mass within
2 kDa of the homotrimer. To establish the composition of
this species unequivocally, the protein complex in question
was denatured with acid, and its monomeric constituents were
identified on the basis of their mass measurements in the
low m/z region (Figure 2B inset). Since protein ions
generated under denaturing conditions in solution do not form
adducts as readily as those produced under native conditions,













N-His sTFR peak 79.7 159.4 ( 2.2c NO
(BHK) 159.5 ( 2.8
shoulder 80.1 160.1 ( 2.7 239.3 ( 2.9
N-His sTFR peak 77.1 154.0 ( 1.4 233.5 ( 3.9d
N251D 154.3 ( 1.8
shoulder 77.1 154.2 ( 1.6 233.9 ( 2.5
154.2 ( 1.2 233.6 ( 2.7
N-His sTFR peake 77.5 154.4 ( 2.6 234.1 ( 2.3d
N317D 155.5 ( 4.0 235.3 ( 3.9
shoulder 77.7 155.4 ( 2.8d 235.0 ( 3.3
N-His sTFR peak 78.1 156.2 ( 2.9 236.4 ( 3.8d




peak 83.6 167.2 ( 3.0 NO
a The calculated mass of the sTFR (residues 121-760) is 71726 Da,
to which is added 440 Da for the V-P-D-K sequence, 823 Da for the
hexa-His tag, and 456 Da for the factor Xa cleavage sequence for a
total mass of 73445 Da. The difference is attributed to the carbohydrate
(see Results and Discussion). b See text. We have determined that the
trimer is made up of a dimer of TFR and a molecule of hTF. c The
bold font indicates the major species present in each sample. d The
precision of the mass determination on the indicated samples is (100.
All other samples have a precision of (20. e In this sample, a species
with a mass of 63470 Da was observed. f NM ) not measured. NO )
not observed.
FIGURE 2: Electrospray ionization mass spectra of sTFR N251D
size exclusion chromatography peaks: main peak (A) and shoulder
(B). Both spectra were acquired under near-native conditions in
solution (50 mM ammonium acetate). The elution profile is shown
on the inset in panel A. Acid denaturation of the shoulder sample
results in emergence of two distinct charge state distributions (inset
in panel B), which correspond to the sTFR mutant and hTF (see
text for more detail).
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significantly higher precision of mass measurement can be
easily afforded. The mass spectrum of the acid-denatured
protein sample reveals the presence of two distinct ionic
species with masses of 79.6 ( 0.1 kDa (charge states +25
through +34) and 78.0 ( 0.1 kDa (charge states +37 through
+45). Despite having similar masses, one of the protein
species carries a significantly higher number of charges in
the gas phase. This provides a rather clear indication that
this protein remains more compact in denaturing solution
than the other (49). This is an expected consequence of the
presence of the large number of disulfide bonds in TF (19
total compared to only 2 in the sTFR), which prevent full
unfolding of the TF polypeptide chain by imposing multiple
conformational constraints. Taken together, measurements
of the mass and the extent of multiple charging of the acid-
denatured components of protein complexes giving rise to
shoulder peaks on size-exclusion chromatograms clearly
indicate that they are composed of both sTFR and TF
monomers.
Binding of hTF to WT and Mutant sTFR Molecules. To
compare the binding characteristics of each mutant sTFR to
WT sTFR, equilibrium constants were calculated using an
SPR assay to measure binding kinetics in real time (17, 30).
For these studies, the binding of three different analytes was
measured: (1) glycosylated Fe2 hTF, (2) FeC hTF, and (3)
Mut-FeC hTF (selected for its slower rate of iron release;
see below) (44). We observed that BHK-derived WT sTFR
bound to glycosylated Fe2 hTF with the same affinity as WT
sTFR produced in the baculovirus/insect system (Table 4).
Additionally, and as described previously, the Fe2 hTF
binding data were fit best with a bivalent model yielding
two KDs, whereas FeC hTF and Mut-FeC hTF were consistent
with a 1:1 model yielding a single KD (30, 44). The results
indicate that the N251D and N727D sTFR mutants bind hTF
with nearly the same affinities as WT sTFR. In the case of
the two FeC hTF constructs, the N317D sTFR mutant
consistently bound with a lower affinity (21.8 ( 12.0%, n
) 4). In contrast, the KD1 for Fe2 hTF binding to the N317D
mutant was within experimental error in both experiments.
Two experiments were required to analyze all the samples,
and the small differences between the two analytes were
consistent with the experimental variability ascribed to
differences in the individual chips.
Kinetic Studies. Iron release rates were determined by
monitoring the increase in fluorescence as iron was released
from FeC hTF in the presence and absence of sTFR. The
fluorescent signal is ascribed to one or more of the five
tryptophan residues in the C-lobe of hTF which become(s)
unquenched and solvent-exposed as iron is released and the
lobe opens (44, 50). In previous studies, the fast rate of iron
release from FeC hTF bound to sTFR yielded large standard
deviations in the rate constants that were measured (19, 30,
44). In the current work, two strategies were employed to
measure the rates with greater precision. In one approach, a
stopped-flow instrument from Applied Photophysics was
used to acquire the data for the FeC hTF/sTFR complexes at
pH 5.6. Kinetic curves for each complex are shown in Figure
3A.
Table 4: SPR Results for Binding of Fe2 hTF, FeC hTF, and







Fe2 hTF 1 WT sTFR BHK 0.47 ( 0.003 15 ( 0.1
1 sTFR N251D 0.51 ( 0.003 14 ( 0.1
1 sTFR N317D 0.59 ( 0.01 19 ( 0.2
Fe2 hTF 2 WT sTFR
insect cellsc
0.65 ( 0.01 10 ( 0.2
2 sTFR N317D 0.57 ( 0.004 15 ( 0.1
2 sTFRN727D 0.44 ( 0.003 13 ( 0.1
FeC hTF 1 WT sTFR BHK 22 ( 0.3
1 sTFR N251D 21 ( 0.3
1 sTFR N317D 31 ( 0.5
FeC hTF 2 WT sTFR
insect cells
28 ( 0.6
2 sTFR N317D 31 ( 0.5
2 sTFRN727D 21 ( 0.3
Mut-FeC hTF 1 WT sTFR BHK 27 ( 0.3
1 sTFR N251D 31 ( 0.3
1 sTFR N317D 41 ( 0.6
Mut-FeC hTF 2 WT sTFR
insect cells
27 ( 0.6
2 sTFR N317D 31 ( 0.5
2 sTFRN727D 23 ( 0.3
a Note that Fe2 hTF binding is described by two dissociation constants
and monoferric hTF binding is described by a single KD. b The
designations 1 and 2 refer to two different SPR chips needed to run all
of the samples. c The WT sTFR in experiment 2 was expressed with a
baculovirus/insect cell system.
FIGURE 3: Progress curves for the rate of iron release from hTF
species in a complex with WT sTFR and the three single
glycosylation mutants of sTFR: (A) FeC hTF and (B) Mut-FeC hTF.
The reduced noise observed in the fluorescent profiles of panel A
is attributed to the greater sensitivity of the stopped-flow instrument
and the averaging of six injections to produce the trace. Note that
the time scales are very different in (A) and (B).
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A second approach to simplify comparisons involved the
use of a mutant (designated Mut-FeC hTF) with a slower
rate of release (30-fold slower in the absence of TFR and
9-fold slower in the presence of TFR) when compared to
FeC hTF (44). This mutant was originally designed to mimic
the composition of a triad of residues found in the C-lobe
of lactoferrin which is well-known to have slower iron release
rates than ovotransferrin or hTF. Typical release curves from
the Mut-FeC hTF/sTFR complexes are shown in Figure 3B.
A summary of the kinetic rate constants for each sTFR bound
to FeC hTF and Mut-FeC hTF is presented in Table 5. The
results clearly show that the N317D sTFR mutant has a 2-3-
fold slower release rate than the WT sTFR and the N251D
or N727D sTFR mutants.
Since our earlier studies (30, 44) utilized sTFR from
baculovirus/insect cells, we wanted to verify the assumption
that the two recombinant forms of the WT sTFR are
functionally equivalent. Because the amino acid sequence
of each WT sTFR differs only by the presence of four extra
amino acids (with a mass of 440 Da) preceding the His tag
in the BHK-derived sTFR, most of the difference in mass
resides in the composition of the carbohydrate. As shown in
Table 3, analysis by mass spectrometry reveals that the
baculovirus/insect cell derived sTFR is slightly larger (see
Discussion). Nevertheless, the SPR data indicate that the
binding of Fe2 hTF to the two recombinant sTFR samples is
identical (Table 4). Additionally, iron release rates for FeC
hTF in a complex with either the BHK or insect cell derived
sTFR are the same within experimental error (Table 5).
DISCUSSION
By transfecting BHK cells with a mutant in which the three
asparagine linkage sites were converted to aspartic acid, we
hoped to express a recombinant form of sTFR that lacked
glycosylation. We anticipated that production of a nongly-
cosylated sTFR would provide a homogeneous preparation
for use in mass spectroscopy studies and might aid in
crystallization trials. Unfortunately, no nonglycosylated sTFR
was secreted into the tissue culture medium of the BHK cells
as indicated by an immunoassay and further confirmed by
Western blot analysis using a probe for the His tag. This
finding differs from expression of hTF, in which glycosy-
lation plays no role in either expression or function (51),
but is consistent with a report of the failure of the nongly-
cosylated mutant to reach the cell surface in TFR-deficient
CHO cells (10). The inability to express the completely
nonglycosylated sTFR led us to produce the single sTFR
glycosylation mutants individually to facilitate an assessment
of the role of each glycosylation site in the expression and
function of the sTFR. In our laboratory, the secreted His-
tagged sTFR from the baculovirus/insect cell medium
obtained from the expression facility at The California
Institute of Technology was purified with a final yield of
13.6 ( 4.4 mg/L, n ) 8. In the present work, we find that
the yield of sTFR from the BHK expression system is
comparable, 11.6 ( 4.3 mg/L, n ) 4. In each case, the yield
of functional sTFR is considerably higher than amounts
reported either from the CHO cell system (2 mg/L) (11)
or from placental preparations (2-6 mg of full-length TFR
per placenta) (52, 53).
As previously noted (11, 54, 55), even in the absence of
the disulfide linkages in the stalk region, the WT and each
of the mutant sTFR constructs form dimers in solution as
clearly shown by their behavior during gel filtration chro-
matography and by mass spectrometry analysis (Table 3).
Although it is clear that glycosylation of two of the three
sites allows expression, it is unclear whether it might be
possible to express a sTFR with a single glycan. Our results
make it tempting to speculate that only the carbohydrate at
position 317 may be crucial to the production of functional
sTFR.
Determining the exact composition of the carbohydrate
at each site is extremely challenging because although BHK
cells and insect cells attach carbohydrate at the consensus
sequences, the composition of the attached carbohydrate is
usually variable in both a cell type- and species-dependent
manner (ref 51 and references cited therein). Interestingly,
in naturally occurring TFR, the complexity of the carbohy-
drate appears to be specific to the position of the Asn residues
in the sequence (32). Thus, it has been reported that human
TFR isolated from placenta and TFR expressed in mouse
NIH-3T3 cells show similar patterns (32); the Asn251 site
featured a complex triantennary, trisialylated carbohydrate
with a fucose core (3009 Da), the Asn317 site had a sialylated
hybrid oligosaccharide (1874 Da), and Asn727 had a high
mannose type oligosaccharide (1866 Da). Our measurements
do not allow such a detailed determination of the carbohy-
drate composition at each site.
Identification of a “trimer” by mass spectrometry analysis
is attributed to the presence of a TFR dimer with a single
molecule of hTF bound. At the resolution of the analysis
the difference in mass between a TFR monomer and a
molecule of hTF is indistinguishable. Using acid denaturation
and analysis in the low m/z region, we were able to make
the distinction unequivocally. As previously reported (39),
hTF is present in the serum substitute Ultroser G at a
concentration of 2-4 mg/L. Due to the high affinity of
Table 5: Kinetics of Iron Release from hTF Mutants with and
without sTFRa
proteinsb




FeC hTF control 3.4 ( 0.1 Cary
FeC hTF + N-His sTFR WT
insect cells
262 ( 44 PTI
FeC hTF + N-His sTFR WT BHK 249 ( 68 PTI
FeC hTF + N-His sTFR WT 238 ( 22 AP
FeC hTF + N-His sTFR N251D 204 ( 9 AP
FeC hTF + N-His sTFR N317D 90 ( 10 AP
FeC hTF + N-His sTFR N727D 175 ( 6 AP
Mut-FeC hTFd 0.087 ( 0.017 Cary
Mut-FeC hTF + N-His sTFR WTd 18 ( 1 PTI
Mut-FeC hTF + N-His sTFR N251D 16 ( 0.1 PTI
Mut-FeC hTF + N-His sTFR N317D 8 ( 1 PTI
Mut-FeC hTF + N-His sTFR N727D 17 ( 0.1 PTI
a Iron release from hTF mutants was determined at 25 °C and pH
5.6 (100 mM MES, 4 mM EDTA, 300 mM KCl). b The control is N-His
Y95F/Y188F hTF-NG. All constructs are in this background. c Mea-
surements were carried out as described in Materials and Methods on
a Varian Cary 100 dual beam spectrophotometer, a Photon Technology
International QuantaMaster (PTI) spectrofluorometer, or an Applied
Photophysics (AP) SX.18MV stopped-flow spectrofluorometer as
indicated above. d The mutant is N-His Y95F/Y188F/R632N/D634N
hTF-NG, and the release rate for the mutant alone has been previously
reported (44). In addition, the rate for the mutant in the presence of
the sTFR from the insect cells was reported as 25.5 ( 0.9 s-1  10-3,
n ) 3 (44).
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the hTF/TFR interaction, it is extremely likely that any hTF
in the tissue culture medium that acquires iron would bind
to the recombinant TFR. Likewise, the complex would be
expected to elute from the gel filtration column as a higher
molecular weight “shoulder”.
Elimination of the carbohydrate at position 251 has little
or no effect on the expression, dimerization, complex
formation, and release of iron from TF compared to WT.
Previous work showed that glycosylation at position 251 is
necessary for protection against proteolysis (34), although
no proteolysis was observed in another study (36). The
carbohydrate at position 251 was not involved in ligand
binding and/or dimerization of the TFR in vivo (34).
Likewise, we observed no interference with complex forma-
tion or dimerization of the N251D mutant, and obviously,
protection from proteolysis is not relevant in expression of
the secreted soluble portion of the TFR.
In our studies, the N317D sTFR mutant expressed poorly
and was more difficult to purify. We note that this mutant
appears to be less soluble and/or is possibly more prone to
aggregation. In the case of the two FeC hTF samples, the
absence of carbohydrate at this position causes a small
difference of 20% in the binding affinity measured at pH
7.4 although, interestingly, no significant difference was
found for binding of Fe2 hTF to this mutant (Table 4).
Examination of the crystal structure of sTFR (Figure 1)
reveals that residue 317 from one monomer is within 4 Å of
W641 and F760 on the other monomer. As described in the
introduction, these two residues comprise a hydrophobic
patch on the TFR that is involved in the binding of hTF.
This patch appears to be responsible for stabilization of apo-
hTF at acidic pH (30). The absence of carbohydrate at
position 317 has a small impact on the affinity for FeC hTF
at pH 7.4. Additionally, the rate of iron release at pH 5.6 is
2-3-fold slower. These results imply that the carbohydrate
at this position helps to attain and/or stabilize the conforma-
tion of the sTFR in a pH-dependent manner. Consistent with
this idea is the observation that the affinity of Fe2 hTF for
the N317D sTFR is the same as that found for WT sTFR
and the other mutants (Table 4). Likewise, the change in
affinity for the hydrophobic patch double mutant was only
observed at pH 6.3 and 5.6. Thus, the finding of equal affinity
for Fe2 hTF at neutral pH is consistent, and the N317D
glycosylation may have a role in stabilizing the bound apo-
hTF at low pH.
Previous studies indicated that the carbohydrate at position
727 is important in proper folding of the TFR and crucial to
transport of the TFR to the plasma membrane (33, 36).
Obviously, production of the soluble TFR does not require
the intracellular trafficking function. In addition, the current
work does not suggest that the sTFR is improperly folded
since the mutant is expressed at a concentration that is
equivalent to the control (Table 2), binds equally well to
the various hTF constructs (Table 4), and yields a similar
acceleration in the rate of iron release from the C-lobe of
hTF (Table 5). Therefore, and within the context of the
soluble TFR, the absence of carbohydrate at position 727
has no impact on any of the measured criteria.
In summary, we present data that demonstrate the impor-
tance of glycosylation in the expression of the sTFR; no
sTFR is expressed when the three sites are mutated to prevent
glycosylation. We show that, in contrast to expression of
full-length TFR, only the carbohydrate at position 317 has a
significant effect on the expression and iron release rates of
the soluble form of the TFR. Additionally, we have shown
that the stopped-flow spectrofluorometer is able to capture
iron release rates with greater precision and sensitivity than
previously used methods.
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Human serum transferrin (hTF) is a bilobal glycoprotein that transports iron to cells. At neutral pH, diferric
hTF binds with nM afﬁnity to the transferrin receptor (TFR) on the cell surface. The complex is taken into the
cell where, at the acidic pH of the endosome (∼pH 5.6), iron is released. Since iron coordination strongly
quenches the intrinsic tryptophan ﬂuorescence of hTF, the increase in the ﬂuorescent signal reports the rate
constant(s) of iron release. At pH 5.6, the TFR considerably enhances iron release from the C-lobe (with little
effect on iron release from the N-lobe). The recombinant soluble TFR is a dimer with 11 tryptophan residues
per monomer. In the hTF/TFR complex these residues could contribute to and compromise the readout
ascribed to iron release from hTF. We report that compared to FeC hTF alone, the increase in the ﬂuorescent
signal from the preformed complex of FeC hTF and the TFR at pH 5.6 is signiﬁcantly quenched (75%). To
dissect the contributions of hTF and the TFR to the change in ﬂuorescence, 5-hydroxytryptophan was
incorporated into each using our mammalian expression system. Selective excitation of the samples at 280 or
315 nm shows that the TFR contributes little or nothing to the increase in ﬂuorescence when ferric iron is
released from FeC hTF. Quantum yield determinations of TFR, FeC hTF and the FeC hTF/TFR complex strongly
support our interpretation of the kinetic data.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
Human serum transferrin (hTF) is an ∼80 kDa bilobal iron binding
glycoprotein that delivers iron to cells by means of receptor mediated
endocytosis. The N- and C-lobes are homologous globular domains
each capable of binding an atom of ferric iron (Fe3+) in a cleft formed
by two subdomains (N1–N2 and C1–C2) in each lobe [1]. At the neutral
pH of ∼7.4, diferric hTF (Fe2 hTF) preferentially binds with nM afﬁnity
to the extracellular portion of the membrane spanning hTF receptor
(TFR) on the cell surface. At this pH, the two monoferric species bind
less tightly than Fe2 hTF and apo hTF binds very poorly [2]. In normal,
healthy individuals, ∼30% of the circulating hTF is iron saturated [3].
At the acidic pH of the endosome (∼5.6) iron is released from Fe2 hTF
and delivered to the cell; at low pH, apo hTF remains bound to the TFR
and is returned to the cell surface where it diffuses into the plasma to
transport more ferric iron [4].
Iron coordination by hTF produces a ligand tometal charge transfer
band, centered at ∼470 nm, which is responsible for the characteristic
salmon pink color of hTF. This coordination also disrupts the π to π⁎
transition of the two liganding tyrosine residues (Tyr95 and Tyr188 in
the N-lobe and Tyr426 and Tyr517 in the C-lobe) resulting in an
increase in the absorbance at 280 nm and creating a shoulder that
extends to ∼410 nm [5]. This shoulder overlaps with the ﬂuorescent
signal of the tryptophan residues causing a signiﬁcant decrease in the
intrinsic ﬂuorescence of Fe2 hTF (∼70%) compared to apo hTF [6].
These ﬁndings served as a basis for the development of various assays
to accuratelymeasure the uptake or release of iron from hTF. Although
monitoring the decrease in the visible absorbance spectrum has been
extensively used to measure the rate constant(s) for iron release, the
most sensitive assays measure the increase in the intrinsic ﬂuorescent
signal when the iron is removed by a chelator. Recently, recombinant
production of the isolated N-lobe and of full length hTF (modiﬁed by
mutation to prevent iron binding in one or both lobes) has allowed a
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more precise assignment of the contributions of each lobe to the
spectral properties of hTF [7–9]. The change in the intrinsic
ﬂuorescent signal is attributed to the eight Trp residues in hTF
(three in the N-lobe and ﬁve in the C-lobe, Fig. 1A). The sensitivity of
this approach has proved to be especially critical to the measurement
of the rate of iron release from hTF bound to TFR isolated from
placenta [10], both because of the limited amount of TFR and its poor
solubility at low pH [11]. Work from Aisen and colleagues has
established the vital role of the TFR in assuring that iron is released at
the appropriate time and in the appropriate place [12–14]. Thus at pH
7.4, the presence of the TFR actually slows the release of iron from each
lobe of hTF, while at pH 5.6 the TFR considerably accelerates iron
release from the C-lobe of hTF (with little effect on the N-lobe) [15–17].
Availability of a recombinant form of the soluble hTF binding
portion of the TFR (sTFR) has simpliﬁed iron release assays by
eliminating the need for detergent [17–19]. Additionally, relatively
large amounts of sTFR can be produced to allow a more extensive
determination of the role of the TFR in iron release from the two lobes
as a function of pH and salt [17]. Such work is essential to fully
understand the complexities of iron release from hTF in order to be
able tomodify its properties in a clinical setting. The interaction of hTF
with its speciﬁc receptor controls iron distribution throughout the
body. Owing to the fact that iron deﬁciency and excess are directly
related to speciﬁc human diseases, understanding this process at the
molecular level should result in a more comprehensive understanding
of iron metabolism [20].
In measuring iron release from the hTF/sTFR complex by
ﬂuorescence, a key issue is whether the sTFR might contribute to
the increase in the ﬂuorescent signal. Since there are 11 Trp residues
per monomer of sTFR (Fig. 1B), this is both a valid and a very important
question. If (as is highly likely), one or more of the 11 Trp residues in
the sTFR undergoes a pH induced change in its local environment, it
would result in an increase (or a decrease) in the intrinsic ﬂuorescent
signal which could compromise an accurate determination of the rate
of iron release from hTF. This potential problem has never been
addressed experimentally. The crystal structure of the sTFR dimer
reveals that each monomer is comprised of: 1) a protease-like domain
(resembling amino and carboxypeptidases, residues 122–188 and
384–606), 2) an apical domain (residues 189–383) and 3) a helical
domain (residues 607–760), which spontaneously associates with
another monomer to form the dimer (Fig. 1B) [21]. Six of the eleven
Trp residues reside in the protease-like domain, four are found in the
helical domain and one is located in the apical domain (Table 1). A
cryo-EM model of the TF/sTFR complex suggests that the C1
subdomain of TF binds to the helical domain of the sTFR [22].
Additionally, the N-lobe appears to make contact with both the helical
domain and the protease-like domain through the N1 and N2
subdomains. We note that placement of the two lobes of TF into the
cryo-EM density map required a 9 Å movement of the N-lobe relative
to the C-lobe. In a remarkable study, thirty different mutants of the
TFRwere evaluated to determine the effect of a particular mutation on
binding of Fe2 hTF, apo hTF and the HFE protein as a function of pH
[23]. Relevant to the current work, two of the four Trp residues
examined affected the binding afﬁnity. The W124A sTFR mutant
showed a 15-fold reduction in binding afﬁnity of Fe2 hTF to sTFR at pH
7.4, but no change in binding of apo hTF at pH 6.3. Conversely, the
W641Amutant resulted in a 55-fold reduction in afﬁnity for apo hTF at
pH 6.3 without any effect on the binding of Fe2 hTF at pH 7.4 [23]. Of
great signiﬁcance, a double sTFR mutant in which Trp641and Phe760
were each replaced with alanine reduced binding and abolished
receptor stimulated iron release at pH 5.6 from full length hTF that
binds iron only in the C-lobe (FeC hTF) [23].
Fig. 1. (A) Structure of monoferric C-lobe hTF [42] depicting the 8 tryptophan residues, shown in blue. N-lobe is colored green, C-lobe is colored dark red. The bound iron is shown in
red. (B) Structure of sTFR (1CX8) depicting the 22 tryptophan residues in the dimer (blue). The subdomains are colored as follows, helical (orange), apical (teal) and protease-like
(magenta). Figure was made using PyMol.
Table 1
Analysis of Trp residue locations/environment in the crystal structure of the sTFR (1CXS)
[21]
Residue # Domain Environment Tested experimentally [23]
Trp124 Protease-like Solvent exposed Yes, involved in binding to
N-lobe of hTF at pH 7.4
Trp 182 Protease-like Burieda No
Trp 357 Apical Solvent exposed No
Trp 412 Protease-like Solvent exposed No
Trp 453 Protease-like Burieda No
Trp 466 Protease-like Burieda No
Trp 528 Protease-like Solvent exposed Yes, no effect
Trp 641 Helical Solvent exposed Yes, involved in binding to
C-lobe of hTF at pH 6.3
and 5.6 [16]
Trp 702 Helical Buried Yes, no effect
Trp 740 Helical Buried between monomers No
Trp 754 Helical Burieda No
a Trp residues 182, 453, 466 and 754 (from opposite monomer) are buried and
clustered together.
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One approach to dissect the spectral properties of one protein in a
complex with another protein is to substitute an unnatural amino acid
analogue with unique spectral properties for the native amino acid
[24]. Native Trp contains two overlapping electronic π–π⁎ transitions
between 240–290 nm (1La and 1Lb) [25]. Experimental and theoretical
predictions show that the 1La transition is the dominant ﬂuorescing
state of Trp in proteins [26,27]. This transition gives rise to the
sensitivity of Trp residues to changes in their local environment due to
the large dipole change upon excitation. L-5-hydroxytryptophan (5-
HTP) is a Trp analogue with an absorbance spectrum that is
signiﬁcantly red-shifted compared to native Trp [28]. This extended
shoulder results from the shift of the 1Lb transition of 5-HTP to lower
energy which allows it to be selectively excited at wavelengths
≥310 nm and distinguished from native Trp [29]. To elucidate whether
or not the sTFR is contributing to the increase in the ﬂuorescent signal
ascribed to the release of iron from hTF, we have incorporated 5-HTP
in place of Trp in both FeC hTF and also in recombinant sTFR. This was
accomplished using our mammalian BHK cell expression system. The
steady-state spectral properties of FeC hTF and sTFR with and without
the 5-HTP substitution are reported. When excited at 280 nm, iron
release from native and 5-HTP FeC hTF (in the absence of sTFR) both
yield similar rate constants indicating that the presence of the
hydroxyl group on the Trp residues does not interfere with this
process. The presence of 5-HTP in sTFR appears to have some effect on
receptor stimulated iron release. However, we demonstrate that the
increase in the intrinsic ﬂuorescent signal observed at pH 5.6 for the
hTF/sTFR complex can be assigned to iron removal from hTF with
minimal contributions from the sTFR, thereby validating the Trp
ﬂuorescence iron release assay for the hTF/sTFR complex.
2. Materials and methods
2.1. Materials
Custom made Dulbecco's modiﬁed Eagle's medium-Ham F-12
nutrient mixture (lacking L-Trp, L-Arg, L-Lys, L-His, L-Met, L-Phe and L-
Tyr), antibiotic–antimycotic solution (100×), 5-HTP, all the L-amino
acids mentioned above and trypsin solutionwere from the GIBCO-BRL
Life Technologies Division of Invitrogen. Fetal bovine serum (FBS) was
obtained from Atlanta Biologicals (Norcross, GA) and was tested prior
to use to ensure adequate growth of our BHK cells. Ultroser G (UG) is a
serum replacement from Pall BioSepra (Cergy, France). Ni-NTA resin
was purchased from Qiagen. Corning expanded surface roller bottles
and Dynatech Immunolon 4 Removawells were obtained from Fisher
Scientiﬁc. The Hi-Prep 26/60 Sephacryl S-200HR and S-300HR
columns were from Amersham Pharmacia. Guanidine hydrochloride
(GdHCl) was from Pierce. Centricon 30microconcentrators and YM-30
ultraﬁltration membranes were from Millipore/Amicon. All other
chemicals and reagents were of analytical grade.
2.2. Protein production and puriﬁcation
The DNAmanipulations used to generate FeC hTF and the sTFR have
been described in detail previously [8,17]. To produce recombinant
samples with 5-HTP substituted for Trp, BHK cells transfectedwith the
pNUT plasmid containing the appropriate cDNA sequencewere placed
into four expanded surface roller bottles [30]. Brieﬂy, adherent BHK
cells were grown in DMEM-F12 containing 10% FBS. This mediumwas
changed twice at two day intervals, followed by addition of DMEM-
F12 containing the serum substitute UG (1%) and 1 mM butyric acid
(BA). The presence of 1 mM BA has been shown to increase the
production of recombinant protein from BHK cells [8]. After one or
two changes in this medium, 200 mL of DMEM-F12 containing 5-HTP
(9.0 mg/L), with BA and UG was added to each roller bottle twice at
two day intervals. (Note that the DMEM-F12 was made complete by
addition of the other 6 missing L-amino acids). Addition of culture
medium containing 5-HTP results in a signiﬁcant deterioration of the
cells. In order to maximize the incorporation, medium containing 5-
HTP was added when production of FeC hTF or sTFR was highest as
determined by a competitive immunoassay using speciﬁc monoclonal
antibodies to either hTF or sTFR [31]. The hexa His-tagged recombi-
nant proteins in the mediumwere captured by passage over a Ni-NTA
column followed by ﬁnal puriﬁcation on a gel ﬁltration column (S-
200HR for hTF and S-300HR for sTFR) [8,17]. Polyacrylamide gel
electrophoresis in the presence of SDS was used to verify the
homogeneity of the all of the recombinant proteins.
FeC hTF/sTFR complexes were prepared by adding a slight molar
excess of sTFR to FeC hTF and reducing to a concentration of 10 mg/mL
(with respect to FeC hTF) using a YM30 Centricon microconcentrator.
Alternatively, the complex was made with a small molar excess of FeC
hTF and isolated by passage over an S-300 column. The four possible
combinations of FeC hTF and sTFR were made ranging from both in
native form to both labeled with 5-HTP.
2.3. Kinetics of iron release
Kinetic assays in the absence or presence of sTFR were carried out
using an Applied Photophysics (AP) SX.18MV stopped-ﬂow spectro-
ﬂuorometer as previously described [9,17]. A monochromator was
used for excitation wavelength selection (280 nm for native Trp and
315 nm for 5-HTP excitation), with a bandpass of 9.3 nm. A 320 nm
cut-on ﬁlter was used to monitor native Trp ﬂuorescence while a
335 nm cut-on ﬁlterwas used tomonitor emission from5-HTP labeled
samples. One syringe contained 375 nM of complex with respect to
FeC hTF or 5-HTP FeC hTF for 280 nm excitation (or 1.88 μM for 315 nm
excitation) in 1.0 mL of 300 mM KCl (pH ∼6.8). The other syringe
contained 200 mM MES, pH 5.6 with 300 mM KCl and 8 mM EDTA.
Data was collected for 50 s (complex) or 500 s (FeC hTF alone); a total
of at least six kinetic traces were combined and averaged. Data was
analyzed using Origin 7.5 software and ﬁtting to either a single
exponential function (y=A1⁎exp(−x / t1)+y0) or a double exponential
function (y=A1⁎exp(−x / t1)+A2⁎exp(−x / t2)+y0).
2.4. Quantum yields of native tryptophan samples
Quantumyields of native hTF, sTFR and the hTF/sTFR complexwere
determined in comparison to an L-tryptophan standard (Φ=0.14)
using a Quantamaster-6 Spectroﬂuorometer (Photon Technology
International, South Brunswick, NJ) [9,32]. L-tryptophan (10 μM) and
protein samples (∼0.5 μM) were added to a cuvette containing either
100 mMHEPES, pH 7.4 (FeC hTF) or 100 mMMES, pH 5.6, 300 mM KCl
and 4 mM EDTA (Apo hTF) and equilibrated at 25 °C for 20 min.
Samples were excited at 280 nm, with 1 nm excitation slits. Emission
scans were recorded and integrated between 305–400 nm (4 nm
emission slits) with a 320 nm cut-on ﬁlter in front of the emission
monochromator and PMT.
2.5. Steady-state ﬂuorescence scans
Corrected steady-state ﬂuorescence spectra were obtained for
native apo hTF, 5-HTP apo hTF, native sTFR or 5-HTP sTFR (∼2 μM). In
each case, sample was added to a cuvette (1.8 mL ﬁnal volume)
containing 100 mM HEPES, pH 7.4 and gently stirred with a small
magnetic stir bar. FeC hTF was generated by adding a slight molar
excess of Fe-NTA to the apo sample and equilibrating for 20 min.
Native and 5-HTP labeled hTF and sTFR constructs were excited at 280
and 315 nm, respectively. Slit widths of 1 nm (excitation) and 0.5 nm
(emission, 2 nm for 315 nm excitation) were used. In the case of
excitation at 280 nm, emission scans were collected between 305–
400 nm; for excitation at 315 nm emission between 325–400 nmwas
recorded. Excitation scans were then collected by setting the emission
wavelength to the λmax and scanning between 250–330 nm.
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2.6. Determination of 5-HTP incorporation
Incorporation of 5-HTP was estimated by comparative analysis of
absorbance spectra as described [33] on a Varian Cary 100 with
temperature control. The absorbance spectrum (269–324 nm) of FeC
hTF and the sTFR (each at a concentration of 10 μM) and of 5-HTP alone
(100 μM) was recorded in 6 M GdHCl (see below).
3. Results
3.1. Kinetics of iron release from native FeC hTF and FeC hTF/sTFR
Our standard protocol for monitoring iron release involves rapid
mixing (by means of a stopped-ﬂow device) of low pH buffer, salt and
a chelator with FeC hTF or the FeC hTF/sTFR complex. Typical results
are shown in Fig. 2A and B. It is immediately clear that both the change
in ﬂuorescence and the time scale of iron release between these two
samples are drastically different in spite of the fact that the same
amount of FeC hTF is present in each. Binding of FeC hTF to the sTFR
results in a ∼75% reduction in the change (1.25 V versus 0.31 V) during
iron release with a 10-fold reduction in the time needed to assure
complete iron removal. Of interest is the appearance of a new feature
in the beginning of the kinetic trace of the complex (Fig. 2B); an initial
small drop in the intensity of the ﬂuorescence (within the ﬁrst 0.2 s) is
followed by the large increase that plateaus (0.31 V) by ∼25 s (and is
ascribed to iron release). Examination of the change in ﬂuorescence of
sTFR alone under our standard conditions (Fig. 2C, black curve), shows
that the initial decrease in the scan of the complex can be assigned to
the sTFR. To validate this assignment we monitored the change in the
ﬂuorescent signal of FeC hTF on the same timescale. As shown in the
inset of Fig. 2A, the initial decrease is completely absent. The time-
based change in ﬂuorescence of the sTFR alone shows a signiﬁcant
initial increase in the signal (0.28 V) that peaks at ∼15 s and is
followed by a slow but steady decrease in the signal. Since it is known
that the sTFR is not very stable at low pH and tends to aggregate in the
absence of hTF [11], aggregation might lead to quenching of the
ﬂuorescent signal, although other explanations, such as photobleach-
ing may be are equally possible. Regardless, there is a falling off of the
signal. Signiﬁcantly, apo hTF bound to sTFR yields no change in signal
at low pH (Fig. 2C, red curve).
3.2. Quantum yield determination
To further measure the effect of binding of FeC hTF to the sTFR on
the change in the ﬂuorescent signal, the quantumyields (Φ) of FeC hTF
alone, the sTFR alone and the FeC hTF/sTFR complex at both pH 7.4 and
pH 5.6 were determined. These pH values were selected to simulate
the iron-bound serum hTF and the apo conformation within the
endosome. Signiﬁcantly, all of the samples showat least some increase
in the Φ at pH 5.6 compared to pH 7.4 varying from 20% for the sTFR
alone to 100% for hTF alone (Table 2). The Φ of the sTFR at both pH
values is considerably higher than the Φ of the FeC hTF alone or in the
complex. For example, at pH 7.4, theΦ is 233% and 43% higher for sTFR
alone in comparison to FeC hTF or the FeC hTF/sTFR complex,
respectively. At pH 5.6, the Φ is 100% and 33% higher for sTFR alone
compared to FeC hTF or the FeC hTF/sTFR complex.
Fig. 2. Stopped ﬂow time-based change in ﬂuorescence of (A) FeC hTF in the absence of
sTFR. Inset is iron release on the same timescale as B and C. (Note that the initial quench
in ﬂuorescence is not present). (B) FeC hTF/sTFR complex. (C) sTFR in the absence of hTF
(black curve). sTFR in the presence of apo hTF (red curve). All samples are in 100 mM
MES, pH 5.6, containing 300 mM KCl and 4 mM EDTA. Excitation at 280 nm, emission
using a 320 nm cut-on ﬁlter. Note differences in X and Y scales.
Table 2
Quantum yields (Φ) of FeC hTF, sTFR and FeC hTF/sTFR complex as a function of pH and
the presence or absence of iron






FeC hTF 0.03±0.01 0.06±0.01 100
sTFR 0.10±0.01 0.12±0.01 20
FeC hTF/sTFR 0.07±0.01 0.09±0.01 29
Values were determined by comparison to a known standard (L-Trp) and calculated as
described [32].
a Samples were incubated in buffer for 20 min in the presence of EDTA and KCl.
b Percent difference is calculated using 100⁎ [ΦHEPES−ΦMES] /ΦHEPES.
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Given the large effect of binding of FeC hTF to the sTFRon the change
in theﬂuorescent signal and the fact that aﬂuorescent signal is observed
for the sTFR alone as a function of the change in pH (Fig. 2A–C), we
needed a means to deﬁnitively dissect the contribution of each.
Therefore 5-HTP labeled FeC hTF and sTFR were produced in our BHK
cell expression system. Substituting 5-HTP for L-Trp in the medium
Fig. 3. Normalized and corrected excitation spectra of native and 5-HTP proteins. (A) Apo hTF and (B) sTFR in 100 mM HEPES, pH 7.4 at 25 °C.
Fig. 4. (A) Fluorescence emission spectrum of native and 5-HTP apo hTF and FeC hTF with excitation at 280 nm. (B) Fluorescence emission spectrum of 5-HTP apo hTF, FeC hTF, and
native sTFR with 315 nm excitation wavelength. (C) Fluorescence emission of native and 5-HTP sTFR with excitation at 280 nm. (D) Fluorescence emission of native apo hTF, FeC hTF
and 5-HTP sTFR with 315 nm excitation wavelength. All emission spectra have been corrected for instrument response.
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resulted inan immediate and substantial decrease inproteinproduction
relative to the production of native FeC hTF and sTFR (∼6–8 mg/L
maximum versus ∼50 mg/L for FeC hTF and ∼35 mg/L for sTFR [8,17]).
Nevertheless, in each case, enough 5-HTP labeled protein (∼3 mg) was
recovered to carry out both the spectral measurements and the iron
release experiments.
3.3. Determination of the incorporation of 5-HTP
The percent of 5-HTP incorporated into FeC hTF and sTFR was
estimated from Eq. (1) [33]:
k5QHTP = 100 1−ðSNA 5QHTP−SNA 5QHTPQproteinð Þ
= SNA 5QHTP−SNA proteinð ÞÞ ð1Þ
where, SNA 5-HTP, SNA 5-HTP-protein, and SNA-protein represent the
area under the curve of the normalized absorbance (NA) spectra
of 5-HTP, 5-HTP-protein and native protein. The incorporation of
5-HTP in FeC hTF and sTFR was calculated to be 20 and 26%, re-
spectively. The transcriptional process in BHK cells could only result
in random incorporation of 5-HTP into at the 8 positions in hTF and
the 11 positions in the sTFR. Since the Trp residues are well distri-
buted in the primary sequences, site speciﬁc incorporation is not
reasonable (or even feasible) in this mammalian expression system.
We note that two strategies to improve the level of incorporation
did not enhance our percentage of incorporation: 1) Inclusion of a
four hour wash-in period with complete medium containing 5-HTP
prior to the batch that was collected and processed, and 2) addition
of 80% 5-HTP and 20% L-Trp to the complete medium instead of 100%
5-HTP.
3.4. Corrected excitation and emission spectra of proteins
containing 5-HTP
Overlaid excitation spectra for native and 5-HTP apo hTF and for
native and 5-HTP sTFR are presented in Fig. 3A and B, respectively. The
red-shifted excitation spectrum typical of 5-HTP with a peak centered
∼315 nm is clearly visible in the spectrum of apo hTF (Fig. 3A). In
contrast, the excitation spectrum of native sTFR shows a substantial
signal above 300 nm (Fig. 3B) and incorporation of 5-HTP sTFR shows
only a modest increase in excitation above 310 nm.
The ﬂuorescence spectra for the various samples excited at 280 and
315 nm are presented in Fig. 4. At 280 nm, both native and 5-HTP FeC
hTF have nearly identical emission maxima/intensities (337 nm) and
each shows a 75% increase in the ﬂuorescent signal when iron is
removed (Fig. 4A). At 315 nm, 5-HTP hTF has a 47% increase in the
ﬂuorescent signal when iron is removed. Upon excitation at 315 nm,
the intensities of 5-HTP apo and 5-HTP FeC hTF are 4.3 and 2.8 times
the intensity of the native sTFR (Fig. 4B), indicating that it should be
feasible to selectively monitor iron release from FeC hTF in the kinetic
assays. Excitation of 5-HTP sTFR at 280 nm reveals a 1.6 fold decrease
in the emission intensity as well as a small blue shift (∼4 nm) in
comparison to native sTFR (Fig. 4C). When excited at 315 nm, 5-HTP
sTFR has N7 times the ﬂuorescence intensity of either native apo or FeC
hTF (Fig. 4D). Collectively these data indicate that there is a large
enough difference between the 5-HTP labeled and native FeC hTF and
sTFR to allow selective excitation and emission of the individual
proteins in a complex and to assign the source of the increase in the
ﬂuorescent signal upon iron release.
3.5. The origin of the ﬂuorescent signal change in the
FeC hTF/sTFR complex
To dissect the contribution of FeC hTF and sTFR to the increase in
ﬂuorescence intensity when bound to each other, we made all
possible combinations of native and 5-HTP labeled complexes and
then excited the samples at both 280 and 315 nm. Signiﬁcantly, we
observe very similar rate constants for iron release from native and
5-HTP FeC hTF in the absence of sTFR (kobsC1 0.58 versus 0.72 min−1,
Table 3). As expected for the control sample containing native FeC
hTF and native sTFR, a strong signal is observed when the complex is
excited at 280 nm (Fig. 5A—blue curve). Furthermore, 5-HTP FeC hTF
in the presence of native sTFR yields an equivalently strong signal
Table 3
Kinetics of iron release from FeC hTF in the absence and presence of the sTFR









Ex: 280 nm Ex: 280 nm Ex: 315 nm Ex: 315 nm
FeC hTF 0.58±0.08 Weak signal
5-HTP FeC hTF 0.72±0.04 0.30±0.01
FeC hTF+sTFR 21.5±2.6 7.7±0.9 Weak signal
5-HTP FeC hTF+sTFR 25.8±3.6 8.3±0.9 14.1±2.0 2.8±0.2
FeC hTF+5-HTP sTFR 16.9±0.5 2.0±1.3 Weak signal
5-HTP FeC hTF+5-HTP sTFR 18.1±1.7 4.0±1.6 22.4±6.2 3.4±1.9
Kinetic curves are presented in Fig. 5A and B.
Fig. 5. Iron release from native and 5-HTP labeled FeC hTF/sTFR complexes. (A) 280
excitation and (B) 315 excitation. All samples were assayed in 100 mM MES, pH 5.6
containing 300 mM KCl and 4 mM EDTA. In ﬁtting each curve the small initial drop in
the ﬂuorescence intensity was removed.
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(Fig. 5A—black curve). The two complexes containing the 5-HTP sTFR
(Fig. 5A—green and red curves) have lower ﬂuorescent changes.
As previously reported in studies that used a steady-state
method to monitor iron release, the single rate constant from the
FeC hTF/sTFR complex was enhanced compared to FeC hTF alone
[23]. In the current work, use of a more sensitive instrument with
stopped ﬂow capability has provided much better kinetic data due
to a signiﬁcant improvement in the signal to noise ratio. In contrast
to the previous report [23], in the current work the kinetic curves
for the complex ﬁt best to a double-exponential function yielding
two rate constants. Signiﬁcantly, both rate constants are faster than
kobsC1 for the FeC hTF alone (Table 3). The important ﬁnding is that
the rate constants for kobsC1 from all of the complexes are
comparable (Table 3); in contrast, kobsC2 for two of the complexes
(FeC hTF/5-HTP sTFR and 5-HTP FeC hTF/5-HTP sTFR) show a 2–4
fold decrease. The fact that the ﬂuorescent signal does not convin-
cingly plateau in either of these complexes probably accounts for the
difference in the second rate constant.
In terms of dissecting and assigning the change in the ﬂuorescent
signal, the crucial experiments are those in which the complexes are
excited at 315 nm (Fig. 5B). (Note that in order to increase the signal
we needed to use 5-fold higher concentration of sample). The most
intense signal comes from the complex of 5-HTP FeC hTF bound to
sTFR (Fig. 5B—black curve). The complex with 5-HTP FeC hTF and 5-
HTP sTFR also yields a reasonably strong signal (Fig. 5B—red curve). In
contrast, the complexes with native FeC hTF bound to either native or
5-HTP labeled sTFR give very low signals (Fig. 5B—blue and green
curves). The results of kinetic analysis of the data in Fig. 5A and B are
presented in Table 3. We obtain similar rate constants for iron release
from the various complexes when excited at 280 nm (320 nm cut-on
ﬁlter) and when excited at 315 nm (335 nm cut-on ﬁlter). Again the
second rate is more altered than the ﬁrst.
4. Discussion
Basic tenets of the TF system are that: 1) At neutral pH, diferric
and monoferric hTF bind to the TFR with nM afﬁnity, 2) at the low
pH within the endosome (pH ∼5.6), iron is released and apo hTF
remains bound to the TFR with nM afﬁnity and, 3) delivery of iron to
cells involves a drop in pH during receptor mediated endocytosis in
which the TFR accelerates iron release from the C-lobe as a function
of the decrease in pH (with little effect on the rate of iron release
from the N-lobe).
An interesting observation, not previously reported, is that there is
a 75% decrease in the change in the ﬂuorescence intensity when iron is
released from FeC hTF bound to the sTFR relative to the change in
ﬂuorescence intensity when iron is released from FeC hTF alone (Fig.
2A and B). This decrease may result from the increase in the overall
ﬂuorescence contributed by the sTFR which might result in a smaller
observed change. Alternatively, we suggest that conformational
changes in FeC hTF induced by the TFR may lead to lower ﬂuorescence
efﬁciencies from one or more of the Trp residues in FeC hTF from the
interaction in the complex. As a result of exposure to pH 5.6, we also
report for the ﬁrst time the fact that the sTFR alone has a small but
reproducible drop in the ﬂuorescence intensity followed by an
increase and then a gradual decrease (Fig. 2C). As described below,
we observe the initial drop in the complex but the other changes are
apparently masked when hTF binds to sTFR as indicated by the red
curve in Fig. 2C. The change in the ﬂuorescence intensity observed
upon iron release from FeC hTF alone (Fig. 2A) is attributed to the
conformational changes around one or more of the ﬁve Trp residues in
this lobe and the loss of energy transfer from Trp to the ligand tometal
charge transfer band. In the Zuccola structure [42], Trp344 and Trp358
in the CI subdomain lie ∼16 and 20 Å from the iron center; in the CII
subdomain Trp460 is closest to the iron (∼13 Å), while Trp441 and
Trp550 are at a distance of 18 and 19 Å, respectively (Fig. 1). The
reduction in the ﬂuorescence intensity observed when FeC hTF is
bound to sTFR (Fig. 2B) is tentatively assigned to the conformational
changes that hTF, and probably the sTFR, undergowhen bound to each
other (see below).
The unexpected changes in the ﬂuorescence intensity for the sTFR
alone (Fig. 2C) as a result of lowering the pH to 5.6 obviously cannot be
ascribed to iron release.We hypothesize that the initial decrease in the
ﬂuorescent signal results from rapid protonation of residues located
near Trp residues in the sTFR. Since it is well documented that
protonated histidine residues reduce Trp ﬂuorescence by serving as
electron-transfer quenchers [34,35], we examined the crystal struc-
ture of sTFR for the presence of His residues in proximity to Trp
residues. A single His residue in each of the three domains of the sTFR
is close to a Trp-residue: His234 in the apical domain is within 5 Å of
Trp357, His699 in the helical domain is 3.4 Å away from Trp702 and
His186 in the protease-like domain is 6.5 Å from Trp466. Obviously,
the change in pH from 7.4 to 5.6 is more likely to result in the
protonation of His residues than any other amino acids.
With regard to the pH-induced increase in the intrinsic ﬂuo-
rescent signal following the initial decrease (Fig. 2C), it is well known
that Trp-to-Trp energy transfer can have an effect on the efﬁciency of
Trp ﬂuorescence [36]. Trp residues 182, 453, 466, and 754 are within
∼6 Å of each other (Table 1). Additionally Trp641 and Trp740 are 5 Å
apart. This proximity means that these two clusters of Trp residues
could participate in homo-FRET interactions. Conformational changes
as a result of lower pH could change the orientation of one or more of
the Trp residues and decrease the efﬁciency of energy transfer
(thereby increasing the intrinsic ﬂuorescence). We also note that
increases in the intrinsic ﬂuorescence of Trp can result from changes
in the charge transfer state between the Trp ring and the amide
backbone [26,27]. The charge transfer state is very sensitive to the
local environment with the rotameric conformation of the Trp
residue(s) to the amide backbone and charged side chains near the
Trp ring contributing the most. Movement of negatively charged
residues away from the indole ring and/or of positively charged
residues toward the indole ring both result in an increase in the
intrinsic ﬂuorescence of Trp. Speciﬁcally, Trp412 in the protease-like
domain is 5.4 Å from Glu156 and Trp466 in the same domain is 5 Å
from Asp184. Similarly, Trp124 in the protease-like domain is within
4.2 Å of Lys600 and Trp412 is 5.3 Å from Lys193. Since the pH change
from 7.4 to 5.6 would not be expected to change the charge of either
the negatively or positively charged residues, only a pH induced
change in conformation in the region in which they reside would
result in an increase in the intrinsic ﬂuorescence.
In the hTF/TFR complex, dynamic movements of each partner are
likely to be limited by the strong afﬁnity with which they interact. In
order for the C-lobe of hTF (which rotates 54° to open the cleft and
release the iron) to remain bound to the sTFR at low pH, one would
predict that that there may well be some compensatory movement by
the TFR. It is known that the presence of the TFR induces long range
conformational changes within the C-lobe of hTF to stabilize the apo
form [16]. Speciﬁcally, a hydrophobic patch on the TFR (comprising
Trp641 and Phe760) interacts with His349 in the C-lobe of hTF to
accelerate pH induced iron release [16]. Restrictions in the conforma-
tional changes in each could contribute to the lower ﬂuorescence
change during iron removal. Weakened iron coordination could lead
to some reduction in the quenching of one or more of the ﬁve Trp
residues in the C-lobe. Another possibility derives from the quantum
yield information in Table 2. The interaction of FeC hTF with the sTFR
results in a non additive change in the quantum yield for the complex,
indicating that Trp residues within each binding partner are quenched
by the interaction.
To determine the contributions of each protein to the change in
the intrinsic ﬂuorescent signal, we incorporated the Trp analogue
5-HTP into FeC hTF and sTFR to allow speciﬁc excitation above
300 nm [32]. The most common strategy to incorporate 5-HTP into
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proteins has been to use a bacterial expression system in combina-
tion with Trp auxotrophs and to target a single Trp residue (well
summarized in two reviews [24,37]). The level of incorporation of
5-HTP in the earlier work varied from less than 20% up to ∼95%
[24]. A mammalian expression system is mandatory to obtain
functional (properly folded) hTF because of its 19 disulﬁde bonds. A
single report usingmammalian cells (human derived 293T) adopted a
unique approach to substitute 5-HTP for the single Trp residue in the
T4 ﬁbritin domain [38].
Because BHK cells do not produce endogenous Trp, the sole source
of this (and other essential amino acids) is the tissue culture medium.
In this regard, the system acts like a “mammalian Trp auxotroph” in
which the cells have access only to the substituted amino acid in the
medium. The BHK cell system has been used successfully to
incorporate 5-ﬂuorotryptophan into the N-lobe of hTF at a level of
∼15% [39] and to label hTF with selenomethionine (∼89% incorpora-
tion) [40]. In the current study we undertook the ambitious goal of
labeling both FeC hTF with eight Trp residues (∼20% incorporation)
and sTFR with 11 residues per monomer (∼26% incorporation) with 5-
HTP. Although these levels are relatively low, excitation of the various
samples at 315 nm demonstrates that the 5-HTP samples provide a
selective optical signal (Fig. 4A–D). All possible combinations of
labeled and native FeC hTF and sTFR constructs weremade. Overall the
kinetic data (Fig. 5A and B) offer compelling evidence that, with
selective excitation, the signal change observed upon lowering the pH
is derived solely from the loss of iron from FeC hTF with little or no
contribution from sTFR. The rate constants derived from the kinetic
curves for loss of iron from FeC hTF alone (whether native or 5-HTP
labeled) are within experimental error when excited at 280 nm (Table
3). Additionally the rate constants for the various complexes are also
very similar (Table 3). There is a slight decrease in the rate constants
(0.55 fold kobsC1 and 0.34 fold kobsC2) for 5-HTP hTF with native sTFR
when excited at 280 or 315 nm. We attribute these variations to the
differences in the size of the side chain (5-HTP) which is being
selectively excited at 315 nm and its unique spectral properties
compared to native Trp [41]. These results provide conﬁdence that the
incorporation of 5-HTP does not compromise the overall structure and
that the source of the intrinsic change in ﬂuorescence is receptor
stimulated loss of iron from FeC hTF.
We note that the actual events giving rise to kobsC1 and kobsC2 are
currently under investigation. Althoughwe suggest that the faster rate
corresponds to pH induced conformational changes within FeC hTF,
stimulated by the sTFR, and that the second rate corresponds to actual
iron release, more experiments are required to conﬁrm this sugges-
tion. The important ﬁnding is that the rates for all of the complexes
(regardless of their source) are similar. Additionally, although the
enhancement is lower than previously reported [16], the difference is
explained by the fact that the quality of the data is much improved by
use a stopped ﬂow instrument.
In summary, our results allow us to conclude that when FeC hTF is
bound to the sTFR the increase in the ﬂuorescence intensity that we
observe for the sTFR alone in response to lowering the pH is abolished
(Figs. 2C and 5B). We report for the ﬁrst time the quenching of the
intrinsic ﬂuorescent signal when FeC hTF is bound to the sTFR and the
observation of a pH-induced small initial decrease in the signal
assigned to the sTFR. We and others can now pursue studies to
characterize the interaction of hTF and the sTFR as a function of pH
and salt concentration with conﬁdence that we are measuring rate
constant(s) from hTF.
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